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Sulfatides are innate glycosphingolipids shown to activate a subpopulation of type II 
NKT cells. Their activation has been reported to sometimes have antagonistic roles 
to those of type I NKT cells in some disease models. This has sparked a lot of 
interest in the synthesis of natural and unnatural sulfatides for an examination 
of their influence on NKT cell responses. The design, synthesis and evaluation of 
type II NKT cell activation of several sulfatide ligands are described in this thesis. 
A two-step methodology has been developed for the rapid assembly of disubstituted 
β-lactones. The first step is olefin cross metathesis (CM) of α-methylene-β-lactones 
with various alkene cross partners to furnish α-alkylidine-β-lactones. These are 
subsequently diastereoselectively reduced. A diverse library of β-lactones, including 
(±)-nocardiolactone has been prepared. Combining this approach with competitive 
activity-based protein profiling (ABPP) identified lead β-lactone inhibitors for several 
serine hydrolases, including disease-associated enzymes and enzymes of 
uncharacterized function.  
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 Chapter 1. 
1.1. Introduction  
1.1.1. Natural Killer  (NK) T Cell 
Natural killer (NK) T cells are among the body’s first line of response in combating 
infectious diseases. They are a subset of T cell lymphocytes, a class of white blood 
cell, pre-armed with mRNA cytokines, which are produced quickly upon activation of 
their T cell receptors for diverse immune responses.1-3 NKT cells are CD1d-
restricted, which means they only recognize lipid antigens presented by CD1d 
proteins for their activation. NKT cells can be classified as either type I or type II, 
based on their T cell receptor (TCR), a heterodimer made up of a variable N-
terminus (designated V) and a C-terminus.4 NKT cells with a variable N-terminus 
(Vα14Jα18 in mice and Vα24Jα18 in humans) are called type I NKT cells 
(classical), or invariant (iNKT) cells. NKT cells which express more diverse TCR 
repertoires are termed type II NKT cells.5  
Type I NKT cells are well characterized. Extensive research has been conducted on 
them using α-galactosylceramide (α-GalCer or KRN7000 (1), Figure 1) and its 
analogs as potent ligands for their stimulation.6 Less, however, is known about type 
II NKT cells, due to a lack of potent ligands that activate them. Studies have shown 
that a specific type of glycolipid, known as sulfatides (see 2, Figure 1), can activate 
one sub-population of type II NKT cells. This dissertation will focus on the synthesis 
of sulfatides as ligands for the activation of type II NKT cells.  
 





Figure 1. Examples of glycolipids      
 
1.1.2. CD1 proteins 
	  
CD1 proteins are antigen-presenting proteins found on the surface of antigen 
presenting cells (APCs) such as dendritic cells, macrophages, and subsets of B 
cells. They are similar in action to class I major histocompatibility complex (MHC) 
proteins. Unlike MHC, CD1 proteins present lipids and glycolipids, both innate (e.g. 
phospholipids,7 glycosphingolipids and sulfoglycolipids8) and foreign (e.g. 
mycobacterial),9 to NKT cell receptors.2 There are five known CD1 proteins, all of 
which are expressed in humans, but only CD1d is expressed in mice and rats. 
Group I proteins includes CD1a, CD1b, CD1c and CD1e, and group II is made up of 
CD1d.2,10 Crystal structure studies showed CD1d (hCD1d, Figure 2) to be 
constituted of a C-terminal part and an N-terminus domain characterized by two 
helices (α1 and α2). They differ from MHC molecules by the presence of two 
hydrophobic pockets designated zone A and C (F in mCD1d) (Figure 2). CD1d is 








































Glycosphingolipids (glycolipids) are amphiphilic molecules found on the cell 
membrane of eukaryotic cells. They can be either neutral (e.g., KRN7000) or acidic 
(e.g., sulfatides). 
The structural skeleton of glycolipids is composed of a hydrophobic ceramide tail 
(lipid) and a hydrophilic sugar head (Figure 3a). The ceramide consists of a 
sphingoid base (phytosphingosine, sphingosine, or sphinganine (Figure 3b) and 
fatty acyl chain connected through N-acylation. The sugar is connected to the 
ceramide through a glycosidic bond that can be either alpha or beta linked (Figure 
3c).  
 









Figure 3. General composition of glycolipids: a. structural skeleton of glycolipids; b. 
types of sphingoid bases; c. glycosidic bonds  
 
Glycolipids found in mammals have the β-configuration, until a recent study by Kain 
and co-workers reported the isolation of C24:1-α-galactosylceramide (3)11 from 
mammals (Figure 4). Agelasphin-9b (4) (KRN7000 is a synthetic analog of 
Agelasphin-9b) was the first glycolipid isolated from a natural source with α-
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1.1.3.1. Glycolipids: Mode of activation of NKT cells 
	  
Two important complexes, binary and ternary, must be formed for glycolipids to 
activate NKT cells. The first complex, formed is the binary complex arising from the 
interaction of the glycolipids with CD1d.  H-bonding interactions between amino acid 
residues in CD1d and the glycolipid ligands provide specificity and stability to the 
complex (Figure 5). The H-bond interaction between the C3-OH of the sphingoid 
base and amino acid D80 (Figure 5c and 5d) directs the fatty acyl chain into pocket 
A and the sphingoid base into pocket C (or F), as depicted in the binary complexes 
of KRN7000-hCD1d reported by Koch et al.12 and of a sulfatide-mCD1d reported by 










Figure 5. Binary complex of CD1d bound glycolipids: a. hCD1d-Bound KRN7000; 
b. mCD1d-bound sulfatide; c. H-bonding network of mCD1d amino acid residues 
and KRN7000; d. H-bonding network of mCD1d amino acid residues and 
sulfatide12,13   
 
These pockets are further stabilized with β-helix sheets via van der Waals 
a. b. 
c. 
	   6	  
interactions. Four of the same H-bonding interactions seen in the CD1d-KRN7000 
binary complex are also observed in CD1d-sulfatide (galactose moiety C2-OH-
D153, C1-O’-T156, sphingoid base moiety C3-OH-D80 and the amide NH-T156) 
(Figure 5c and 5d). In addition to these four interactions, sulfatide forms three extra 
H-bonds with CD1d (C6-OH-R79, sulfate group with Q154, and the carbonyl group 
of the amide with Met69). The sulfate group and carbonyl interactions are H2O 
mediated (Figure 5d).  
Upon formation of the binary complex, the sugar moieties of the glycolipids are 
pinned down between the α-1 and α-2 helices of CD1d, ready to interact with the T 
cell receptors on the surface of NKT cells.  The interaction of the sugar moieties 
with the T cells results in the formation of the ternary complex. Successful formation 
of the ternary complex activates NKT cells to release different cytokines, 




Figure 6. Activation of NKT cells for cytokine secretionref 
 
These cytokines, based on their biological activities, can be classed as having T 
helper 1 (Th1) and T helper 2 (Th2) types of responses. Th1 cytokines include IFN-




T helper 1 response (Th1)





APC = antigen presenting cells
Glycolipid
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mechanism for the immune system to fight diseases, such as viral, bacterial, and 
parasitic infections. Th1 cytokines have also been shown to have antitumor activity.6 
Th2 cytokines include IL-4, IL-5, IL-10 and IL-13. They are responsible for 
autoimmuno-regulatory activities, which are relevant for the treatment of diabetes 
and other autoimmune conditions. The most studied glycolipids for NKT cell 
activation are KRN7000 for type I NKT cells and recently sulfatides for type II NKT 
cells. 
 1.1.4. Sulfatides  
	  
Sulfatides are natural glycolipids mostly found in the myelin sheaths in the central 
nervous system. Thudichum was the first person to isolate a lipid with a sulfate 
moiety from brain tissue and gave it the name sulfatide.14 The sulfatides isolated 
from human cells are comprised of various molecular species that differ in their 
ceramide moieties expressly in the acyl chain including chain length, number and 
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Sulfatides can be presented by all classes of CD1 molecules to T cells to activate 
them for cytokine secretion.10 The sulfate group at the C-3 position of the sugar 
differentiates sulfatides from other glycolipids structurally. They have a β-glycosidic 
configuration, in contrast to KRN7000, which has an α-glycosidic linkage. The β-
glycosidic linkage in sulfatides causes their sugar moieties to elongate out farther 
from the α-helices of CD1d. There they interact in a diagonal docking mode with the 
TCR on the surface of some type II NKT cells, found above the A pocket of CD1d  
(Figure 8a and 8c).16 The α-glycosidic bond in KRN7000 causes the sugar moiety to 
be buried more in the α-helices of CD1d, favoring it’s presentation to type I NKT 
cells positioned above the F or C pocket of CD1d (Figure 8b) in a parallel docking 


























Figure 8. Overview of docking orientation; a.  Type II NKT cell complex with the 
mCD1d-sulfatide; b. Type I NKT cell complex with mCD1d-KRN7000 (α-GalCer); c. 
Type II NKT cell- mCD1d-sulfatide complex viewed from the cleft of CD1d; d. Type I 
NKT cell-mCD1d-KRN7000 complex viewed from the cleft of CD1dref 
 
The recognition of sulfatides as activators of a subset of type II NKT cells has 
inspired crystal structure studies of CD1d-sulfatide-type II NKT complexes to 
eucidate how sulfatides interact with the NKT cells. Two independent research 
groups, one led by Rossjohn16 and the other by Zajonc,17 recently solved the crystal 
structure of sulfatide reactive-TCRs of type II NKT cells, using cis-tetracosenoyl 
sulfatide-CD1d-XV19 TCR complex and lyso-sulfatide (free amine, has no acyl 
chain)-CD1d-Hy19.3 TCR complex (9a and 9b), respectively. Neither study showed 
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The only H-bonding interaction observed was between the C2-OH of the sugar and 
tryptophan residue W97β (unlike the KRN7000-type I NKT TCR interaction, which 
showed a compacted H-bonding interaction of the sugar moiety and TCRs).Ref The 
complexes were stabilized, in addition to the C2-OH-W97β H-bond, by van der Waal 
interactions of the TCRs amino acid residues and the ligands. The lack of an 
intricate H-bonding network between the sulfate moiety of sulfatides suggested that 
other β-glycolipids can activate type II NKT cells. It also validated β-GlCer 
stimulation of XV19 TCR, although this happens to a lesser extent than with 
sulfatides.18 
 
Figure 9. Type II NKT cells TCR interactions with sulfatides; a. XV19 TCR 
interaction with cis-tertracosenoyl sulfatide shown in magenta, van der Waal 
interaction shown in red dashes and H-bonds shown in black dash;16 b. Hy19.3 
TCR interaction with lyso-sulfatide (free amine, has no acyl chain attached) shown 
in yellow, H-bond and van der Waal interactions are shown in blue dashes17 
 
a. b. 
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1.1.4.1. Immunostimulatory activity of some natural sulfatide and type II NKT  
             cells 
The fact that NKT cells have been shown to play an important role in 
immunoregulatory activities has drawn lot of attention toward them as potential 
therapeutic agents. However in order to fully explore NKT cells for biological 
purposes it is critical for the less characterized type II NKT cell activation and 
cytokine secretion mechanism to be understood. Several recent studies have 
revealed type II NKT cells to have distinct and sometimes-complementary effects in 
comparison to type I NK T cells. For example, cytokines secreted by type II NKT 
cells have been demonstrated to enhance tumor growth, while type I NKT cells 
secrete cytokines cause tumor death.6,19 Sulfatide activation of type II NKT cell 
subpopulations has provided a break-through for these studies, even though initial 
experiments conducted to identify active sulfatides were arduous. This is mainly due 
to their structural similarities as highlighted in Figure 7, which makes isolation of 
individual species challenging. Early analyses were carried out with a mixture of 
sulfatides. Modifications in the ceramide moiety can influence the interactions the 
ligands have with CD1d and T cell receptors and, consequently, also the type of 
responses induced.  
The sulfatide-CD1d complex recognition by type II NKT cells was first reported by 
Jahng et al.8 in their search for ligands that can activate type II NKT cells using Hy 
19.3 (which is a subclone of XV19, a sulfatide-reactive type II NKT cell). Hy 19.3 
was treated with different CD1d-glycolipid complexes, including sulfatide mixtures, 
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KRN7000 (α-GalCer), β-GalCer (β-anomer of KRN7000) and mono-GM1 (with a 
negatively charged sialic acid instead of sulfate), but only the sulfatide mixtures 
were able to stimulate the secretion of cytokines (IFN-γ and IL-4). In a later 
publication Kumar and co-workers demonstrated that the sulfatide active against Hy 
19.3 was lyso-sulfatide 6 (see Figure 7 for structure).20 Other individual sulfatides, 2, 
5 and 7, which were part of the previously analyzed mixture, were inactive. Wilson 
and co-workers, when developing the first CD1d-sulfatide binary complex (CD1d-
sulfatide 7), tested 7 with other sulfatides (its saturated acyl chain version 2, short 
chain 5 and lyso-sulfatide 6) for cytokine proliferation, and 7 displayed the highest 
stimulation of 3H-thymidine (a cell proliferation assay to test the potency of ligands 
in stimulating lymphocytes) secretion.13  
Although many factors influence glycolipid stimulation of NKT cells, information thus 
far on sulfatide activation of type II NKT cells suggests the stability of the antigen-
NKT cell ternary complex to be what differentiates individual sulfatide stimulatory 
results.21 Highlighted below is information on the functional roles exhibited by type II 
NKT cells in immuno-regulation. 
Multiple sclerosis (MS) 
MS, also known as encephalomyelitis disseminate, is an inflammatory disease of 
the brain, and its animal model counterpart is called experimental autoimmune 
encephalomyelitis (EAE). NKT cells are targets for MS treatment because studies 
have shown MS infected regions to be enriched with glycolipid species. Early 
treatment of EAE mice with cytokines secreted from sulfatide-reactive type II NKT 
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cells prevented clinical disease symptoms by inactivating the IFN-γ and IL-4 
production by pathogenic myelin glycoprotein reactive T cells that cause the 
inflammation.8 The mechanism for prevention of EAE is proposed in a another 
report by Kumar and co-workers, one of the principal investigators in the previous 
studies, to be via the inactivation of dendritic cells and type I NKT cells after 
sulfatide administration.20 This type II NKT cell mediated anergy induction of type I 
NKT cells is also argued by them to be important in the potential treatment of 
inflammatory liver disease.22 
Tumor Immunity 
The fact that type I NKT cells produce cytokines are capable of preventing tumor 
metastasis in mice in response to KRN7000 treatment has resulted in type I NKT 
cells been screened for tumor immunity. In contrast to type I NKT cells, sulfatide-
reactive type II NKT cells released cytokines enhance tumor metastasis by 
suppressing immunosurveillance (the method employed by the immune system to 
recognize transformed cells in order to inhibit their growth into neoplastic tissues).19 
Ambrosino et al. evaluated sulfatides’ stimulatory activity in tumor metastasis using 
three mice genotypes, Jα18KO mice (only express type II NKT cells not type I NKT 
cells), WT mice (contain both type I and type II NKT cells) and CD1dKO mice (do 
not express either NKT cells). The Jα18KO mice showed augmented tumor 
metastasis, depicted in the graph (Figure 10) by the number of nodules, while type I 
NKT cells prevented metastasis, indicated by the low nodules present in WT mice.  
The CD1dKO mice showed no response. The lower nodule levels in WT mice 
	   14	  
suggests an antagonizing effect of type I and type II NKT cells in tumor immunity, 
invoking a new immunoregulatory axis that needs to be resolved to understand 











Figure 10. The CD1d-restricted type II NKT cells down-regulate tumor 
immunosurveillance and the absence of type I NKT cells correlates with a higher 
susceptibility of tumor growth19 
 
 
Type I diabetes 
Subramanian et al. have demonstrated that sulfatide 2 activation of type II NKT cells 
causes the secretion of IL-10 (a Th2 cytokine), which helps protect non-obese mice 
from type I diabetes.21 A similar observation was made by Durate et al.23 
Parasitic infection 
The antagonistic role of type I and type II NKT cells is not only observed in tumor 
immunity but is also seen in the presence of parasitic infection. The evaluation of 
the role-played by NKT cells in Trypanosoma cruzi infection (the cause of Chagas 
disease, a chronic inflammation) revealed that type II NKT cells (Jα18KO mice 
expressed only type II NKT cells) enhance proinflammation in infected mice and 
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eventually caused their death (Figure 11). Conversely type I NKT cells performed a 
anti-inflammatory function, cross-regulating the type II NKT cells activities and 






















Figure 11. T. cruzi infection in mice, Jα18KO mice (only expressed type II NKT 
cells) enhances proinflammation, eventually causing mortality, while in wild type 
mice (which expressed both NKT cell types), the type I NKT cells present counter-
balanced the type II NKT cells activity, indicated by the increase in mice survival 
rate 24  
 
 
Graft-versus-host disease (GVHD) 
Bone marrow transplant (BMT), albeit an effective treatment for cancer, has the 
consequences of causing GVHD, a disease that frequently arises as a result of 
complications during the process. NKT cells have been shown to be effective in 
preventing it. Kim et al.25 showed both IL-4 and INF-γ cytokines secreted by type II 
NKT cells to protect against GVHD. IL-4 guards against GVHD through the 
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deversion of the immune system toward a Th2-type response. Exley et al.26 also 
reported a Th2-biased cytokine profile in GVHD treatment. The INF-γ derived mode 
of controlling GVHD is through the expression of Fas-L, inducing apoptosis of donor 
T cells. The type I NKT cells produced INF-γ also prevents GVHD but they engage 
the host T in contrast to the donor T cells by type II NKT cells.  
Ulcerative colitis (UC) 
This is an inflammatory bowel disease characterized as a Th2 response 
inflammation. Type II NKT cells from the lamina propria in ulcerative colitis patients 
expressed an increased level of IL-13, a Th2 cytokine, which in turn elevates the 
inflammation. Presence of type II NKT cells is a critical piece to be considered in the 
treatment of UC.27  
Hepatitis  
NKT cells are a target for hepatitis treatment, a disease condition characterized by 
the presence of inflammatory cells and tissues in the liver. Type I NKT cells been 
shown to mediate concanavalin A (a letin carbohydrate binding protein) induced 
experimental hepatitis. Kumar and co-workers have reported cytokines secreted by 
type II NKT cells upon sulfatide injection to prevent this type I induced liver 
damage.22 The mode of this prevention is through the inactivation of pathogenic 
type I NKT cells. 
1.1.5. Structure Activity Relationship (SAR) on Sulfatides 
	  
To date there have been no SAR studies done on sulfatides. Current research 
efforts are tfocused on identifying lead sulfatide targets from those isolated from 
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human cells. However, with the information now available from crystal structure 
studies on the sulfatide-TCR interaction of type II NKT cells, SAR studies should be 
easier. 
1.1.6. Purpose of Study 
	  
The potential of exploring type II NKT cells for therapeutic purposes based on their 
vital role in immune responses inspired us to synthesize the natural and unnatural 
sufatides shown in Figures 12 and 13 for further studies. The targets in Figure 12 
were selected for structure-activity studies on the effect of the number of 
unsaturations in the acyl chain on the ability of the lipids to stimulate type II NKT 
cells. Previous biological analyses by our collaborators at the NIH had shown that 
target 7, which has a double bond in its acyl chain, stimulated higher secretion of 
both IFN-γ and IL-4 than sulfatide 2, which has no double bond in its acyl chain. 
These data suggested that the degree of unsaturation in the acyl chain affects the 
ability of the lipids to stimulate type II cells.  Sulfatide 9, which has an extra double 
bond in its acyl chain, was also targeted to evaluate the effect of a higher degree of 
unsaturation. Phytosphingosine analogs 10–12 of compounds 2, 7 and 9 were also 
targeted. These were of interest because the α-galactosylceramide family of 
agonists for iNKT cells are largely phytosphingosine-containing ceramides, whereas 
the natural sulfatides that had been found to stimulate type II NKT cells are 
sphingosine based. Therefore, it is of interest to determine the role of the 
sphingosine-phytosphingosine difference in the specificity of these glycolipids for 
different subsets of NKT cells. 










Figure 12. Initial sulfatide targets 
 
Two novel sulfatides 13 and 14 (Figure 13) were also targeted to further probe the 
effect of the ceramide moiety on the nature of the immune response of sulfatide-
reactive type II NKT cells. Their design was based on what is known about 
compounds that elicit a biased activation of type I NKT cells (iNKT cells). Ligands 
13 and 14 have acyl chain and sphingoid base that are found in analogs 15 and 16 
(respectively) of KRN7000 that have been shown to induce a Th1 type response in 
iNKT cells. For compound 15 the Th1 bias is attributed to π-π stacking with aromatic 
residues in the A’ pocket of CD1d.28 The ternary crystal structure of 16 shows that 
the sphingoid base has an increased buried surface area.29 It is not clear how such 
interactions with CD1d are going to impact the response of type II NKT cells in 
comparison to iNKT cells, as structural information about CD1d/ceramide 
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a starting point for this. This dissertation will focus on the synthesis and initial 








Figure 13.	  Unnatural sulfatides and KRN7000 analogs 
1.1.7. Glycosylation approaches 
 Glycosphingolipids are normally synthesized by one of two approaches (A or B, 
Figure 14). In both pathways glycosylation is the key and most problematic step. In 
pathway A, the galactosyl donor (i) is coupled to a ceramide acceptor (ii). Pathway 
B uses a sphingoid base (iv) as the acceptor, and the product of this reaction (v) 































































































16; Plakoside A analog of KRN7000
F
9
15; analog of KRN7000
OH
C24H49
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A key consideration when selecting protocols for glycosylation reactions is the α- 
and β-glycosidic bond selectivity. Although the thermodynamically stable product is 
the α-glycosidic linkage, it is not always the predominant product.  Protecting 
groups,ref leaving groupsref and solventsref have been manipulated to enhance α- or 
β-product preference. Solvent manipulations have been successful in favoring α-
anomers and have been extensively used in the synthesis of α-glycosphingolipids 
(KRN7000 and analogs).  
Just as solvents have been used to favor α-anomer formation, appropriate 
protecting groups have been used to give selectively β-anomers. This phenomenon 
is called anchimeric assistance, also referred to as neighboring group participation, 
and is a common strategy utilized in carbohydrate chemistry to give β-selectivity. 
The concept relies on having a protecting group (acetate, benzoyl or pivaloyl group) 
at the C-2 position of the sugar to stabilize the formed oxocarbeniun ion, as shown 
in Figure 15. The C-2 acetate-protecting group on the sugar interacts with the 
anomeric carbon, converting the open oxocarbenium ion A (formed after the leaving 
group departs) to a cyclic oxocarbenium ion B, blocking the α-face and leaving the 
β-face accessible for nucleophilic attack. This leads to the formation of β-glycosidic 
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1.1.8. Approaches to previously synthesized sulfatides 
Sulfatides, like other glycosphingolipids, have been prepared using both 
glycosylation approaches highlighted in Figure 14. In addition to formation of the 
glycosidic bond, regioselective installation of the sulfate group at the sugar moiety 
(C3-OH) is a critical step in sulfatide synthesis. The sulfate moiety is acid sensitive 
and unstable to most reaction conditions, by default making its installation late stage 
and ideally the last step in the reaction sequence.  
Early syntheses of sulfatides depended on protecting group manipulation strategies. 
In 1997 Tanahashi and co-workers30 synthesized various sulfatides as selectin 
ligands/inhibitors using a pathway A glycosylation approach and protecting groups 
to systematically install the sulfate group (Scheme 1). Their synthesis of sulfatide 22 
commences with coupling of trichloroacetimdate donor 18 (prepared from using at 
least three orthogonal protecting groups) with ceramide acceptor 19 to give 20. 
Selective deprotection of the levulinoyl (Lev) group gave 21. Sulfation of the C3-OH 
with sulfur trioxide pyridine (Py•SO3) complex yielded a sulfatide intermediate that 
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A similar protecting group sulfation strategy was used by Marinier et al.31 to prepare 
sulfatide 5, using a pathway B glycosylation strategy (Scheme 2). Helferich 
glycosylation conditions were used to couple bromo galactose donor 23 with 
sphingosine acceptor 24 to give glycolipid 25 with 9% α-product (separable). Global 
cleavage of the acetyl and benzoyl protecting groups gave azido-glycolipid 26. 
Acetonide protection of the sugar moiety (C3-OH and C4-OH), followed by benzoyl 
protection of the rest of the hydroxyl groups, furnished glycolipid 27. Reduction of 
the azide group, followed by acylation gave 28. Cleavage of the acetonide group, 
followed by acetate protection of C4-OH via an orthoester gave the free C3-OH 
product 29. This product underwent sulfation with either ammonium sulfur trioxide 
(Me3.N•SO3) complex or sulfur trioxide pyridine (Py•SO3) complex to give 30. 






















































1. DMP, PTSA, 60 oC
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To address the lengthy protecting group strategy and to achieve a more economical 
regioselective sulfation, Flitsch and co-workers developed a dibutylstannylene 
acetal approach.32 The methodology relies on the formation of the dibutylstannylene 
acetal at the C3-OH and C4-OH of saccharides or glycolipids (Scheme 3). The 
reaction proceeds by refluxing saccharides or glycolipids like 31 with Bu2SnO in 
MeOH to form the cyclic dibutylstannylene acetal 32. This increases the 
nucleophilicity of the equatorial alcohol (C3-OH) to react selectively with the 
Me3N•SO3 complex gave target-sulfated compounds 7, 34 and 35. This sulfation 
strategy is now the most widely applied synthetic route to prepare β-sulfatides33-36 









Scheme 3. Flitsch’s dibutylstannylene acetal synthesis of sulfatides 
 
1.1.9.	  Summary  
Although the effect of sulfatide-reactive type II NKT cells is not well defined with 
respect to their effect on immune responses, the summarized data presented here 
suggests they sometimes have different roles than type I NKT cells. These findings 
suggest a new immunoregulatory axis that needs to be analyzed to understand the 
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functional role-played by NKT cells and to develop drug candidates. The successful 
syntheses of sulfatide targets (2 and 9–13) and their analyses in the activation of 
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1.2.	  Discussion 
1.2.	  1.	  Research objective 
The goal of this study is to synthesize sulfatides 2, and 9–13. The synthesis of 
sulfatide 10 was embarked upon first, based on the priorities of our collaborators.  
1.2. 2.	  Synthesis of sulfatide 10 
Pathway A glycosylation route was explored in our initial strategy to sulfatide 10, 
which would be obtained in three main reactions (sulfation, deprotection and 
glycosylation) from previously known compounds (Figure 16). Sulfation of advanced 
intermediate 36 would furnish target 10. In turn, 36 could be obtained from 37 by 
cleavage of the ester protecting groups. Coupling of sugar donor 17 with ceramide 
acceptor 38 would give 37. Sugar donor 17 could be obtained in two steps from 
commercially available β-pentaacetyl-D-galactose and ceramide 38 in four steps 







Figure 16. Retrosynthesis to sulfatide target 10  
 
Tetraacetyl trichloroacetimidate sugar 17 was chosen as the sugar donor because 
of the successes reported in the literature in obtaining β-selectively and the ease of 
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Chemoselective benzylamine cleavage of commercially available β-pentacetyl-D-
galactose 39 gave lactol 40 (Scheme 4). This was converted to the desired 






Scheme 4. Synthesis of trichloroacetimidate sugar donor 17 
 
 
The synthesis of ceramide acceptor 38 started with acylation of commercially 
available phytosphingosine (43) with the p-nitrophenol activated ester (42) of 
tetracosanoic acid 41 to give 44 (Scheme 5). Trityl protection of the primary alcohol 
gave diol 45. Benzoyl protection of the secondary alcohols gave 46. Cleavage of the 
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The sugar donor 17 and acceptor 38 were coupled in the presence of BF3•OEt2 as 
an activator to give glycolipid 37, along with its α-anomer and other side products 
(Scheme 6). Purification of the desired product 37 from its α-anomer and an 
impurity assumed to be hydrolyzed sugar donor (on the basis of NMR analysis) was 
very difficult. Thus no clean product was isolated. Another sugar donor with a 





Scheme 6. Glycosylation of sugar donor 17 and acceptor 38 to give 37 
 
Thiogalactosyl donor 47 was chosen as the alternative sugar donor, based on the 
successes we have had using thiophenol as a leaving group. It was obtained from 
BF3•OEt2-catalyzed thioglycosylation of β-pentaacetyl-D-galactose (39) with 
thiophenol.  Glycosylation of sugar 47 with ceramide acceptor 38 gave desired 
product 37, again along with its α-isomer. This time the separation was much 
easier, providing β-product 37. Cleavage of the ester protecting groups of 37 gave 
free glycolipid 36, which was subjected to Flitsch’s protocol for selective sulfation of 
the C3-OH of the galactose moiety.32 Glycolipid 36 was refluxed with Bu2SnO in 
MeOH, furnishing cyclic dibutylstannylene acetal 48. Treatment of 48 with 
Me3N•SO3 complex gave target sulfatide 10. Although both 13C NMR and Hi-Res 
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Bu2SnO related impurities that couldn’t be removed after multiple purifications on 













Scheme 7. Thioglycosidic sugar donor 47 route to prepare sulfatide 10 
 
To overcome the purification problem encountered following Flitsch’s procedure for 
the synthesis of sulfatide 10, we decided to explore a sulfation strategy in the 
presences of protecting groups to avoid using Bu2SnO. Sugar donor 53, a similar 
sugar donor to the one utilized by Tanahashi (see Scheme 1), was prepared. 
Global cleavage of the acetate protecting groups of 47 gave 49 (Scheme 8), which 
was then subjected to two protection reactions. First acetonide protection then 
benzoyl protection of the remaining hydroxyl groups furnished galactose 50. 
Chemoselective removal of the acetonide protecting group gave 51. C4-OH acetate 












OAc CH2Cl2, 0 oC - rt
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which was treated with levulinic acid to give Lev-protected galactose 53. 
Glycosylation of sugar donor 43 with ceramide acceptor 38 gave impure product 54. 
The rest of the reaction protocol was attempted with this to test the practically of the 
approach prior to purification studies. Hydrazine acetate catalyzed selective 
facilitatede of the levulinoyl group gave the free C3-OH glycolipid 55, which 
underwent sulfation using Me3N•SO4 in DMF to give impure 56. Global deprotection 















Scheme 8. Lev-protecting group approach to synthesize sulfatide 10 
 
Because of the unsuccessful formation of sulfatide 10 using Tanahashi’s approach, 
Marinier’s approach using sugar donor 50, an intermediate available to us from the 























1. DMP,  PTSA, DMF
80 oC
2. BzCl, py, 43%
  (over three steps yield)
80% aq. AcOH
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gave product 57, but attempted cleavage of the acetonide protecting groups using 






Scheme 9. Acetonide sugar donor 50 approach to prepare sulfatide 10 
 
1.2.2.1.	  1-Butanol/H2O partition purification technique to remove the Bu2SnO 
impurity  
While exploring routes to prepare sulfatide 10, we continued to search for 
purification techniques to remove the Bu2SnO related impurity. Dr. Petr Illarionov 
from the University of Birmingham suggested partitioning of the sulfatide in a 1-
butanol/H2O mixture and then centrifiguing to isolate the sulfatide in the 1-butanol 
layer. Sulfatide 10 was prepared again following Scheme 7 and subjected to the 
new purification technique before column chromatography on silica gel. This 
resulted in removing  >98% of the Bu2SnO related impurity, providing sulfatide 10, 











33, NIS, AgOTf, 4Å MS
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1.2.3.	   Retrosynthetic approaches to synthesize sulfatides (2 and 9–13) via 
pathway B glycosylation strategy 
Pathway B glycosylation was chosen to prepare the rest of the sulfatide targets, as 
it provides amino-glycolipids 59 and 60, functionalization of which through acylation 
would gave advanced intermediates (Figure 17). Sulfation of these intermediates 
would complete the synthesis of the sphingosine- (2, 9, 13) and phytosphingosine- 
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Amino-glycolipids 59 and 60 in turn can be obtained from cleavage of the ester 
protecting groups, followed by reduction of the azide in the glycosylation products of 
sugar donor 17 with acceptors 24 and 61 respectively.  
 
To prepare the sphingosine-sulfatide targets (2, 9 and 13) the sphingosine starting 
material required to give desired acceptor 24 was synthesized from D-ribo-
phytosphingosine (43) instead of buying it from an expensive commercial source. 
The protocol of Wang et al. was followed for the azide protection of 
phytosphingosine 43 (Scheme 10). The reaction proceeded via a diazo transfer 
reaction of the amine with Tf3N, generated in situ from NaN3 and Tf2O.38 TBDPS 
protection of the primary alcohol gave diol 62. The free diols in 62 were activated 
with thionyl chloride to give the cyclic sulfite, which was oxidized with catalytic 
RuCl2•3H2O to give cyclic sulfate 63. Opening of 63 with Bu4NI, followed by DBU 
promoted elimination gave a sulfated olefin, and subsequent aqueous H2SO4 
hydrolysis gave sphingosine 64. Benzoyl protection of the secondary alcohol gave 
65. Cleavage of the TBDPS group was first attempted with TBAF, but no desired 
product was isolated. Instead the benzoyl group migrated to the primary position, 
and 66 was obtained. 2 M HCl, generated in situ (AcCl in MeOH), following the 














Scheme 10. Synthesis of sphingosine acceptor 24 
 
The coupling of sugar donor 17 and acceptor 24, catalyzed by BF3•OEt2, gave 
glycolipid 25 with its α-anomer 67 detected by NMR and acetylated-sphingosine 68 
(Scheme 11). Separation of the desired product 25 from its α-anomer 67 was very 






















1. SOCl2, Et3N, CH2Cl2
2. RuCl2.3H2O, NaIO4
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1. DBU, Bu4NI, Tol
2. H2SO4, THF/H2O 76% 
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The difficult separation of desired product 25 from α-anomer 67 and the competing 
formation of 68 prompted us to prepare another sugar donor with a different 
protecting group on the C-2 position that could provide anchimeric assistance, but 
be less prone to undergo trans-esterification. It was also important that the α-
anomer be easily separable. Benzoyl- and pivaloyl-protected trichloroacetimidate 





Figure 18. Alternative sugar donors 69 and 70 
 
Several methods were attempted to prepare benzoyl-protected trichloroacetimidate 
sugar donor 69, but no clean product was isolated. Therefore the synthesis of sugar 
donor 70 was undertaken. Global pivalyol protection of D-galactose (71) gave 72 
(Scheme 12).40 Cleavage of the anomeric pivaloyl group using either hydrazine or 
BnNH2 to give 73 was unsuccessful. A two- step hydrolysis employed by Menger 
and Mbadugha in the cleavage of anomeric benzoyl-protected sugar was utilized to 
give lactol 73.41 Pentapivaloyl galactose 72 was first treated with HBr (33% in 
AcOH) to give a bromo sugar, which was treated with Ag2CO3 in aqueous acetone 
to give lactol 73. Activation of lactol 73 to trichloroacetimidate sugar donor 70 



















Scheme 12. Synthesis of sugar donor 70 
 
BF3•OEt2-catalyzed glycosylation of acceptor 23 with sugar donor 70 gave 
glycolipid 74 and its α-anomer 75 as a minor product (Scheme 13). Combi-flash 
column chromatography was used to separate 74 from 75. NaOMe catalyzed 
cleavaged of the pivaloyl-protecting groups in 74, followed by H2S reduction42 of the 
azido group, gave free amino-glycolipid 59, the required intermediate for the 






Scheme 13. Synthesis of amino-glycolipid 59  
 
Once amino-glycolipid 59 was obtained, the syntheses of the required activated 
esters (77, 84, and 88) were undertaken. The p-nitrophenol ester was chosen as 
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group. PNP ester 77 was easily prepared from its corresponding commercially 












Scheme 14. Synthesis of esters 77 and 84 
 
The required carboxylic acids for esters 84 and 88 were not commercially available 
and had to be prepared. Alkyne zipper reaction of 78 to produce terminal alkyne 79 
(Scheme 14b) initiated the synthesis of ester 84. CuI-catalyzed alkylation of 79 with 
propargyl bromide 80, facilitated by NaI and CsCO3 in DMF, gave skipped-diyne 81. 
This was treated under Lindlar hydrogenation reaction conditions to give skipped-
diene 82 with 17% of its inseparable trans isomer. Dess Martin perdiodinane 
(DMAP) oxidation of alcohol 82 to an aldehyde, and succeeding oxidation of the 
aldehyde with NaClO2 using NaH2PO4•H2O as a buffer furnished acid 83. PNP 
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1. DMP, CH2Cl2, 43%
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Activated ester 88 was prepared in 3 steps (Scheme 15). Sonogashira cross 
coupling of acid 85 with p-fluoro-iodo benzene 86 gave 87 with inseparable 
impurities. Hydrogenation of alkyne 87 to its corresponding alkane and subsequent 






Scheme 15. Synthesis of acyl chain 88 
 
Amino-glycolipid 59 was acylated with the appropriate p-nitrophenol activated esters 
(42, 84 or 88) in pyridine to give the advanced intermediates (89a–89c), ready for 
sulfation (Scheme 16). Selective installation of the sulfate group at the C3-OH of the 
glycolipid’s sugar moieties proceeded via Flitsch’s Bu2SnO approach with 
Me3N•SO3 providing sulfatides 2, 9, and 13. The amount of Bu2SnO used was cut to 
1.2 equiv. instead of the 2 equiv. described in the original procedure. This made the 














1. Pd/C, AcOH, MeOH, H2
2. PNP, DCC, DMAP, CH2Cl2






















Scheme 16. Completion of sulfatide targets 2, 9 and 13  
 
The partitioning of the sulfatides in a mixture of 1-butanol/H2O was necessary 
before column chromatography as described in the early preparation of target 10 to 
remove the Bu2SnO related impurity. Although this approach works, it was material 
depleting and the procedure had to be repeated multiple times even after column 
chromatography for some lipids (Figure 19a, shows the 1H-NMR spectra of a 
sulfatide aliphatic region after column chromatography and Figure 19b is the 1H-
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Figure 19. 1H-NMR spectra of a sulfatide; a. After 1st partition in 1-Butanol/H2O and 
column; b. After further partitioning of sample used to take NMR in (a)  
 
 
The phytosphingosine acceptor 61 (Scheme 17) was prepared to begin the 
synthesis of sulfatide targets 10–12. Benzoyl protection of the secondary alcohols of 
62 gave 91. Desilylation of the primary TBDPS protecting-group with AcCl in MeOH 






Scheme 17. Synthesis of phytosphingosine acceptor 61 
 
Similar reaction sequences as described in Schemes 13 and 16 were followed to 
prepare targets 10–12 (Scheme 18). Glycosylation of 61 with sugar donor 70 gave 
glycolipid 92 and its α-anomer as a minor product, which was separated using 
normal column chromatography. NaOMe catalyzed deprotection of the ester groups; 
followed by H2S reduction of the azido group gave free amino-glycolipid 60. This 
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than 20% yield (unclean). Acylation of 60 with the activated esters gave 
intermediates 36 93a and 93b. These were subjected to the typical sulfation 
conditions to produce sulfatides 10–12. Target 10 was synthesized again to obtain a 












Scheme 18. Synthesis of sulfatides 10–12 
 
1.2.4. Tetrachlorophthalimide as an amino-protecting group: Improve  
glycosylation reaction yield 
Switching from acetate- to pivaloyl-protecting groups on the sugar moiety produced 
a much cleaner reaction, resulting in easier purification of 74 and 92. However, the 
search for reaction conditions that would give if not absolute β-selectivity but greater 
isolation yield by suppressing α-anomer formation was continued. Since the ester 
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of participating in anchimeric assistance, factors that could lead to the α-anomer 
formation under these coupling conditions were examined and hypothesized as 
being as the result of two features: 1.  the rate the cyclic oxocarbenium ion like B is 
formed before nucleophilic attack (Figure 15);  2. the nucleophilicity of the 
sphingosine acceptor. This latter theory is well studied; hence it was selected for 
analysis.  Previous studies on glycosylation reactions have shown the presence of 
H-bond interaction between the C1-O and N-H of the amide withdraws electron 
density from the primary hydroxyl group causing it to be less nucleophilic (see 
sphingosine 94, Figure 20).43 To address this issue, acceptors with protecting 
groups on the C-2 amine, like azide (azido-sphingosine acceptor 24), have been 
utilized. These donate electron density, by acting as H-bond acceptors to the 
primary hydroxyl group, consequently increasing its nucleophilicity (Figure 20). In 
response to this Panza and co-workers recently published the use of 
tetrachlorophthalimide (TCP) (with a greater electron donating effect on the C1-OH) 
as an effective protecting group for sphingoid bases in glycosylation reactions 
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The TCP-protecting group was attractive in many ways; Panza and co-workers use 
of 95 in their glycosylations gave them 97 (100% isolated) regardless of the sugar 
donor (69 or 96) used. It was also easily removed with ethylene diamine to give the 
free amino glycolipid, which was acylated in a one-pot reaction to yield 98 (Scheme 
19). As a result of these successes with acceptor 95, we decided to prepare it to 




Scheme 19. Panza’s application of 95 as an efficient acceptor in glycosylation 
 
Treatment of phytosphingosine (43) with tetrachlorophthalic anhydride in DMF  gave 
99. This was converted to N-TCP-sphingosine acceptor 95 (Scheme 20), following 
the same reaction sequences described previously for the preparation of  










































69; LG = Imidate (α)
96; LG = SBox (β) 95
H2N
NH2,  EtOH1.
2. Stearic acid, EDC, HOBt
    THF/EtOH, 85%
    (over 2 steps)
AgOTf, for 96, 81% 
(99% based on recovered 95)
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Scheme 20. Synthesis of sphingosine 95 
 
 
Coupling of sugar donor 70 with acceptor 95 catalyzed by BF3•OEt2 gave β-product 
104 (68%, 84% based on recovered 95) and it’s α-isomer (~5%) (Scheme 21). The 
reaction was not 100% β-selective as was observed by Panza and co-workers 
(Scheme 19). However, the separation of the two anomers was easier, and the 
glycosylation yield improved. Unfortunately cleavage of the N-TCP group was 
unsuccessful using ethylene diamine (at room temp as reported by Panza or by 
heating it to 60 oC). The isolated product was acylated and only partially N-TCP 














1. SOCl2, Et3N, CH2Cl2
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Scheme 21. Attempted cleavage of N-TCP protecting group to give 105 
 
Other cleavage protocols known to remove the N-TCP group, such as hydrazine, 
NaBH4 in THF/MeOH and benzylamine, were used but to no avail; all resulted in 
messy reactions.   Cleavage of the ester groups before removing the N-TCP group 
also failed. 13C NMR spectra’s showed TCP related peaks after multiple 
chromatographic purifications. Glycosylation using the sugar donor 69 or 96 (sugar 
donors were not 100% clean, used by Panza were tried, but both gave inseparable 
products. In summary, switching the N-sphingosine protecting group from an N-
azide to N-TCP improved the glycosylation yield and purification of the desired β-
product, but its ineffective removal makes its utility limited.  
The total synthesis of sulfatide sphingosine 2, 9, 13 and phytosphingosine targets 
10–12 were completed in 13 and 9 steps respectively from commercially available 
phytosphingosine and D-galactose. Compounds were sent for evaluation to assess 
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1.2.5.	  Results: activity of prepared sulfatides (2, 7, 9–13) in stimulating type II 
NKT cells 
The first experiment conducted with the sulfatides was to evaluate if NKT cells in 
general would recognize their CD1d tetramers. Therefore, the sulfatide-CD1d 
prepared tetramers were treated with liver lymphocytes.  As shown in Figure 21 and 
22 (gated cells) all prepared sulfatides were reactive towards NKT cells, and novel 
sulfatide 13 had the lowest interaction (Figure 22, indicated by the small number of 
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Figure 22. Sulfatide 13 reactive against liver lymphocytes 
 
Once it was confirmed that the prepared ligands could interact with NKT cells, they 
were next screened simultaneously with PBS57 (107), an analog of KRN7000, 
against T cells (sulfatides stains shown on the y-axis and PBS57 stains shown on 
the x-axis, Figure 23). The purpose of this analysis was to check if the sulfatides 
would interact with the same NKT cells as PBS57 (in this case type I NKT cells). 
The data obtained showed sulfatides to be recognized by a distinct population of T 
cells (probably type II NKT cells) different from type I NKT cells, as no double 























Figure 23. Cross-staining of sulfatides and PBS57 on NKT cells; sulfatide stains 
shown on the y-axis and PBS57 stains shown on the x-axis 
 
 
Because some type II NKT cell hybridomas have been shown to recognize specific 
sulfatides, the sulfatide ligands were screened to determine if they would interact 
with the same subpopulation of type II NKT cells. The gated T cells (Figure 24) from 
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and  C24:1 (7) and (c) C24:0 (2) and C24:2 (9) suggested the ligands to have 
reactivity largely towards identical NKT cells. 
Figure 24. Sulfatides 2, 7 and 11 targets largely identical subpopulation of NKT 
cells; a. phyto-C24:1 (11) and C24:0 (2) loaded CD1d tetramers; b. C24:1 (7) and 




The ability of the prepared sulfatides to stimulate NKT cells to secrete cytokines 
was also examined, and preliminary in vitro studies revealed them to stimulate the 
secretion of both Th1 and Th2 cytokines (illustrated by IFN-γ and IL-4 production 
responsively, Figure 25). The phytosphingosine analogs exhibited the highest 
activity with phyto-C24:0 (10) being the most potent ligand and phyto-C24:2 (10) 
displayed the lowest (comparing phyto-sulfatides). In contrast to the 
phytosphingosine-sulfatides, the sphingosine-sulfatides displaying an opposite 
cytokine production pattern; the number of unsaturations present in their acyl chains 
correlates with their ability to elicite cytokine production, manifested clearly in the 
amount of IL-4 produced. Target C24:2 (9)  stimulated a higher secretion of IL-4 
than C24:1 (7), which showed stronger cytokine production than C24:0 (2).  
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Figure 25. Cytokine secretion ability of prepared sulfatides 
 
In conclusion, all the prepared natural and unnatural sulfatides activate NKT cells to 
release cytokines. The phytosphingosine analogs emerging as the strongest ligands 
revealed new data that both type I and type II NKT cells are potently stimulated by 
phytosphingosine sphingoid bases. The distinct NKT cells the compounds targeted 
in comparison to PBS57 implied these NKT cells to be type II NKT cells, as PBS57 
interacts specifically with type I NKT cells. The sulfatide-reactive T cells need to be 
isolated to confirm this hypothesis, which is part of the future studies to be 
conducted with the ligands. All of the ligands have been prepared again to verify 
their stimulatory pattern. In vivo tumor immunity experiments will be conducted once 
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1.2.6.	  Synthesis of new natural sulfatides 8-(S), 111 and 112 
At about the same time that we completed the synthesis of the sulfatide targets  (2, 
9–13) we were approached by Prof. Lucia Mori’s of the Singapore Immunology 
Network (SigN). Their lab is also interested in the evaluation of natural (bovine 
brain) sulfatide extracts for the activation of T cells. The Mori lab uses mass 
spectrometry for sulfatide structural analysis and identification of potential active 
ligands from mixtures of natural sulfatides bought from commercial providers. After 
multiple HPLC and mass spectrometric analyses, targets 8-(S), 108–112 (Figure 
26), were selected as potential potent compounds against T cells present in the 
sulfatide mixtures. Thus a collaboration was initiated with our lab to complete their 
synthesis so they could confirm their activities and do further studies with them on 
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The new targets (8-S, 111 and 112) can also be accessed from advanced amino-
glycolipid 59 by doing acylation and sulfation as the previous targets. The order the 
compounds are presented in Figure 2.7 is a representation of the priority order, but 
because of the complicated reactions required to prepare some of the acyl chain, 
the wish list was narrowed first to synthesize targets 8-S, 111 and 112. The 
preparation of the appropriate acyl chains launched their synthesis (Scheme 22). 
The commercially available fatty acids archidic (elcosanoic) acid (113) and erucic 
acid (115) were activated with p-nitrophenol to give their corresponding PNP-esters 
114 and 116 respectively. The acid precursor 119 to acyl chain 120 is not 
commercially available and was prepared in three steps from tetracosanoic acid 
(41) following Mori’s et al. protocol.45 Red phosphorus catalyzed bromination of 41 
in the presence of bromine gave (rac)-α-bromo tetracosanoic acid 117. Hydrolysis 
of 117 with 2M NaOH gave (rac)-α-hydroxy tetracosanoic acid 118. Amano-lipase 
PS facilitated kinetic resolution using vinyl acetate in the presence of BHT gave 
enantiopure acetate-protected (S)-α-hydroxy tetracosanoic acid 119. p-Nitrophenol 
























Scheme 22. Synthesis of acyl chains 114, 116 and 120 
 
The acylation of amino-glycolipid 59 with PNP-activated esters 114, 116 and 120 
gave glycolipids 121a–121c. NaOMe cleavage of the acetate group in 121a was 
done before sulfation. The lipids were then subjected to the developed sulfation 
procedure to provide sulfatides 8-(S), 111 and 112. The compounds were sent to 
























a. Synthesis of acyl chain 114
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120c. Synthesis of acyl chain 120


















Scheme 23. Completion of the synthesis of sulfatides 8-S, 111 and 112  
 
1.2.7.	  Activity of sulfatides 8-(S), 111 and 112 
Unfortunately, none of the ligands were able to stimulate the T cells to secrete 
cytokines, even though their molecular weights correspond to previously analyze 
active sulfatide mixtures. Nonetheless they served as a tool, narrowing down the 
probable compounds to synthesize and test. Thorough HPLC and mass 
spectrometry were further conducted on mixtures of sulfatides bought from Fluka 
and Matreya. Upon further charaterization of HPLC fractions, the most potent 
fraction had a compound with molecular weight of m/z 860.6026 –Na+. One possible 
structure for m/z 860.6026 is 111, already synthesized and tested as inactive. 
Another possible structure to match the m/z 860.6026 is sulfatide 122 which would 
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Note: 115a  was first subjected to NaOMe, CH2Cl2/MeOH to cleave the actate group before sulfation
9 C8H17
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tetracosenoic acid (C24:1) instead of  the C-18 chain length (d:18-sphingosine) and  





Figure 27. Possible structures for m/z 860.6026 –Na+ 
 
The active HPLC fraction from Fluka showed both d:16- and d:18-sphingosine base 
sulfatides with m/z 860.6026 (Figure 28a and 28c), while the fraction from Matreya 
which had almost pure d:18 sulfatide  was inactive (Figure 28b and 28d). The 
observed inactivity of 111 (see Figure 28c and d) coupled with the experimental 
data of the Fluka and Matreya sulfatide mixtures lead to the assumption that 122 









































Figure 28. Structural deduction of m/z 860.6026 –Na+; a. MS of sulfatide mixtures 
from Fluka; b. Sulfatides mixture from Matreya; c. stimulatory activity of sulfatide 
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1.2.8.	  Synthesis of sulfatide 122 
To prepare sulfatide 122, the synthesis of the d:16-sphingosine was required as it 
was expensive to buy from a commercial provider (10mg for $175.00 or 100mg for 
$1,400.00). The Garner aldehyde (125) was chosen as the chiral pool source for its 




Figure 29. Retrosynthesis of d:16-sphingosine 125 using Garner aldehyde 
 
 
The commercial cost of Garner aldehyde (125) was also very expensive (1g for 
$209.00); therefore, it was prepared from Boc-L-serine (127), which is much 
cheaper. Following the traditional Garner aldehyde synthesis from Boc-L-serine 
(Scheme 24), the carboxylic acid group was converted to a methyl ester using MeI 
and K2CO3 as the base, giving 128. The primary alcohol and nitrogen of the 
carbamate were protected with DMP to give oxazolidine 129. This was subjected 
under DIBAL-H reduction conditions to give Garner aldehyde (125) and its over 
reduced alcohol product. The low yielding steps and the inefficient DIBAL-H 
reduction caused us to pursue an alternative route.  
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A Weinreb amide route was appealing; because of the high yield reported by 
Siciiano et al. in their reduction of various substituted Weinreb amides to 
aldehydes.46 The protection of the alcohol and nitrogen of Boc-L-serine to give 
oxazolidine 130 commenced the strategy (Scheme 25). Activation of 130 with a 
Weinreb amide salt gave 131. LiAlH4 reduction of 131 granted Garner aldehyde 






Scheme 25. Synthesis of the Garner aldehyde via a Weinreb amide route 
 
The low reactivity of Garner aldehydes under our reaction conditions calls for a new 
plan to prepare sphingosine 123. The successful synthesis of d:18-sphingosine via 
olefin cross metathesis (CM) reported by Katsumura and co-workers47 inspired us to 
investigate CM methodology (Scheme 26). The new path began with TBS protection 
of Weinreb amide 132 to give 133. Nucleophilic addition of vinyl magnesium 
bromide (134) to 133 generated enone 135 in 20% yield. The low yield was as a 
result of the silyl group being cleaved during the acidic work-up. Since enough 
product was obtained, however, 135 was subjected to Hoffman’s chemoselective 
and diastereoselective reduction48 of the enone carbonyl using LiAl(tOBu)3H in 
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of allylic alcohol with 1-tridecene (137) gave sphingosine 138. The secondary 
hydroxyl group in 138 was protected with a benzoyl group followed by silyl group 
deprotection to give desired sphingosine 140. The purification of 138 from 136 was 
very tedious for a couple of reasons; 1. The amount of 1-tridecene for the CM 
reaction was 4 equiv. leading to a lot of its homo-coupled product; 2. the reaction 
didn’t go to completion, and the product and starting material had close retention 
times. To overcome these issues, CM was done on enone 135 to give 141, which 
was reduced to give 138. Again, loss of the TBS group during acidic work-up 













Scheme 26. Synthesis of d:16-sphingosine using CM 
 
Glycosylation of acceptor 140 was first tried with our optimized sugar donor 70 
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inseparable α-anomer 144 and other byproducts. The  bromo sugar donor 142, an 
intermediate in the synthesis of 70 was tried next. Acceptor 140 and bromo sugar 
142 were reacted following a classical Helferich glycosylation procedure (Scheme 
27). Although coupling occured, the outcome was the same as with the acetimidate 





Scheme 27. Attempted glycosylations 
 
At this point we had run out of sphingosine intermediates to prepare the precusors 
to the ceramide and we had to start again from Weinreb amide 132. The TBDPS 
analog 148 of 138 was prepared to avoid the the issues faced with TBS group 
cleavage (Scheme 28). As was seen in synthesis of 138, CM before 
diastereoselective reduction of enone precursor 146 provided 148 more efficiently. 
TBAF was used for the removal of the silyl group in 148. The treatment of the N-
Boc-sphingosine with a TFA/CH2Cl2 mixture removed the Boc group and the free 
amino d:16-sphingosine was directly acylated with PNP-activated ester 77 in the 
presence of pyridine to give ceramide 149. This product underwent protecting group 


























Hg(CN)2, CH3NO2, 80-85 oC for 142
+
70; X = Imidate
142; X = Br
 BF3.OEt2, 4Å MS, CH2Cl2 for 70
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primary hydroxyl group, subsequent benzoyl protection of the secondary hydroxyl 












Scheme 28. Synthesis of ceramide acceptor 150 
 
Gratifyingly the coupling of ceramide acceptor 150 with sugar donor 70 promoted by 
BF3•OEt2 furnished glycolipid 151 (Scheme 29). No α-anomer was isolated 
supporting hypothesis (1) stated in section 1.2.4. It is likely the α-anomers in the 
glycosylation reactions of Scheme 13 and 18 were formed because the cyclic 
oxocarbenium ion intermediate required wasn’t completely formed before the azido-
base acceptors  24 and 61 attacked, which are stronger nucleophiles. In contrast, 
150’s low reactivity favored the successful formation of  the  cyclic oxocarbenium 
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2. TFA/CH2Cl2
3. 77, py, 40 oC, 74% 






C8H1712 1. TrCl, Et3N, EtOAc, 80 oC, 71%
2. BzCl, DMAP, py, 67%















	   61	  
side product isolated was the trans-esterification product 152 (~9%). A NaOMe 
cleavage procedure was employed to remove the ester protecting groups to yield 
153. Sulfation of 153, finally gave 122. Sulfatide 122 and the free amino d:16 
sphingosine 123 are currently being tested for their stimulation of T cells using 









Scheme 29. Completion of 122 syntheses 
 
It happens that it is not only the Mori lab that is interested in d:16-sphingosine lipids. 
Dr. Torta and co-workers at Singapore Lipidomics Incubator (SLING) requested 154 
a phosphate analog of 123. Their lab is involved in studying long chain base 
phosphates (LCBP) and they believe 154 might be involved in important biological 
functions. To prepare 154, the N-Boc protected sphingosine 155 (an intermediate 
after TBAF cleavage of 148) was reacted with trimethoxy phosphate to give methyl 







CH2Cl2, 0 oC, 33%















1. Bu2SnO, MeOH, reflux































	   62	  
phosphoric acid 154 (Scheme 30). Phosphate 154 was sent, along with 123, as a 






Scheme 30. Synthesis of d:16-sphingosine phosphate 154 
 
In summary we have completed the synthesis of four additional sulfatides (8-S, 111, 
112 and 122) and d:16-sphingosine phosphate 154. Targets 8-S, 111 and 112 were 
prepared in 13 steps from commercially available phytosphingosine and D-galactose 
and target 122 was prepared in 14 steps from D-galactose and Boc-L-serine. Also, a 
more efficient CM methodology of enones have been developed for the preparation 
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1.3. EXPERIMENTAL: Sulfatides 
 
1.3.1. General Experimental 
 
Tetrahydrofuran (THF) was dried using a solvent dispensing system (SDS) with a 
column of neutral alumina. Pyridine, toluene, dimethylformamide (DMF), methylene 
chloride (CH2Cl2), deuterated chloroform (CDCl3), methanol (MeOH), deuterated 
methanol and ethanol (EtOH) were dried over 4Å molecular sieves (MS).  
N-tert-BOC-L-serine and hexacosanoic acid were purchased from Novabiochem 
and TCI, respectively. The other reagents were purchased from Acros, Alfa Aesar 
or Aldrich and used without further purification.  
All reactions were conducted under an atmosphere of N2 in glassware that had 
been dried overnight in an oven at 120 οC. Where appropriate, control of the 
reaction temperature was achieved with a solid CO2/acetone bath, an ice bath or a 
heated oil bath. 
1H NMR spectra were recorded at 500 MHz, 400 MHz and/or 300 MHz and 
calibrated to the residual CHCl3 peak in CDCl3 at 7.26 ppm, to the TMS peak at 0.0, 
or to the residual MeOH peak in MeOD at 3.34 ppm. 13C NMR spectra were 
recorded at 125 MHz, 100 MHz, and/or 75 MHz and calibrated to the residual CHCl3 
peak in CDCl3 at 77.23, or to the residual MeOH peak in MeOD at 49.5 ppm. The 
following abbreviations are used for peak multiplicities: app (apparent), s (singlet); 
br s (broadened singlet); d (doublet); dd (doublet of doublet); ddd (doublet of doublet 
of doublets); dddd (doublet of doublet of doublet of doublets); dt (doublet of triplets); 
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tt (triplet of triplets) t (triplet); q (quartet); quin (quintet); m (multiplet). Coupling 
constants, J, are reported in Hertz (Hz). 
IR spectra were recorded on a Brucker FT-IR spectrometer. High-resolution mass 
spectra (HiRMS) were obtained on an AccuTOF instrument equipped with a DART 
ionization source. 
Melting points were observed in open Prex capillary tubes and are uncorrected. 
Specific rotations [α]D were obtained on a JASCO polarimeter using the sodium D-
line as a source, and the concentration (c) is expressed in g per 100 mL.  
Flash chromatography was performed on Silica Gel, 40 micron, 32-63 flash silica 
from Sorbent. Thin layer chromatography was performed on silica gel (Silicycle 
Silica Gel 60 F254 glass plates). Compounds were visualized by UV, 5% 
phosphomolybdic acid in ethanol, 0.5% potassium permanganate in water or a 
solution of ethanol/H2SO4/AcOH/p-anisaldehyde (135:5:1.5:3.7). Ceric molybdate in 
a solution of H2O/ammonium molybdate/ceric ammonium molybdate/ H2SO4 (235 
mL: 12 g: 0.5 g: 15mL) was used for sulfatides. 
Compounds 9544 and 99–10344 were prepared according to literature procedures. 
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General sulfation procedure 
Glycolipids (1 equiv) and Bu2SnO (1.2 equiv) were refluxed in MeOH (0.016 M) for 2 
h. The solvent was evaporated under reduced pressure. The resulting dibutyl-
stannylene complex was treated with Me3N•SO3 (2 equiv) in THF (2 mL).32,34 The 
mixture was stirred at rt from between 2 to 6 h. TLC was used to monitor the 
reaction. The solvent was evaporated, and the residue dissolved in a 1:1 mixture of 
CH3Cl3/MeOH (4 mL). Dowex (Na+ resin) was added. The mixture was then stirred 
for 10 min, followed by filteration and concentration. The crude product was 
partitioned in a mixture of 1-butanol/H2O (1:1, v/v) and centrifuged. The 
supernatants (1-butanol, containing the sulfatides) was collected and concentrated. 
Purification by flash column chromatography on silica gel (CH2Cl2/MeOH, 10 to 
15%) gave the sulfatides. 
 
(2S,3R,4E)-1-(3-O-Sodiumsulfonyl-β-D-galactopyranosyloxy)-2-(N-
tetracosanoylamino)octadec-4-en-3-ol (2). Sulfatide 2 was isolated as a white 
solid (4.2 mg, 35%): mp 204.0−205.0 oC; [α]25D  6.98 (c 0.38, CHCl3/MeOH, 3:2); IR 
(neat) 3400 (br), 2917, 2850, 1646, 1466, 1258, 1066, 801 cm-1; 1H NMR (400 MHz, 
CDCl3/CD3OD, 3:2) δ  5.67 (dt, J = 15.3, 6.7 Hz, 1H), 5.42 (dd, J = 15.3, 6.6 Hz, 
1H), 3.81–3.74 (m, 4H), 3.58–3.56 (m, 2H), 2.15 (t, J = 7.9 Hz, 2H), 2.00–1.98 (m, 
2H), 1.66–1.45 (m, 2H), 1.41–1.25 (m, 62H), 0.87 (t, J = 6.9 Hz, 6H); 13C NMR (100 
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68.2, 62.2, 54.2, 37.4, 33.4, 32.9, 31.5, 30.7, 30.6, 30.6, 30.5, 30.4, 30.3, 30.3, 




tetracosanoylamino)octadec-4-en-3-ol (8-S). Sulfatide 8-S was isolated as a 
white solid (2.4 mg, 39%): 1H NMR (500 MHz, CDCl3/CD3OD, 3:2) δ 5.72 (dt, J = 
15.2, 6.9 Hz, 1H), 5.45 (dd, J = 15.4, 7.2 Hz, 1H), 4.00–3.96 (m, 2H), 3.83 (dd, J = 
11.8, 6.9 Hz, 1H), 3.72−3.70 (m, 1H), 3.69 (dd, J = 10.5, 3.4 Hz, 1H), 3.56 (dd, J = 
5.5, 5.5 Hz, 1H), 2.05–1.98 (m, 2H), 1.81−1.74 (m, 1H), 1.65−1.61 (m, 1H), 1.56–
1.49 (m, 1H), 1.46–1.26 (m, 61H), 0.88 (t, J = 6.7 Hz, 6H); 13C NMR (125 MHz, 
CHCl3/CD3OD, 3:2) δ 176.7, 135.3, 129.7, 104.4, 81.4, 75.8, 72.9, 72.5, 70.4, 69.3, 
68.5, 62.5, 54.5, 35.5, 33.3, 32.8, 30.6, 30.6, 30.5, 30.4, 30.3, 30.3, 30.2, 26.3, 




tetracosadienoylamino)octadec-4-en-3-ol (9). Sulfatide 9 was ioslated as an off 






















	   67	  
3:2); IR (neat) 3370 (br), 2918, 2850, 1644, 1467, 1258, 1066 cm-1; 1H NMR (400 
MHz, CDCl3/CD3OD, 3:2) δ 5.70 (dt, J = 15.3, 6.6 Hz, 1H), 5.44 (dd, J = 15.4, 7.4 
Hz, 1H), 5.40–5.29 (m, 4H), 4.34 (d, J = 7.7 Hz, 1H), 3.64 (dd, J = 10.3, 3.2 Hz, 1H), 
3.57 (dd, J = 5.7, 5.7 Hz, 1H), 2.77 (dd, J = 6.3, 6.3 Hz,  4H), 2.17 (t, J = 7.6 Hz, 
2H), 2.08–2.00 (m, 7H), 1.65–1.51 (m, 2H), 1.40–1.27 (m, 48H), 0.91–0.86 (m, 6H); 
13C NMR (100 MHz, CHCl3/CD3OD, 3:2) δ 175.8, 135.2, 131.1,  130.4, 128.9, 
104.5, 81.4, 75.8, 72.9, 70.6, 69.9, 68.6, 62.4, 54.5, 37.4, 33.2, 32.8, 32.4, 30.6, 
30.5, 30.5, 30.4, 30.4, 30.3, 30.2, 28.1, 28.1, 26.9, 26.6, 23.5, 23.4, 14.7; HRMS 
(TOF) calcd for C48H92NO11 [M –Na ]+ m/z 886.6078, found 886.6058. 
 
(2S,3S,4R)-1-(3-O-sodiumsulfonyl-β-D-galactopyranosyloxy)-2-(N-
tetracosanoylamino)octadecane-3,4-diol (10). Sulfatide 10 was isolated as a 
white solid (3.2 mg, 18%): mp 184.0.0−185.0 oC; [α]25D  10.43 (c 0.49, CHCl3/MeOH, 
3:2); IR (neat) 3429 (br), 2917, 2850, 1632, 1467, 1224, 1070, 801 cm-1; 1H NMR 
(400 MHz, CDCl3/CD3OD, 3:2) δ  5.35–5.32 (m, 1H), 3.81 (dd, J = 11.8, 7.2 Hz, 
1H), 3.76–3.71 (m, 2H), 3.66–3.64 (m, 1H), 3.59–3.56 (m, 1H), 2.15 (t, J = 7.5 Hz, 
2H), 2.04–2.00 (m, 1H), 1.60–1.51 (m, 5H), 1.41–1.26 (m, 62H), 0.87 (t, J = 7.0 Hz, 
6H); 13C NMR (100 MHz, CDCl3/CD3OD) δ 175.8, 104.2, 81.2, 75.8, 74.8, 73.2, 
70.5, 70.1, 68.3, 62.3, 51.2, 37.3, 32.8, 32.6, 30.6, 30.6, 30.4, 30.3, 30.2, 28.0, 
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(2S,3S,4R)-1-(3-O-Sodiumsulfonyl-β-D-galactopyranosyloxy)-2-(N-15Z-
tetracosenoylamino)octadecane-3,4-diol (11). Sulfatide 11 was isolated as a 
white solid (5.3 mg, 58%): mp 211.4−212.4 oC; [α]25D  8.33 (c 0.50, CHCl3/MeOH, 
3:2); IR (neat) 3367 (br), 2917, 2850, 1643, 1466, 1224, 1066, 812 cm-1; 1H NMR 
(400 MHz, CDCl3/CD3OD, 3:2) δ  5.37–5.30 (m, 2H), 4.34 (d, J = 7.7 Hz, 1H), 3.81 
(dd, J = 4.9, 3.1 Hz, 1H), 3.76–3.56 (m, 2H), 3.70–3.64 (m, 2H), 3.59–3.57 (m, 2H), 
2.20 (t, J = 7.6 Hz, 2H), 2.04–2.00 (m, 4H), 1.64–1.50 (m, 4H), 1.44–1.26 (m, 56H), 
0.87 (t, J = 6.4 Hz, 6H); 13C NMR (100 MHz, CDCl3/CD3OD) δ 175.8, 130.8, 104.2, 
81.3, 75.8, 74.9, 73.2, 70.5, 70.1, 68.3, 62.3, 51.2, 37.4, 37.3, 32.9, 32.8, 30.7, 
30.7, 30.6, 30.6, 30.5, 30.4, 30.4, 30.3, 30.2, 30.2, 28.1, 27.0, 26.9, 23.6, 14.8; 
HRMS (TOF) m/z calcd for C48H90NO12S [M  –Na]+ 906.6340, found 906.6339. 
 
(2S,3S,4R)-1-(3-O-Sodiumsulfonyl-β-D-galactopyranosyloxy)-2-(N-15Z,18Z-
tetracosadienoylamino)octadecan-3,4-diol (12). Sulfatide 12 was isolated as an 
off white solid (8.0 mg, 48%): mp 172.0−173.0 oC;  [α]25D  11.15 (c 0.49, 
CHCl3/MeOH, 3:2); IR (neat) 3400 (br), 2917, 2850, 1637, 1467, 1226, 1061 cm-1; 
1H NMR (500 MHz, CDCl3/CD3OD, 3:2) δ  5.41–5.30 (m, 4H), 3.81–3.78 (m, 1H), 
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2.20 (t, J = 7.3 Hz, 2H), 2.07–2.02 (m, 4H), 1.59–1.52 (m, 4H), 1.38–1.26 (m, 49H), 
0.88 (m, 6H); 13C NMR (125 MHz, CDCl3/CD3OD, 3:2) δ 175.8, 131.1, 131.0, 128.9, 
128.9, 104.2, 81.3, 75.8, 74.8, 73.3, 70.5, 70.1, 68.3, 62.3, 54.4, 37.3, 37.3, 32.8, 
32.6, 32.4, 30.6, 30.5, 30.4, 30.3, 30.2, 28.1, 28.1, 26.9, 26.8, 26.5, 23.5, 23.4, 




fluorobenzylundecanoylamino)octadec-4-en-3-ol (13). Sulfatide 13 was isolated 
as a white solid (6.2 mg, 39%): mp 213.0−214.0 oC; [α]25D 1.68 (c 0.62, 
CH2Cl2/MeOH, 3:2); IR (neat) 3387 (br), 2919, 2850, 1634, 1511, 1466, 1225, 1065, 
820 cm-1; 1H NMR (400 MHz, CDCl3/CD3OD, 3:2) δ 7.12 (dd, J = 8.3, 5.7 Hz, 2H), 
6.93 (t, J = 8.8 Hz, 2H),  5.68 (dt, J = 15.2, 6.8 Hz, 1H), 5.43 (dd, J = 15.2, 7.3 Hz 
,1H), 4.33 (d, J = 7.7 Hz, 1H), 4.27–4.21 (m, 4H), 3.97–3.94 (m, 1H), 3.83–3.72 (m, 
3H), 3.59–3.54 (m, 2H),  2.56 (t, J = 7.6 Hz, 2H), 2.16 (t, J = 7.6 Hz, 2H), 2.00 (m), 
1.59–1.55 (m, 4H), 1.36–1.25 (m, 36H), 0.87 (t, J = 6.4 Hz, 3H); 13C NMR (100 
MHz, CDCl3/CD3OD, 3:2) δ 174.9, 162.1 (dC-F, J = 240.7 Hz), 139.5, 135.3, 130.7, 
130.6, 130.4, 128.6, 115.7 (dC-F, J = 20.9 Hz), 115.6, 81.4, 75.8, 72.7, 70.6, 69.7, 
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Na]+ m/z 802.4581, found 802.4552. 
 
(2S,3R,4E)-2-(N-13Z-dodecenoylamino)-1-(3-O-sodiumsulfonyl-β-D-
galactopyranosyloxy)octadec-4-en-3-ol (111). Sulfatide 111 was isolated as an 
off white solid (5.1 mg, 20%):  1H NMR (400 MHz, CDCl3/CD3OD, 3:2) δ 5.73–5.67 
(m, 1H), 5.44 (dd, J = 14.8, 7.3 Hz, 1H), 5.34 (br s, 2H), 5.00 (br s, 1H), 3.63–3.58 
(m, 4H), 2.17 (m, 2H), 2.02 (br s, 6H), 1.57 (br s, 2H), 1.27 (br s, 50H), 0.89–0.86 
(m, 6H); 13C NMR (100 MHz, CDCl3/CD3OD) δ 175.8, 135.3, 130.8, 130.4, 104.4, 
83.5, 75.8, 72.8, 70.6, 69.8, 68.4, 62.3, 54.5, 37.4, 37.4, 33.3, 32.8, 30.7, 30.6, 
30.5, 30.4, 30.4, 30.3, 30.2, 30.2, 28.1, 26.9, 23.5, 14.7; HRMS (TOF) m/z calcd for 
C46H86NO11S [M – Na]+ 860.5922, found 860.5923. 
 
(2S,3R,4E)-1-(3-O-Sodiumsulfonyl-β-D-galactopyranosyloxy)-2-(N-
elcosanoylamino)octadec-4-en-3-ol (112). Sulfatide 112 was isolated as an off 
white solid (6.3 mg, 74%): mp 189.2−191.4 oC; IR (neat) 2919, 2851, 1739, 1366, 
1217 cm-1; 1H NMR (400 MHz, CDCl3/CD3OD, 3:2) δ 7.70 (s, 1H), 5.70−5.67 (m, 
1H), 5.45−5.37 (m, 1H), 4.00−3.96 (m, 2H), 3.76−3.75 (m, 3H), 3.59−3.56 (m, 2H), 
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0.88−0.86 (m, 6H); 13C NMR (100 MHz, CDCl3/CD3OD, 3:2) δ 135.4, 130.3, 104.3, 
81.3, 75.7, 72.7, 70.5, 69.7, 68.3, 62.2, 55.3, 37.4, 33.3, 32.8, 30.6, 30.3, 30.2, 




tetracosenoylamino)hexadec-4-en-3-ol (122). Sufatide 122 was isolated as a 
white solid (5.2 mg, 52%): mp 183.1−184.6 oC;  [α]25D  2.99 (c 0.52 CHCl3/MeOH, 
3:2); IR (neat) 3351 (br), 2918, 2850, 1643, 1466, 1227, 1068 cm-1; 1H NMR (500 
MHz, CDCl3/CD3OD, 3:2) δ 5.69 (dt, J = 15.3, 6.7 Hz, 1H), 5.43 (dd, J = 15.2, 7.6 
Hz, 1H), 5.36−5.30 (m, 2H), 4.32 (d, J = 7.7 Hz, 1H), 4.26–4.25 (m, 2H), 4.21 (dd, J 
= 10.2, 4.0 Hz, 1H), 4.12–4.09 (m, 3H), 3.96–3.95 (m, 2H),  3.82 (dd, J = 11.6, 6.6 
Hz, 1H), 3.78–3.73 (m, 2H), 3.60–3.55 (m, 2H), 2.16 (t, J = 7.6 Hz, 2H), 2.03–2.01 
(m, 6H),  1.60−1.54 (m, 2H), 1.42–1.26 (m, 50H), 0.88 (t, J = 6.5 Hz, 6H); 13C NMR 
(125 MHz, CDCl3/CD3OD, 3:2) δ 175.7, 135.3, 130.8, 130.3, 104.4, 81.3, 75.7, 72.8, 
70.5, 69.8, 68.4, 62.4, 54.3, 37.4, 33.3, 32.8, 32.9, 30.6, 30.6, 30.5, 30.5, 30.5, 
30.4, 30.4, 30.3, 30.3, 30.2, 30.2, 28.1, 26.9, 23.6, 14.8; HRMS (TOF) m/z calcd for 
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(2,3,4,6-Tetra-O-acetyl-α-D-galactopyranoside)-1-trichloroacetimidate (17). 
DBU (43.0 µL, 0.29 mmol) was added drop-wise to a stirred solution of (2,3,4,6)-
tetra-O-acetyl-α/β-D-galactopyranoside) (40) (0.20 g, 0.57 mmol) in CH2Cl2 (1 mL) 
at 0 oC. After 5 min, Cl3CCN (0.12 mL, 1.15 mmol) was added drop-wise, the 
reaction was slowly warmed to rt and stirred overnight. The next day saturated 
aqueous NH4Cl (2 mL) was added, and the product was extracted using CH2Cl2 (3 X 
10 mL). The combined organic layers were dried (MgSO4) and concentrated. The 
crude product was purified by flash column chromatography on silica gel (petroleum 
ether/EtOAc, 85:15) to give 17 with its β-anomer (0.15 g, 53%) as a yellowish oil.37 
Peak assignments for 17: 1H NMR (400 MHz, CDCl3) δ 8.66 (s 1H), 6.60 (d, J = 3.4 
Hz, 1H), 5.56 (dd, J = 3.0, 1.0 Hz, 1H), 5.41 (app d, J = 3.1 Hz, 1H), 5.38 (app dd, J 
= 3.5 Hz, 1H), 4.44 (app dd, J = 6.5, 6.5 1H), 4.12 (dd, J = 11.3, 6.6, Hz, 1H), 4.08 
(dd, J = 11.3, 6.6, Hz, 1H), 2.17 (s, 3H), 2.02 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 170.5, 170.3, 170.3, 170.2, 161.2, 93.8, 69.2, 67.7, 67.6, 
67.1, 61.5, 20.9, 20.8, 20.8, 20.8.  
 
(2S,3R,4E)-2-Azido-3-(O-benzoyl)octadec-4-en-1-ol (24). AcCl (0.75 mL, 10.5 
mmol) was added drop-wise to MeOH (19 mL) at 0 oC. (2S,3R,4E)-2-azido-(3- 
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Et2O (19 mL) was added to the in situ generated HCl solution.39 The reaction 
solution was stirred for 2 d. Saturated aqueous NaHCO3 was added. The two layers 
were separated, and the aqueous layer was extracted with CH2Cl2 (3 X 25 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated. The crude 
product was purified by flash column chromatography on silica gel (petroleum 
ether/EtOAc, 90:10) to give 24 (0.15 g, 62%) as slightly yellow oil.:49 1H NMR (400 
MHz, CDCl3) δ 8.07−8.05 (m, 2H), 7.60−7.56 (m, 1H), 7.45 (t, J = 7.8 Hz, 2H), 
6.01−5.91 (m, 1H), 5.64−5.58 (m, 2H), 3.82−3.73 (m, 2H), 3.63 (ddd, J = 11.6, 6.9, 
4.6 Hz, 1H), 2.11−2.03 (m, 3H),  1.42−1.35 (m, 2H), 1.32−1.25 (m, 20H), 0.88 (t, J = 
7.0 Hz, 3H).13C NMR (100 MHz, CDCl3) δ 165.7, 139.0, 133.5, 130.0, 130.0, 128.7, 




Tetra-O-acetyl-α/β-D-galactopyranoside)-1-trichloroacetimidate (17) (0.12 mg, 0.25 
mmol) and (2S,3R,4E)-2-azido-3-(benzoyloxy)octadec-4-en-1-ol (24) (0.11 g, 0.26 
mmol) were dissolved in dry CH2Cl2 (7 mL), and the solution was stirred in the 
presence of 4Å MS (100 mg) at rt for 30 min. BF3•OEt2 in dry CH2Cl2 (18 µL in 0.5 
mL) was then added drop-wise at 0 oC. The reaction was slowly warmed to rt and 
stirred for 4 h. The reaction mixture was diluted with petroleum ether (5 mL) and 
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organic layer was separated, and the aqueous phase was extracted with CH2Cl2 (3 
X 10 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated. Purification by flash column chromatography on silica gel (petroleum 
ether/EtOAc, 80:20) gave 25 (8.1 mg, β-anomer) as a slightly yellowish oil:34 1H 
NMR (500 MHz, CDCl3) δ 8.04 (d, J = 7.7 Hz, 2H), 7.55 (t, J = 7.3 Hz, 1H), 7.43 (t, J 
= 7.5 Hz, 2H), 5.92 (dt, J = 14.8, 6.8 Hz, 1H), 5.62−5.52 (m, 2H), 5.37−5.36 (m, 1H), 
5.22 (dd, J = 10.2, 8.0 Hz, 1H), 5.01 (dd, J = 10.4, 3.2 Hz, 1H), 4.50 (d, J = 7.9 Hz, 
1H), 4.13−4.07 (m, 2H), 3.92−3.88 (m, 3H), 3.60−3.56 (m, 1H), 2.13 (s, 4H), 2.09 (s, 
4H), 2.00 (s, 4H), 1.97 (s, 4H),  1.38−1.34 (m, 2H), 1.45 (br s, 18H), 0.86 (t, J = 7.0 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 170.5, 170.4, 170.3, 169.5, 165.3, 139.2, 
133.4, 130.1, 129.9, 128.6, 122.9, 101.2, 74.9, 71.0, 68.7, 68.1, 67.1, 63.7, 61.4, 
32.5, 32.1, 29.8, 29.7, 29.6, 29.5, 29.3, 28.9, 22.8, 20.9, 20.8, 20.8, 20.7, 14.3; 
trans-esterification sphingosine product 68: 1H NMR (500 MHz, CDCl3) δ 8.07−8.05 
(m, 2H), 7.60−7.56 (m, 1H), 7.46 (t, J = 8.0 Hz, 2H), 5.96 (dt, J = 14.4, 6.8 Hz, 1H), 
5.61−5.55 (m, 2H), 4.23 (dd, J = 11.6, 4.5 Hz, 1H), 4.13 (dd, J = 11.5, 7.9 Hz, 1H), 
3.98 (ddd, J = 8.5, 4.4, 4.4 Hz, 1H), 2.11 (s, 3H), 2.10−2.07 (m, 2H), 1.41−1.35 
(quin, 2H), 1.32−1.24 (m, 20H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
δ 170.7, 165.4, 139.3, 133.5, 130.0, 128.7, 122.9, 74.8, 63.4, 63.2, 32.6, 32.1, 29.9, 
29.8, 29.6, 29.6, 29.3, 28.9, 22.9, 20.9, 14.3. 
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(2S,3S,4R)-1-(β-D-galactopyranosyloxy)-2-(N-tetracosanoylamino)octadecane-
3,4-diol (36). p-Nitrophenyltetracosanoate (42) (0.03 g, 0.07 mmol) was added to a 
solution of (2S,3S,4R)-2-amino-1-(β-galactopyranosyloxy)octadecane-3,4-diol (60) 
(30.0 mg, 0.06 mmol) in pyridine (1 mL). The mixture was stirred in a preheated oil 
bath at 40 oC overnight. The reaction was concentrated and purified by flash column 
chromatography on silica gel (CH2Cl2/MeOH, 95:5) to give 36 as a white solid (15.7 
mg, 35%): mp 198.7−199.8 oC; [α]25D  10.20 (c 0.49, CHCl3/MeOH, 3:2); IR (neat) 
3304, 2915, 2849, 1625, 1468, 1077, 718 cm-1; 1H NMR (400 MHz, CDCl3/MeOD, 
3:2) δ  4.25–4.12 (m, 1H), 3.87–3,86 (m, 1H),  3.82 (dd, J = 11.6, 6.7 Hz, 2H), 3.75–
3.69 (m, 2H), 3.61–3.47 (m, 5H), 2.20 (t, J = 7.5 Hz, 2H), 1.68–1.52 (m, 4H), 1.44–
1.27 (m, 64H), 0.88 (t, J = 6.5 Hz, 6H); 13C NMR (100 MHz, CDCl3/MeOD, 3:2) δ 
175.6, 104.8, 76.3, 75.4, 74.5, 73.3, 72.4, 70.2, 70.1, 51.5, 37.4, 33.2, 32.8, 31.3, 
30.7, 30.6, 30.6, 30.5, 30.3, 30.3, 30.2, 26.8, 26.8, 23.5, 14.7; HRMS (TOF) m/z 



























	   76	  
(N-tetracosanoylamino)octadecane-1-ol (38) (0.28 g, 0.30 mmol) were azeotroped 
in toluene (3 x 10 mL). The mixture was then dissolved in dry CH2Cl2 (27 mL) under 
N2, followed by the addition of activated 4Å MS (0.20 g). The mixture was cooled to 
−40 oC and (NIS) (0.08 g, 0.34 mmol) and AgOTf (0.03 g, 0.10 mmol) were then 
added. The mixture was stirred at −20 oC for 5 h. The generated magenta mixture 
was warmed to rt. Et3N (0.5 mL) was added. The solution was filtered through a pad 
of celite, the celite was further washed with CH2Cl2 (20 mL) and the filtrate was 
concentrated. Purification by flash column chromatography on silica gel (petroleum 
ether/EtOAc 80:20) afforded 37 (83 mg, 23%) as a colorless oil: 1H NMR (400 MHz, 
CDCl3) δ 8.02−7.98 (m, 4H), 7.60–7.52 (m, 2H), 7.47−7.39 (m, 4H), 6.17 (d, J = 9.1 
Hz, 1H), 5.56 (dd, J = 8.0, 3.4 Hz, 1H), 5.35−5.32 (m, 1H), 5.30–5.28 (m, 1H), 5.07 
(dd, J = 10.4, 7.9 Hz, 1H), 4.93 (dd, J = 10.4, 3.4 Hz, 1H), 4.60 (dddd, J = 9.2, 9.2, 
3.6, 3.6 Hz, 1H), 4.40 (app d, J = 7.8 Hz, 1H), 3.97−3.89 (m, 2H), 3.82−3.72 (m, 
3H), 2.23 (t, J = 7.5 Hz, 2H), 2.22−2.17 (m, 1H), 2.10 (m, 3H), 2.03−1.99 (m, 2H), 
2.03−2.00 (m, 1H), 1.97 (m, 3H), 1.96 (m, 3H), 1.94 (m, 3H), 1.90−1.82 (m, 2H), 
1.72−1.60 (m, 2H), 1.24−1.20 (m, 60H), 0.88−0.85 (m, 6H); 13C NMR (100 MHz, 
CDCl3) δ 173.2, 170.4, 170.2, 169.7, 166.5, 165.2, 133.4, 133.2, 130.2, 130.0, 
128.7, 128.6, 100.9, 74.0, 73.1, 70.9, 70.9, 68.9, 67.1, 67.0, 61.1, 48.4, 36.9, 32.1, 
29.9, 29.8, 29.8, 29.7, 29.7, 29.6, 29.6, 29.5, 25.8, 25.8, 22.9, 20.9, 20.8, 20.7, 
14.3. 
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(2S,3S,4R)-3,4-Dibenzoyloxy-2-(N-tetracosanoylamino)octadecan-1-ol (38). 
pTsOH•H2O (0.77 g, 4.1 mmol) was added to solution of (2S,3R,4S)-3,4-
dibenzoyloxy-2-(N-tetracosanoylamino)-1-triphenylmethoxyoctadecane (46) (2.42 g, 
2.03 mmol) in a mixture of MeOH/CH2Cl2 (15:32 mL).50 After 6 h TLC showed 
complete consumption of starting material. The reaction was quenched with 
saturated aqueous NaHCO3 (25 mL), and the product was extracted with CH2Cl2 (3 
X 50 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated to give 38 (2.42 g, 63%) as a colorless solid: mp 45.6−46.5 oC; [α]25D 
1.43 (c 0.85, CH2Cl2); IR (neat) 3350 (br), 2920, 2851, 1720, 1451, 1271, 1112, 710 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 7.2 Hz, 2H), 7.97 (d, J = 7.2 Hz, 2H), 
7.59−7.52 (m, 2H), 7.46−7.39 (m, 4H), 6.08 (d, J = 8.2 Hz, 1H), 5.22 (ddd, J = 8.6, 
4.4, 4.4 Hz, 1H), 4.69 (ddd, J = 7.2, 7.2, 7.2 Hz, 1H), 4.39−4.43 (m, 2H), 3.99−3.95 
(m, 1H), 3.52 (d, J = 5.3 Hz, 1H), 2.28−2.16 (m, 2H), 1.96−1.82 (m, 2H), 1.61 (quin 
J = 7.2 Hz, 2H), 1.41−1.12 (m, 64H), 0.87 (t, J = 6.4 Hz, 6H); 13C NMR (100 MHz, 
CDCl3) δ 174.0, 167.1, 167.0, 133.5, 130.0, 129.9, 129.7, 128.7, 128.6, 75.8, 73.2, 
64.2, 51.4, 37.0, 32.1, 29.9, 29.8, 29.7, 29.7, 29.6, 29.5, 29.4, 25.9, 25.7, 22.9, 
14.3; HRMS (ESI) calcd for C56H94NO6 [M
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(2,3,4,6)-Tetra-O-acetyl-1-hydroxyl-α/β-D-galactopyranose (40). BnNH2 (0.98 
mL, 3.1 mmol) was added to a solution of (1,2,3,4,6)-penta-O-acetyl-β-D-
galactopyranoside (39) (1.00 g, 2.56 mmol) in dry THF (15 mL) at rt. The solution 
was allowed to stir overnight. The next day the reaction was cooled to 0 oC and then 
neutralized to pH 7 with 1N HCl. The product was extracted with CH2Cl2 (3 X 25 
mL). The combined organic extracts were dried (MgSO4), filtered and concentrated. 
The crude product was purified using flash column chromatography on silica gel 
(petroleum ether/EtOAc, 70:30) to give 40 as a colorless oil (0.59 g, 64%, 4:1): 1H 
NMR (400 MHz, CDCl3) δ 5.47 (dd, J = 3.5, 3.5 Hz, 1H), 5.43 (app d, J = 2.3 Hz, 
1H), 5.38 (dd, J = 10.8, 3.3 Hz, 1H) 5.10 (dd, J = 10.8, 3.2 Hz, 0.8H), 5.05−5.03 (m, 
0.2H), 4.68 (dd, J = 7.9, 7.9, Hz, 0.2H), 4.44 (dd, J = 6.5, 6.5, Hz, 0.8H), 4.13 (dd, J 
= 12.9, 8.6, Hz, 0.8H), 4.09−4.02 (m, 1.2H), 3.94 (app d, J = 6.8 Hz, 0.2H), 3.91 
(app d, J = 3.3 Hz, 0.8H), 2.13 (s, 0.6H), 2.11 (s, 2.4H), 2.06 (s, 3H), 2.02 (s, 3H), 
1.96 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.8, 170.7, 170.5, 170.3, 90.7, 68.5, 
68.4, 67.4, 66.2, 61.9, 20.9, 20.8, 20.8, 20.8. 
p-Nitrophenyl ester preparation 
p-Nitrophenol (1.1 equiv) and DMAP  0.2 equiv.) were added to a flask charged with 
carboxyl acid (1.0 equiv.) in dry CH2Cl2 (0.014 M) and stirred for 15 min. DCC (1.04 
equiv) in dry CH2Cl2 (0.12 M) was then added slowly. The solution was allowed to 
stir at rt overnight. The reaction was filtered through a pad of celite and the celite 
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Purification via flash chromatography on silica gel (petroleum ether/EtOAc, 95:5) 
yielded PNP-activated esters. 
  
p-Nitrophenyltetracosanoate (42). Compound 42 was isolated as a white solid 
(0.29 g, 73%): mp 81.9−82.2 oC; IR (neat) 2916, 2849, 1752, 1535, 1347, 1203, 
1136, 1107, 927, 868, 717 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.29−8.25 (m, 2H), 
7.29−7.26 (m, 2H), 2.59 (t, J = 7.4 Hz, 2H), 1.76 (quin, J = 7.3 Hz 2H), 1.45−1.26 
(m, 40H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.5, 155.8, 
145.4, 125.4, 122.6, 34.6, 32.2, 29.9, 29.8, 29.7, 29.6, 29.4, 29.3, 25.0, 22.9, 14.3; 
HRMS (ESI) calcd for C30H52NO4 [M
 
+ H]+ m/z 490.3891, found 490.3921. 
 
p-Nitrophenyl 15Z-tetracosenoate (77). Compound 77 was isolated as a colorless 
solid (0.50 g, 73%): mp 35.5−36.0 oC; IR (neat) 2916, 2850, 1753, 1593, 1536, 
1490, 1471, 1350, 1203, 1138, 926, 868, 717 cm-1; 1H NMR (400 MHz, CDCl3) δ 
8.18 (d, J = 8.7 Hz, 2H), 7.19 (d, J = 8.6 Hz, 2H), 5.27 (dt, J = 15.3, 11.6 Hz, 2H), 
2.51 (t, J = 7.3 Hz, 2H), 1.96−1.91 (m, 4H), 1.68 (quin, J = 7.0 Hz, 2H), 1.34−1.19 
(m, 32H), 0.80 (t, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.4, 155.7, 
145.4, 130.1, 130.0, 125.3, 122.6, 34.5, 32.1, 30.0, 29.8, 29.8, 29.7, 29.6, 29.5, 
29.4, 29.2, 27.4, 24.9, 22.9, 14.3; HRMS (ESI) calcd for C30H50NO4 [M
 
+ H]+ m/z 
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p-Nitrophenyl 15Z,18Z-tetracosedienoate (84). Compound 84 was afforded as a 
colorless solid/oil (29.0 mg, 73%): IR (neat) 2922, 2852, 1768, 1593, 1524, 1490, 
1464, 1345, 1208, 1098, 863 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.18 (d, J = 9.0 Hz, 
2H), 7.19 (d, J = 8.9 Hz, 2H), 5.33−5.21 (m, 4H), 2.71−2.64 (m, 2H), 2.52 (t, J = 7.4 
Hz, 2H), 1.97 (dt, J = 6.2, 6.2 Hz, 5H), 1.68 (quin, J = 7.2 Hz, 2H), 1.36−1.20 (m, 
26H), 0.81 (t, J = 6.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.4, 155.7, 145.4, 
130.3, 128.1,125.3, 122.6, 34.5, 31.7, 29.8, 29.8, 29.6, 29.5, 29.4, 29.2, 27.6, 27.4, 
25.8, 24.9, 22.8, 14.2; HRMS (ESI) calcd for C30H48NO4 [M
 
+ H]+ m/z 486.3578, 
found 486.3570. 
 
p-Nitrophenyl 11-(p-fluorophenyl)undecanoate (88). Pd/C (0.16 g, 10% wt) and 
AcOH (0.3 mL) were added to a solution of 11-(p-fluorophenyl)-10-undecanoic acid 
(87) (0.23 g, 0.82 mmol) in MeOH (5.5 mL). The reaction was purged with H2 for 10 
min and then allowed to stir under H2 until TLC showed complete consumption of 
starting material. The suspension was filtered through a pad of celite, and the celite 
was washed with CHCl3/MeOH (1:1, 6 mL). The filtrate was concentrated under 
reduced pressure. The crude product was purified via flash column chromatography 
on silica gel (petroleum ether/EtOAc, 90:10) to give p-nitrophenyl-11-(p-
fluorophenyl)undecanoic acid (0.17 g) as a white solid: 1H NMR (300 MHz, CDCl3) δ 
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(t, J = 7.4 Hz, 2H), 1.68−1.53 (sept, J = 7.4 Hz, 4H), 1.35−1.28 (m, 12H); The 11-(p-
fluorophenyl)undecanoic acid  was then activated to its corresponding PNP ester 
following standard conditions to give clean ester 88 as a colorless solid/oil (72 mg, 
33%): IR (neat) 2923, 2851, 1758, 1592, 1527, 1508, 1488, 1343, 1200, 1141, 
1103, 925, 818, 716 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 9.0 Hz, 2H), 
7.27 (d, J = 4.1 Hz, 2H), 7.11 (dd, J = 8.1, 5.6 Hz, 2H), 6.95 (t, J = 8.7 Hz, 2H), 
2.61−2.55 (m, 4H), 1.75 (quin, J = 7.2 Hz, 2H), 1.58 (quin, J = 8.0 Hz, 2H), 
1.44−1.30 (m, 12H); 13C NMR (100 MHz, CDCl3) δ 171.5, 161.3 (dC-F, J = 241.4 Hz), 
155.7, 145.5, 138.6, 129.9, 129.8, 125.4, 122.6, 115.13 (dC-F, J = 20.8 Hz), 35.3, 
34.5, 31.8, 29.7, 29.6, 29.6, 29.4, 29.4, 29.2; HRMS (ESI) calcd for C23H29FNO4 [M
 
+ H]+ m/z 402.2075, found 402.2109. 
 
p-Nitrophenylelcosanoate (114). Compound 114 was isolated as a white solid 
(0.18 g, 71%): mp 73.1−73.4 oC; IR (neat) 2916, 2849, 1752, 1535, 1472, 1347, 
1203, 1136, 1104, 927, 856, 718 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.27 (dt, J = 
10.1, 3.1 Hz, 2H), 7.27 (dt, J = 10.2, 3.1 Hz, 2H), 2.59 (t, J = 7.4 Hz, 2H), 1.76 (quin, 
J = 7.4 Hz 2H), 1.45−1.26 (m, 32H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 171.5, 155.8, 145.5, 125.4, 122.6, 34.6, 32.1, 29.9, 29.8, 29.7, 29.6, 29.4, 
29.3, 25.0, 22.9, 14.3; HRMS (ESI) calcd for C26H44NO4 [M
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p-Nitrophenylerucicoate (116). Compound 116 was afforded as a colorless 
solid/oil (0.497 g, 73%): IR (neat) 2918, 2850, 1753, 1592, 1533, 1489, 1345, 1203, 
1136, 927, 854, 719 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 9.0 Hz, 2H), 
7.20 (d, J = 9.1 Hz, 2H), 5.31−5.24 (m, 2H), 2.52 (t, J = 7.5 Hz, 2H), 1.97−1.92 (m, 
4H), 1.68 (quin, J = 7.3 Hz 2H), 1.36−1.26 (m, 28H), 0.81 (t, J = 7.0 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 171.5, 155.8, 145.5, 130.1, 130.2, 125.4, 122.6, 34.6, 
32.1, 30.0, 29.8, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 25.0, 22.9, 14.3; HRMS (ESI) 
calcd for C28H46NO4 [M
 
+ H]+ m/z 460.3421, found 460.3438. 
 
p-Nitrophenyl (2S)-O-acetyl tetracosanoate (120). Compound 120 was afforded 
as a white solid (35 mg, 56%): mp 63.9−62.9 oC; [α]25D  −14.23 (c 0.86, CH2Cl2); IR 
(neat) 2914, 2849, 1768, 1734, 1518, 1472, 1347, 1251, 1202, 1159, 922, 871, 714 
cm-1; 1H NMR (500 MHz, CDCl3) δ 8.29−8.26 (m, 2H), 7.29 (dt, J = 5.5, 3.5 Hz, 2H), 
5.13 (dd, J = 6.5, 6.5 Hz, 1H), 2.18 (s, 3H), 2.02−1.97 (m, 2H), 1.52 (quin, J = 7.1 
Hz, 2H), 1.41−1.26 (m, 38H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
171.0, 168.6, 155.1, 145.8, 125.5, 122.5, 72.6, 32.1, 31.1, 29.9, 29.8, 29.8, 29.7, 
29.6, 29.3, 25.3, 22.9, 20.7, 14.3; HRMS (ESI) calcd for C32H54NO6 [M
 
+ H]+ m/z 
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(2S,3R,4S)-2-(N-Tetracosanoylamino)octadecan-1,3,4-triol (44). p-Nitrophenyl 
tetracosanoate (42) (2.62 g, 5.34 mmol) was added to a solution of ribo-
phytosphingosine (43) (1.41 g, 4.45 mmol) in dry pyridine (56 mL). The mixture was 
stirred in a preheated oil bath at 50 oC overnight. The solvent was evaporated, and 
the solid residue was purified via flash column chromatography on silica gel 
(CH2Cl2/MeOH, 95:5) to yield 44 as a white solid (2.88 g, 97%): mp 119.0−119.5 oC; 
[α]25D  2.43 (c 0.16, CHCl3/MeOH, 3:2); IR (neat) 2916, 2849, 1750, 1490, 718 cm-1; 
1H NMR (400 MHz, CDCl3/CD3OD, 3:2) δ 4.09 (dd, J = 9.2, 4.9 Hz, 1H), 3.78 (dd, J 
= 11.3, 4.4 Hz, 1H), 3.71 (dd, J = 11.3, 5.0 Hz, 1H),  3.56−3.54 (m, 2H), 2.22 (t J = 
7.4 Hz, 2H), 1.64−1.58 (m, 4H), 1.54−1.52 (m, 2H), 1.48−1.27 (m, 62H), 0.88 (t, J = 
7.0 Hz, 6H); 13C NMR (100 MHz, CDCl3/CD3OD, 3:2) δ 175.7, 76.6, 73.5, 62.3, 
53.1, 37.4, 33.8, 32.8, 30.7, 30.6, 30.4, 30.3, 30.2, 26.8, 23.5, 14.7; HRMS (ESI) 
calcd for C42H86NO4 [M
 
+ H]+ m/z 668.6551, found 668.6562. 
 
(2S,3S,4R)-2-(N-tetracosanoylamino)-1-triphenylmethoxyoctadecan-3,4-diol 
(45). Trityl bromide (2.08 g, 6.45 mmol) was added to a mixture of (2S,3S,4R)-2-(N-
teracosanoylamino)octadecan-1,3,4-triol (44) (2.88 g, 4.30 mmol) in dry pyridine (18 
mL).50 The mixture was stirred in preheated oil bath at 50 oC overnight. The solvent 















	   84	  
flash chromatography on silica gel (petroleum ether/EtOAc, 90:10) to provide 45 
(2.96 g, 76%) as a clear, crystalline solid: mp 41.9−42.3 oC; [α]25D 12.0 (c 1.35, 
CH2Cl2); IR (neat) 2917, 2850, 1656, 1467, 1069, 906, 702 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.41−7.39 (m, 6H), 7.32−7.29 (m, 6H), 7.26−7.23 (m, 3H), 6.03 (d, J 
= 8.3 Hz, 1H), 4.25 (dddd, J = 8.3, 4.2, 4.2, 4.2 Hz, 1H), 3.59−3.54 (m, 1H), 3.50 
(dd, J = 9.8, 3.6 Hz, 1H), 3.42−3.77 (m, 1H),  3.34 (dd, J = 9.8, 4.6 Hz, 1H),  3.11 (d, 
J = 8.4 Hz, 1H), 2.24 (d, J = 7.7 Hz, 1H), 2.14 (t J = 7.4 Hz, 2H), 1.69−1.67 (m, 1H), 
1.60 (quin J = 7.2 Hz, 2H), 1.47−1.37 (m, 3H), 1.33−1.26 (m, 62H), 0.88 (t, J = 6.6, 
6H); 13C NMR (100 MHz, CDCl3) δ 173.4, 143.4, 128.7, 127.6, 128.1, 87.9, 75.8, 
73.4, 63.2, 50.7, 37.1, 33.5, 32.1, 29.9, 29.9, 29.7, 29.6, 29.6, 26.0, 26.0, 22.9, 
14.3; HRMS (ESI) calcd for C61H99NNaO4 [M
 
+ Na]+ m/z 932.7466, found 932.7453. 
 
(2S,3S,4R)-2-(N-Tetracosanoylamino)-3,4-dibenzoyloxy-1-triphenylmethoxy-
octadecane (46). BzCl (2.26 mL, 19.5 mmol) was added to a solution of 
(2S,3S,4R)-2-(N-tetracosanoylamino)-1-triphenylmethoxyoctadecan-3,4-diol (45) 
(2.96 g, 3.25 mmol) and DMAP (66 mg, 0.54 mmol) in pyridine (27 mL).50 The 
reaction mixture was allowed to stir overnight. Ice-cold H2O (50 mL) was added. 
The solution was extracted with CH2Cl2 (3 X 30 mL). The combined organic layers 
were dried (MgSO4), filtered and concentrated. The crude product was purified 
using flash column chromatography on silica gel (petroleum ether/EtOAc, 95:5) 
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2852, 1723, 1449, 1277, 1049, 703 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 
7.2 Hz, 2H), 7.88 (d, J = 7.2 Hz, 2H), 7.60−7.53 (m, 2H), 7.40 (dt, J = 7.4, 7.4 Hz, 
2H), 7.30−7.28 (m, 8H), 7.15−7.08 (m, 9H), 5.94 (d, J = 9.3 Hz, 1H), 5.78 (dd, J = 
9.0, 2.5 Hz, 1H), 5.34 (ddd, J = 10.0, 2.9, 2.9 Hz, 1H), 4.57 (dddd, J = 9.0, 9.0, 3.4, 
3.4 Hz, 1H), 3.33 (dd, J = 9.8, 3.6 Hz, 1H), 3.28 (dd, J = 9.7, 3.2 Hz, 1H), 2.23−2.11 
(m, 2H),  1.94−1.77 (m, 2H), 1.62 (q J = 6.9 Hz, 2H), 1.41−1.12 (m, 64H), 0.89−0.85 
(m, 6H); 13C NMR (100 MHz, CDCl3) δ 172.9, 166.6, 165.3, 143.7, 133.2, 133.1, 
130.6, 130.2, 130.0, 130.0 128.9, 128.6, 128.6, 128.0, 127.2, 87.2, 74.4, 73.4, 62.1, 
49.0, 37.2, 32.2, 29.9, 29.9, 29.8, 29.7, 29.7, 29.6, 29.6, 29.6, 25.9, 22.9, 14.3; 
HRMS (ESI) calcd for C75H107NNaO6 [M
 
+ Na]+ m/z, 1140.7991 found 1140.7941. 
 
(2,3,4,6)-tetra-O-acetyl-1-β-D-thiophenylglactopyranoside (47). BF3•Et2O (2.4 
mL, 17.9 mmol) was added drop-wise to a solution of thiophenol (1.58 mL, 15.37 
mmol) and penta-O-acetyl-D-galactose  (39) (2.0 g, 5.1 mmol) in CH2Cl2 (20 mL) at 0 
oC.  The reaction solution was slowly allowed to warm to rt and stirred overnight. 
The reaction mixture was diluted with CH2Cl2 (28 mL) and neutralized with saturated 
aqueous NaHCO3 (80 mL) at 0 oC. The layers were separated, and the aqueous 
layer was further extracted with CH2Cl2 (3 X 20 mL). The combined organic layers 
were dried (MgSO4), filtered and concentrated. Purification by flash chromatography 
on silica gel (petroleum ether/EtOAc, 80:20) afforded 47 (1.75 g, 85%) as slightly 
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(t, J = 3.5 Hz, 3H), 5.40 (d, J = 3.1 Hz, 1H), 5.23 (dd, J = 9.9, 9.9 Hz, 1H), 5.04 (dd, 
J = 9.9, 3.3 Hz, 1H), 4.71 (app dd, J = 10.0 Hz, 1H), 4.18 (dd, J = 11.4, 7.0 Hz, 1H), 
4.10 (dd, J = 11.4, 6.2 Hz 1H), 3.93 (app ddd, J = 6.6, 6.6 Hz, 1H), 2.10 (s, 3H), 
2.07 (s, 3H), 2.03 (s, 3H), 1.96 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.5, 170.3, 
170.2, 169.6, 132.7, 132.6, 129.0, 128.3, 86.7, 74.6, 72.2, 67.4, 67.4, 61.8, 67.4, 
67.4, 29.8, 21.0, 20.8, 20.8, 20.7. 
 
Phenyl-1-thio-β-D-galactopyranoside (49). (2,3,4,6)-tetra-O-acetyl-1-thiophenyl-β-
D-galactopyranoside (47) (1.15 g, 2.83 mmol) was dissolved in a mixture of 
MeOH/CH2Cl2 (11:11 mL). NaOMe (3.3 mL, 17 mmol, 0.5 M in MeOH) was added 
drop-wise to pH = 9. The mixture was stirred for 2 h at rt. The solution was then 
neutralized to pH = 7 using Dowex 50W x 2-100 (H+). The resin was filtered off, and 
the filtrate was concentrated to afford 49 as a yellowish solid (0.82 g).51 The crude 
product was used in the next step without purification. 
 
2,6-Dibenzoyloxy-3,4-O-isopropylidene-1-thiophenyl-β-D-galactopyranoside 
(50). 2,2-Dimethoxypropane (5.7 mL) and pTsOH•H2O (0.03 g) were added to a 
solution of phenyl-1-thio-β-D-galactopyranoside (49) (1.27 g, 5.37 mmol) in DMF 
(5.7 mL).52 The solution was stirred in a preheated oil bath at 80 oC for 1.5 h. The 
reaction was neutralized to pH 7 with saturatedNaHCO3 and filtered. The filtrate was 
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BzCl (1.5 g, 1.2 mL, 10.3 mmol). The solution was allowed to stir overnight. The 
next day, MeOH ( 5 mL) was added and the reaction mixture was concentrated. The 
syrup was dissolved in CH2Cl2 (10 mL) and washed with 2 M HCl (10 mL) and then 
saturated aqueous NaHCO3 (10 mL), dried (MgSO4), filtered and concentrated. The 
crude product was purified using flash column chromatography on silica gel 
(petroleum ether/EtOAc, 95:5) to yield 50 as  a white solid (1.08 g, 43%): mp 
145.3−145.5 oC; [α]25D 32.9 (c 1.33, CH2Cl2); IR (neat) 2886, 1711, 1451, 1368, 
1262, 1068, 1025, 874, 745, 705, 589, 551 cm-1;1H NMR (400 MHz, CDCl3) δ 8.08 
(d, J = 8.1 Hz, 4H),  7.63−7.56 (m, 2H), 7.49−7.43 (m, 6H), 7.17 (t, J = 7.4 Hz, 1H), 
7.07 (t, J = 7.7 Hz, 2H), 5.35 (dd, J = 10.0, 7.0 Hz, 1H), 4.81 (d, J = 10.0 Hz, 1H), 
4.74 (dd, J = 11.9, 3.6 Hz, 1H) 4.63 (dd, J = 11.9, 8.3 Hz, 1H), 4.42 (dd, J = 5.6, 5.6, 
Hz, 1H), 4.35 (dd, J = 5.4, 4.1 Hz, 1H), 4.24 (ddd, J = 5.6, 3.4, 3.4 Hz, 1H), 1.62 (s, 
3H), 1.38 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 166.5, 165.6, 133.9, 133.4, 132, 
130.1, 130.1, 130.0, 129.9, 129.0, 128.7, 128.6, 127.8, 111.3, 86.3, 74.7, 73.9, 
72.1, 64.3, 29.9, 27.9, 26.6; HRMS (ESI) calcd for C29H29O7S [M
 
+ H]+ m/z 
521.1629, found 521.1654. 
 
2,6-Dibenzoyloxy-1-thiophenyl-β-D-galactopyranoside-3,4-diol (51). 80% 
aqueous AcOH (9.3 mL) was added to a flask charged with 2,6-dibenzoyloxy-3,4-O-
isopropylidene-1-thiophenyl-β-D-galactopyranoside (50) (1.08 g, 2.07 mmol).52 The 
mixture was stirred in a preheated oil bath at 60 oC for 4 h. The reaction was 
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purified using flash column chromatography on silica gel (Petroleum ether/EtOAc, 
60:40) to give 51 (0.83 g, 84%) as a white solid: mp 160.4−161.9 oC; [α]25D 12.14 (c 
1.49, CH2Cl2); IR (neat) 3523, 2158, 1976, 1701, 1601, 1450, 1264, 1069, 690, 597 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 7.5 Hz, 4H), 7.56 (tt, J = 7.4, 7.4 Hz, 
2H), 7.45−7.38 (m, 6H), 7.18 (t, J = 7.4 Hz, 1H), 7.09 (t, J = 6.2 Hz, 2H), 5.37 (dd, J 
= 9.2, 9.2 Hz, 1H), 4.83 (d, J = 10.0 Hz, 1H), 4.66 (ddd, J = 12.1, 6.7, 5.3 Hz, 2H) 
4.15 (s, 1H), 3.92 (dd, J = 6.2, 6.2 Hz, 3H), 3.70 (d, J = 4.8 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ 166.9, 166.7, 133.5, 133.4, 132.0, 130.2, 129.9, 129.8, 129.7, 128.9, 
128.6, 127.8, 86.3, 76.6, 73.6, 72.0, 69.3, 64; HRMS (ESI) calcd for C26H25O7S [M
 
+ 
H]+ m/z 481.1316, found 481.1345. 
 
4-O-Acetyl-2,6-O-dibenzoyl-1-thiophenyl-β-D-galactopyranoside-3-ol (52). 
PTSA (5.0 mg, 0.26 mmol) was added to a solution of phenyl-2,6-dibenzoyloxy-1-
thio-β-D-galactopyranoside-3,4-diol (51) (0.10 g, 0.21 mmol) and triethyl 
orthoacetate (5  mL, 27 mmol) in toluene (5 mL).31 After 1 h, TLC showed complete 
consumption of starting material. Et3N (0.2 mL was added, followed by the addition 
of H2O (4 mL). The product was extracted with EtOAc (3 X 10 mL). The combined 
organic layers were washed with 1 M aqueous NaHCO3 (3 X 10 mL), H2O (2 X 10 
mL) and brine (10 mL). The EtOAc was dried (MgSO4), filtered and concentrated. 
The crude product was purified via flash column chromatography on silica gel to 
provide 52 and its inseparable C3-OAc regioisomer, ~10% (0.10 g) as a white fluffy 
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7.62−7.58 (m, 2H), 7.49−7.44 (m, 6H), 7.23 (tt, J = 6.3, 0.4 Hz, 1H), 7.14 (t, J = 7.7 
Hz, 2H), 5.52 (d, J = 3.1 Hz, 1H), 5.29 (dd, J = 9.7, 9.7 Hz, 1H), 4.90 (app d, J = 
10.0 Hz, 1H) 4.50 (dd, J = 11.6, 7.6 Hz, 1H), 4.43 (dd, J = 11.5, 5.2 Hz, 1H), 
4.14−4.02 (m, 2H), 2.78 (d, J = 6.0 Hz, 1H), 2.20 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 171.1, 166.9, 166.3, 133.8, 133.5, 133.0, 132.6, 130.2, 130.0, 129.1, 
128.7, 128.7, 128.2, 86.7, 75.4, 72.9, 71.9, 70.3, 63.0, 21.0. 
 
4-O-Acetyl-2,6-dibenzoyloxy-3-O-levulinoyl-1-thiophenyl-β-D-
galactopyranoside (53). Levulinic acid (0.03 mL, 0.3 mmol), EDC•HCl (0.05 g, 0.3 
mmol) and DMAP (6 mg, 0.05 mmol) were added to a solution of 4-O-acetyl-2,6-
dibenzoyloxy-1-thiophenyl-β-D-galactopyranoside-3-ol (52) (0.1 g, 0.2 mmol) in dry 
CH2Cl2 (2 mL).36 The reaction was wrapped in aluminum foil, and the solution was 
stirred until TLC showed complete consumption of starting material. The reaction 
was diluted with CH2Cl2 (10 mL) and then washed with H2O (10 mL) and saturated 
aqueous NaHCO3 (10 mL) successively. The organic phase was dried (MgSO4), 
filtered and concentrated. The crude product was purified using flash column 
chromatography on silica gel (petroleum ether/EtOAc, 80:20) to give 53 and its 
inseparable C-4 regiosiomer as a colorless oil (0.1 g): peak assignment for 53: 1H 
NMR (400 MHz, CDCl3) δ 8.04−8.00 (m, 4H), 7.59 (t, J = 7.2 Hz, 2H), 7.48−7.43 (m, 
6H), 7.23 (tt, J = 6.6, 1.4 Hz, 1H), 7.15 (t, J = 14.8 Hz, 2H), 5.61−5.52 (m, 2H), 5.28 
(dd, J = 10.0, 3.4 Hz, 1H), 4.52 (dd, J = 14.6, 3.2 Hz, 1H), 4.41−4.37 (m, 1H), 4.17 
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2.00 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 205.8, 171.9, 170.3, 166.1, 165.5, 
133.6, 133.5, 132.9, 132.5, 130.1, 129.9, 129.0, 128.7, 128.2, 87.2, 74.9, 72.4, 
68.0, 67.8, 62.6, 37.8, 29.6, 28.0, 20.9; HRMS (ESI) calcd for C33H33O10S [M
 
+ H]+ 




3,4-dibenzoyloxy-2-(N-tetracosanoylamino)octadecan-1-ol (38) (0.46 g, 0.48 mmol) 
and 4-O-acetyl-2,6-dibenzoyloxy-3-O-levulinoyl-1-thiophenyl-β-D-galactopyranoside 
(53) (0.20 g, 0.32 mmol) were azeotroped in toluene (3 x 10 mL). The mixture was 
then dissolved in dry CH2Cl2 (9 mL) under N2, followed by the addition of activated 
4Å MS (0.20 g). The mixture was cooled to −40 oC, and then NIS (0.10 g, 0.40 
mmol) and AgOTf (30 mg, 0.11 mmol) were added. The mixture was stirred at −20 
oC for 5 h. The generated magenta mixture was warmed to rt.  Et3N (0.5 mL) was 
added. The mixture was filtered through a pad of celite, the celite was washed with 
CH2Cl2 (20 mL) and the filtrate was concentrated. Purification by flash column 
chromatography on silica gel (petroleum ether/EtOAc 80:20) afforded 54 with a 
trace of an inseparable unknown product  (0.38 g) as a slightly yellowish oil. Peak 
assignment for 54: 1H NMR (500 MHz, CDCl3) δ 8.02−7.98 (m, 5H), 7.96 (d, J = 7.8 
Hz, 2H), 7.91 (d, J = 7.9 Hz, 2H), 7.58−7.51 (m, 4H), 7.46−7.38 (m, 7H), 6.10 (d, J = 
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5.19 (dd, J = 10.3, 3.3 Hz, 1H), 4.63−4.56 (m, 2H), 4.10−4.06 (m, 3H), 3.96 (dd, J = 
6.4, 6.4 Hz, 1H), 3.66 (dd, J = 9.9, 3.4 Hz, 1H), 2.64−2.54 (m, 2H), 2.47−2.41 (m, 
1H), 2.40−2.33 (m, 1H), 2.17−2.13 (m, 4H), 2.05−2.00 (m, 4H), 1.96−1.90 (m, 1H), 
1.87−1.76 (m, 3H), 1.51−1.40 (m, 2H), 1.38−1.19 (m, 60H), 0.88−0.85 (m, 6H); 13C 
NMR (125 MHz, CDCl3) δ 205.9, 173.1, 171.9, 170.3, 166.3, 165.9, 165.5, 165.1, 
133.6, 133.4, 133.3, 133.1, 130.3, 130.1, 130.0, 130.0, 129.9, 129.8, 129.5, 129.4, 
128.7, 128.6, 128.6, 128.5, 100.8, 73.9, 72.9, 71.0, 70.9, 69.8, 67.3, 67.1, 61.5, 
71.0, 70.9, 67.8, 67.3, 67.1, 48.0, 37.9, 36.6, 32.1, 29.9, 29.9, 29.9, 29.8, 29.7, 




dibenzoyloxy-2-(N-tetracosanoylamino)octadecan-1-ol (38) (0.42 g, 0.44 mmol) and 
2,6-dibenzoyloxy-3,4-O-isoproylidene-1-thiophenyl-β-.-galactopyranoside (50) (0.19 
g, 0.36 mmol) were azeotroped in toluene (3 x 10 mL). The mixture was then 
dissolved in dry CH2Cl2 (10 mL) under N2, followed by the addition of activated 4Å 
MS (0.20 g). The mixture was cooled to −40 oC; then (NIS) (0.10 g, 0.45 mmol) and 
AgOTf (0.03 g, 0.13 mmol) were added. The reaction mixture was stirred at −20 oC 
for 5 h. The magenta mixture was to warm to rt, followed by the addition of Et3N (0.5 
mL). The solution was filtered through a pad of celite, the celite was washed with 
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chromatography on silica gel (petroleum ether/EtOAc 95:5) afforded 57 (0.15 g, 
30%) as a slightly yellowish oil: 1H NMR (500 MHz, CDCl3) δ 8.05 (dd, J = 8.1, 0.9 
Hz, 2H), 8.01 (dd, J = 8.1, 1.0 Hz, 2H), 7.96 (dd, J = 8.0, 0.8 Hz, 1H), 7.63−7.58 (m, 
1H), 7.57−7.52 (m, 2H), 7.49−7.43 (m, 6H), 7.39 (t, J = 7.9 Hz, 2H), 7.28−7.23 (m, 
1H), 7.13 (t, J = 7.8 Hz, 2H), 6.15 (d, J = 9.6 Hz, 1H), 5.71 (dd, J = 10.2, 2.2 Hz, 
1H), 5.31−5.28 (m, 2H), 4.66 (dd, J = 5.1, 2.6 Hz, 1H), 4.53 (dd, J = 7.9, 2.5 Hz, 
1H), 4.49 (ddd, J = 8.1, 2.6, 2.6 Hz, 1H), 4.41 (dd, J = 12.1, 3.1 Hz, 1H), 4.26 (dd, J 
= 12.0, 8.2 Hz, 1H), 4.11 (dd, J = 7.7, 1.3 Hz, 1H), 3.74 (ddd, J = 8.3, 2.7, 2.7 Hz, 
1H), 3.57 (dd, J = 9.8, 2.2 Hz, 1H), 3.10 (dd, J = 9.8, 2.7 Hz, 1H), 2.29−2.17 (m, 
2H),  1.95−1.82 (m, 3H), 1.38 (s, 3H), 1.35−1.20 (m, 68H), 0.89−0.86 (m, 6H); 13C 
NMR (125 MHz, CDCl3) δ 172.9, 166.6, 166.3, 165.2, 134.9, 133.6, 133.2, 133.1, 
130.3, 130.2, 129.9, 129.9, 129.8, 128.9, 128.5, 128.5, 126.2, 120.3, 110.1, 97.2, 
74.2, 71.9, 71.4, 71.2, 70.4, 67.6, 64.3, 62.6, 32.1, 29.9, 29.9, 29.8, 29.8, 29.7, 
29.6, 29.5, 28.1, 26.1, 25.9, 24.6, 22.9, 14.4. 
 
(2S,3R,4E)-2-Amino1-(β-galactopyranosyloxy)octadec-4-en-3-ol (59). NaOMe 
(0.5 M, 4 mL, 2.10 mmol) was added to a solution of (2S,3R,4E)-2-azido-3-
benzoyloxy-1-(2,3,4,6-tetra-O-pivaloyl-β-galactopyranoside)octadec-4-ene (74) 
(0.32 g, 0.35 mmol) in a mixture of CH2Cl2/MeOH (2.8:2.8 mL). The reaction was 
stirred at rt for 1h. The reaction was neutralized with Dowex (H+ resin). The mixture 
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CHCl3/MeOH (1:1, 10 mL). The filtrate was concentrated and purified using flash 
column chromatography on silica gel (CH2Cl2/MeOH, 85:15) to give (2S,3R,4E)-2-
azido-1-(galactopyranosyloxy)octadec-4-en-3-ol as a white solid (0.12 g, 69%):42  1H 
NMR (500 MHz, CDCl3/CD3OD, 3:2) δ 6.21 (dt, J = 11.7, 6.6 Hz, 1H), 5.94 (dd, J = 
15.5, 7.3 Hz, 1H), 4.64–4.4 (m, 3H), 4.31 (s, 1H), 4.26–4.16 (m, 3H), 4.00 (dd, J = 
9.2, 9.2 Hz, 1H), 3.96–3.92 (m, 3H), 2.49 (dt, J = 6.8, 6.8 Hz, 2H), 1.84–1.80 (m, 
22H) 1.30 (t, J = 7.0 Hz, 3H). 13C NMR (125 MHz, CDC13/CD3OD = 3:2) δ 1361, 
129.0, 104.4, 76.0, 74.4, 72.9, 72.8, 72.1, 72.0, 69.9, 69.7, 69.6, 66.5, 62.3, 62.2, 
33.3, 32.8, 30.5, 30.5, 30.5, 30.4, 30.3, 30.2, 30.1, 29.9, 23.5, 14.7; (2S,3R,4E) -2-
azido-1-(galactopyranosyloxy)octadec-4-en3-ol (90 mg, 0.20 mmol) in a mixture of 
pyridine/H2O (1:1, 6 mL) was saturated with H2S for 15 min. The reaction was 
stirred for 48 h. The solvent was evaporated, and the crude product was purified by 
flash column chromatography on silica gel (CH2Cl2/MeOH, 80:20) to give 59 (0.71 g, 
80%) as yellowish brown crystals:42  [α]25D  −3.65 (c 1.0, (CHC13/MeOH, 3:2); IR  
3356, 2920, 2851, 1466, 1053 cm-1; 1H NMR (400 MHz, CDC13/CD3OD, 3:2) δ 6.12 
(dt, J = 14.7, 6.7 Hz, 1H), 5.78 (dd, J = 15.3, 7.3 Hz, 1H), 4.59 (d, J =  7.4 Hz, 1H), 
4.43 (dd, J =  6.6, 6.6 Hz, 1H), 4.29 (dd, J =  10.4, 7.2 Hz, 2H), 4.24 (app d, J =  2.1 
Hz, 1H), 4.19 (dd, J =  11.8, 7.0 Hz, 1H), 4.12–4.07 (m, 2H), 3.72–3.70 (m, 1H),  
2.41 (dt, J = 6.6, 6.6 Hz, 2H), 1.80–1.61(m, 22H), 0.84 (t, J = 7.0 Hz, 3H). 13C NMR 
(100 MHz, CDCl3/CD3OD, 3:2) δ 135.9, 129.2, 104.0, 75.7, 74.0, 73.2, 71.8, 69.7, 
62.3, 55.6, 33.0, 32.5, 30.3, 30.2, 30.1, 30.0, 29.8, 23.3, 14.6; HRMS (TOP) m/z 
calcd for C24H48NO7 (M+ + H) 462.3425, found 462.3405. 
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(2S,3S,4R)-2-Amino-1-(β-galactopyranosyloxy)octadecan-3,4-diol (60). NaOMe 
(3.9 mL, 1.97 mmol) was added to a solution of (2S,3S,4R)-2-azido-3,4-
dibenzoyloxy-1-(tetra-O-pivaloyl-β-galactopyranoside)octadecane (92) (296 mg, 
0.28 mmol) in a mixture of CH2Cl2/MeOH (3.4/3.4 mL).42 The solution was stirred at 
rt for 1.5 h. The reaction was acidified to pH 2 with dowex (H+ resin). The mixture 
was filtered through a pad of celite, and the celite was washed with 1:1 mixture of 
CHCl3 and MeOH (15 mL). The filtrate was concentrated and triturated with 
petroleum ether/EtOAc (85:15) to give (2S,3S,4R)-2-azido-1-(β-
galactopyranosyloxy)octadecan-3,4-diol (134 mg, 94%) as a white solid: [α]25D 18.88 
(c 6.643, CHCl3/MeOH, 3:2); IR (neat) 3355 (br), 2915, 2849, 2096, 1255, 1071, 
719 cm-1; 1H NMR (400 MHz, CDCl3/CD3OD, 3:2) δ  4.28 (d, J = 7.2 Hz, 1H), 4.13 
(dd, J = 10.6, 5.0 Hz, 1H), 3.96 (d, J = 10.3 Hz, 1H), 3.97 (s, 1H), 3.82 (dd, J = 11.5, 
6.5 Hz, 1H), 3.70–3.63 (m, 4H), 3.58–3.49 (m, 3H), 1.67–1.56 (m, 2H), 1.42–1.25 
(m, 24H), 0.87 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDC13/CD3OD, 3:2) δ 104.3, 
76.1, 74.9, 74.4, 72.7, 72.1, 69.9, 69.4, 63.1, 62.3, 33.2, 32.8, 30.6, 30.5, 30.5, 
30.2, 26.6, 23.5, 14.7; HRMS (ESI) calcd for C24H48N3O8 [M
 
+ H]+ m/z 506.3436, 
found 506.3511. 
The product was carried forward to reduction. (2S,3S,4R)-2-azido--1-(β-
galactopyranosyloxy)octadecan-3,4-diol (13 mg, 0.27 mmol) in a mixture of 
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h.42 The solvent was evaporated to give 60 (136 mg, crude) as a yellowish brown 
powder, which was carried forward without purification.  
 
(2S,3S,4R)-2-Azido-(3,4-dibenzoyloxy)octadecan-1-ol (61). AcCl (9.10 mL) was 
added drop-wise to MeOH (230 mL). (2S,3S,4R)-2-azido-(3,4-dibenzoyloxy-1-tert-
butyldiphenylsilyloxy)octadecane (91) (5.43 g, 6.99 mmol) in Et2O (230 mL) was the 
added drop-wise.39 The solution was stirred for 2 d. Saturated aqueous NaHCO3 
was added to neutralize the reaction to pH 7. The two layers were separated, and 
the aqueous layer was extracted with CH2Cl2 (3 X 100 mL). The combined organic 
layers were dried (MgSO4), filtered and concentrated. The crude product was 
purified by flash column chromatography on silica gel (petroleum ether/ EtOAc 
90:10) to give 61 (2.14 g, 69%) as a colorless solid:53 mp 54.0−55.0 oC; [α]25D 17.3 
(c 1.05, CHCl3); IR (neat) 2918, 2107, 1712, 1246, 1109, 1026, 706, 685 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.05 (d, J = 7.3 Hz, 2H), 8.01 (d, J = 7.3 Hz, 2H), 7.59 (t, 
J = 7.4 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 7.44 (t, J = 7.8 Hz, 2H), 7.40 (t, J = 7.8 Hz, 
2H), 5.61−5.56 (m, 2H), 4.03−4.00 (m, 1H), 3.88−3.79 (m, 2H), 3.11 (s, 1H), 
2.02−1.87 (m, 2H), 1.57−1.38 (m, 2H), 1.40−1.26 (m, 22H), 0.88 (t, J = 7.0 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 166.1, 165.7, 133.7, 133.3, 129.9, 129.8, 129.3, 
128.7, 128.5, 73.4, 73.0, 63.3, 62.2, 32.0, 29.7, 29.7, 29.7, 29.5, 29.5, 29.4, 25.5, 
22.8, 14.2; HRMS (ESI) calcd for C32H46N3O5 [M
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(2S,3S,4R)-2-Azido-1-(tert-butyldiphenylsilyloxy)octadecan-3,4-diol (62). NaN3 
(20.5 g, 31.5 mmol) was dissolved in a mixture of H2O (50 mL) and CH2Cl2 (85 mL) 
and cooled to 5 oC. Tf2O (10.5 mL, 63.0 mmol) was slowly added via syringe over 
15 min. The resulting mixture was vigorously stirred in a ice bath for 2 h. The in situ 
generated Tf2N3 in the CH2Cl2 was separated and the aqueous phase was then 
extracted with CH2Cl2 (2 X 24 mL). The combined organic layers were washed with 
saturated aqueous Na2CO3 (100 mL). This solution was added to a suspension of 
ribo-phytosphingosine (43) (10.0 g 31.5 mmol), K2CO3 (6.53 g, 47.3 mmol) and 
Cu2SO4 (79.0 mg, 0.32 mmol) in a mixture of H2O (100 mL) and MeOH (200 mL) at 
0 oC. The solution was allowed to stir at rt overnight. The next day, the solvents 
were evaporated. H2O (300 mL) was added to the solid residue and resulting 
mixture was allowed to stir for 2 h. The product was extracted with EtOAc (3 X 200 
mL). The combined organic layers were filtered through celite, and the filtrate was 
concentrated to yield (2S,3S,4R)-2-azidooctadecan-1,3,4-triol (14.6 g, crude) as a 
bluish solid.54 This product was carried forward to the next step without purification. 
TBDPSCl (13 mL, 51 mmol) was added drop-wise to 2S,3S,4R)-2-azidooctadecan-
1,3,4-triol (14.6 g, 42.6 mmol) and DMAP (0.26 g, 2.1 mmol) mixture in dry pyridine 
(47 mL) and CH2Cl2 (200 mL). The mixture was stirred for 48 h. The reaction was 
diluted with EtOAc (200 ml) and washed with brine (200 mL), dried  (MgSO4), 
filtered and concentrated under reduced pressure. The crude product was purified 
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provide 62 as slightly yellow oil (17.0 g, 70%):53  [α]25D 16.9 (c 1.13, CDCl3); IR 
(neat) 2923, 2853, 2097, 1428, 1111, 823, 738, 700, 503 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.70 (d, J = 7.2 Hz, 4H), 7.48−7.39 (m, 6H),  4.04 (dd, J = 11.0, 4.2 Hz, 
1H), 3.92 (dd, J = 10.9, 5.7 Hz, 1H), 3.69 (s, 2H), 3.37 (ddd, J = 5.4, 5.4, 5.4 Hz, 
1H), 2.49 (d, J = 3.1 Hz, 1H), 1.97 (s, 1H), 1.60−1.39 (m, 4H), 1.35−1.26 (m, 20H), 
1.09 (s, 9H), 0.88 (t, J = 7.0, 3H); 13C NMR (100 MHz, CDCl3) δ 135.9, 135.8, 
132.8, 132.7, 130.3, 128.1, 74.4, 72.6, 64.4, 63.6, 32.1, 32.1, 29.9, 29.9, 29.8, 29.8, 
29.6, 27.0, 25.9, 22.9, 19.3, 14.3; HRMS (ESI) calcd for C34H56N3O3Si [M
 
+ H]+ m/z 
582.4085, found  582.4119. 
 
(2S,3S,4R)-2-Azido-3,4-dioxathiolan)-1-(tert-butyldiphenylsilyloxy)octadecane 
(63). Et3N (5.2 mL, 55 mmol) and SOCl2 (2.64 mL, 36.4 mmol) were successively 
added to a solution of (2S,3S,4R)-2-azido-1-(tert-butyldiphenylsilyloxy)octadecan-
3,4-diol (62) (7.52 g, 18.2 mmol) in CH2Cl2 (70 mL) at 0 oC. The solution was stirred 
for 30 min. The reaction mixture was poured into brine solution (150 mL). The 
resulting mixture was separated and the aqueous layer was extracted with EtOAc 
(150 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated under reduced pressure. The cyclic sulfite residue was dried under 
high vacuum for 2 h. The resulting oil was dissolved in CCl4/CHCl3/H2O (1:1:1, 78 
mL). RuCl3•3H2O (0.132 mg, 0.645 mmol) and NaIO4 (8.06 g, 37.5 mmol) were 
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2 h. Sat. NaHSO4 (100 mL) and saturated aqueous NaSO3 (65 mL) were added to 
the mixture. The mixture was separated and the aqueous phase was extracted with 
EtOAc (100 mL). The combined organic layers were dried over (MgSO4), filtered 
and concentrated. The crude product was purified by flash column chromatography 
on silica gel (petroleum ether/EtOAc, 95:5) to give 63 (7.01 g, 72%) as colorless 
oil:55  1H NMR (400 MHz, CDCl3) δ 7.70−7.67 (m, 4H),  7.49−7.4 (m, 6H), 4.99 (ddd, 
J = 11.2, 5.1, 2.9  Hz, 1H), 4.94−4.91 (m, 1H), 4.05 (dd, J = 11.3, 2.3 Hz, 1H), 3.90 
(dd, J = 11.3, 5.2 Hz, 1H), 3.69 (ddd, J = 7.6, 5.1, 2.3 Hz, 1H), 1.99−1.89 (m, 1H), 
1.79−1.72 (m, 1H), 1.67−1.57 (m, 2H), 1.47−1.28 (m, 22H), 1.10 (s, 9H),  0.89 (t, J = 
7.0 Hz, 3H); 13H NMR (100 MHz, CDC13) δ 135.8, 135.8, 132.4, 132.2, 130.7, 
130.4, 128.2, 86.7, 80.1, 63.8, 59.4, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.2, 28.3, 
26.9, 25.4, 22.9, 19.4, 14.3. 
 
(2S,3R,4E)-2-Azido-1-(tert-butyldiphenylsilyloxy)octadecen-3-ol (64). TBAI 
(6.03 g, 16.3 mmol) was added to a solution of (2S,3S,4R)-2-azido-3,4-
dioxathiolan)-1-(tert-butyldiphenylsilyloxy)octadecane (63) (7.01 g, 10.9 mmol) in 
toluene (220 mL). DBN (1.0 mL, 12 mmol) was added drop-wise to the solution. The 
reaction mixture was refluxed for 2 h. The solution was allowed to cool to rt. A 
mixture of H2O/H2SO4(conc.)/THF (2.5 mL, 1.9 mL, 28 mL) was added to the solution 
and the reaction was stirred for 3 h. Saturated aqueous NaHCO3 (76 mL) was 
added to neutralized the reaction solution to pH 7, and the resulting mixture was left 
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was dried (MgSO4), filtered and concentrated. The crude product was purified by 
flash column chromatography on silica gel (petroleum ether/EtOAc, 95:5) to give 64 
(4.41 g, 71%) as a yellow oil:55  1H NMR (400 MHz, CDCl3) δ 7.71−7.67 (m, 4H), 
7.47−7.38 (m, 6H), 5.74 (dt, J = 14.9, 6.6 Hz, 1H), 5.47−5.42 (m, 7.2 Hz, 1H), 4.2 
(br s, 1H), 3.84−3.77 (m, 2H), 3.51 (ddd, J = 5.0, 5.0, 5.0  Hz, ,1H), 2.11 (d, J = 3.7  
Hz, 1H), 2.02 (dt, J = 6.8, 6.8 Hz, 1H), 1.36−1.27 (m, 22H), 1.08 (s, 9H), 0.89 (t,  J = 
7.0 Hz, 3H). 13C NMR (100 MHz, CDC13) δ 135.8, 135.6, 133.0, 130.1, 128.0, 73.0, 
67.1, 64.5, 42.8, 32.5, 32.1, 29.9, 29.8, 29.7, 29.6, 29.4, 29.2, 26.9. 
 
(2S,3R,4E)-2-Azido-(3-benzoyloxy-1-tert-butyldiphenylsilyloxy)octadec-4-ene 
(65). BzCl (2.3 mL, 20 mmol) was added to a solution of (2S,3R,4E)-2-azido-1-(tert-
butyldiphenylsilyloxy)octadecen-3-ol (64) (2.70 g, 4.91 mmol) and DMAP (90 mg, 
0.74 mmol) in pyridine (43 mL). The reaction mixture was stirred overnight. Ice-cold 
H2O (50 mL) was added, and the solution was extracted with CH2Cl2 (3 X 30 mL). 
The combined organic layers were dried (MgSO4), filtered and concentrated. Flash 
column chromatography purification of the crude product on silica gel (petroleum 
ether/EtOAc, 95:5) gave 65 (2.51 g, 79%) as a slightly yellow oil: 1H NMR (400 
MHz, CDC13) δ 8.01 (dd, J = 8.0, 0.9 Hz, 2H), 7.69−7.64 (m, 4H), 7.57 (dt, J = 6.9, 
1.6 Hz, 1H), 7.46−7.37 (m, 6H), 7.35−7.31 (m, 2H), 5.89 (dt, J = 15.1, 6.7 Hz, 1H), 
5.67 (dd, J = 7.9, 4.8 Hz, 1H), 5.51 (dd, J = 15.4, 8.0 Hz, 1H), 3.85−3.81 (m, 1H), 
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0.89 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDC13) δ 165.4, 138.7, 135.8, 133.3, 
133.1, 132.9, 130.3, 130.1, 130.0, 130.0, 128.6, 128.0, 128.0, 123.4, 74.5, 66.0, 
63.6, 32.5, 32.1, 29.9, 29.8, 29.6, 29.6, 29.3, 28.9, 26.9, 22.9, 19.3, 14.4.  
 
(2,3,4,6-Tetra-O-pivaloyl-α-D-galactopyranoside)-1-trichloroacetimidate (70). 
DBU (0.86 mL, 5.74 mmol) was added drop-wise to a stirred solution of (2,3,4,6)-
tetra-O-pivaloyl-α/β-D-galactopyranoside-1-ol (71) (2.00 g, 5.74 mmol) in CH2Cl2 (10 
mL). After 5 min, Cl3CCN (1.2 mL, 11 mmol) was added drop-wise. The reaction 
was stirred at 0 oC for 2 h. Saturated aqueous NH4Cl (50 mL) and the mixture was 
extracted with CH2Cl2 (3 X 30 mL). The combined organic layers were dried 
(MgSO4), filtered and concentrated. The crude product was purified by flash column 
chromatography on silica gel (petroleum ether/EtOAc, 95:5) to give 70 (1.87 g, 53%) 
as a slightly yellowish viscious oil:42 1H NMR (400 MHz, CDC13) δ 8.65 ( br s, 1H), 
6.60 (d, J = 3.5 Hz, 1H), 5.56–5.54 (m, 1H), 5.52−5.11 (m, 1H), 5.40 (dd, J = 10.6, 
3.6 Hz, 1H), 4.47 (app ddd, J = 6.5, 6.5 Hz, 1H), 4.08 (dd, J = 11.4, 7.4 Hz, 1H), 
4.03 (dd, J = 11.3, 6.0 Hz, 1H),1.25 (s , 9H), 1.13 (s , 9H), 1.12-1.11 (m, 18H).13C 
NMR (100 MHz, CDCl3) δ 178, 177.6, 177.4, 177.0, 160.9, 93.7, 91.1, 70.0, 67.9, 
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(1,2,3,4,6)-Penta-O-pivaloyl-β-D-galactopyranoside (72). A mixture of 
pyridine/CH2Cl2 (35/21 mL) was added to D-galactose (5.00 g, 27.8 mmol). Then 
pivaloyl chloride (27.0 mL, 222 mmol) was added drop-wise to the solution. The 
reaction was stirred at rt for 30 min. It was then placed in a preheated oil bath at 80 
oC for 5 d. Then, the solvent was removed using high vacuum. The residue was 
transferred into a separatory funnel, and H2O (100 mL) was added. The two layers 
were separated, and the organic layer was washed with H2O (2 X 60 mL) and 
saturated aqueous NaHCO3 (3 X 100 mL). The organic layer was dried (MgSO4), 
filtered and concentrated. The crude product was recrystallized from EtOH to give 
72  (9.01 g, 69%) as a white solid:40  1H NMR (400 MHz, CDC13) δ 5.71 (d, J = 8.3 
Hz, 1H), 5.44−5.43 (m,  1H), 5.36 (dd, J = 10.2, 8.1 Hz, 1H), 5.17 (dd, J = 10.4, 7.4 
Hz, 1H), 4.16  (dd, J = 10.3, 6.5 Hz, 1H), 4.09 (app ddd, J = 6.7, 6.7 Hz, 1H), 3.99 
(dd, J = 10.3, 6.9 Hz, 1H), 1.28 (s, 9H), 1.19 (s, 9H), 1.16 (s, 9H), 1.12–1.12 (m, 
18H);  13C NMR (100 MHz, CDC13) δ 178.0, 177.4, 177.0, 176.8, 176.7, 92.4, 72.0, 
71.3, 67.9, 66.9, 66.7, 60.9, 39.3, 39.0, 38.9, 27.4, 27.3, 27.2, 27.1. 
                
(2,3,4,6)-Tetra-O-pivaloyl-1-α/β-D-galactopyranoside-1-ol (73). Hydrogen 
bromide (33% in AcOH, 9 mL) was added to a stirred solution of (1,2,3,4,6)-penta-
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2 h, the reaction was quenched with sat. NaHCO3  (100 mL); the two layers were 
separated. The organic layer was washed with brine (100 mL), dried (MgSO4), 
filtered and concentrated. The residue was dissolved in acetone/H2O solution (34 
mL, 3 mL). To this solution, Ag2CO3  (3.65 g, 13.2 mmol) was added and mixture 
was stirred for 1.5 h. The mixture was filtered through a pad of celite, and the celite 
was washed with CH2Cl2 (30 mL). The crude product was purified by flash column 
chromatography on silica gel (Petroleum ether/ EtOAc, 90:10) to give 73 (5.85 g, 
88%) as a colorless, viscious oil: 1H NMR (400 MHz, CDCl3) δ 5.44–5.31 (m, 3H), 
5.07–5.04 (m, 0.42H), 5.00 (dd, J = 10.7, 3.5 Hz, 1H), 4.68 (d, J = 7.1 Hz, 0.27H), 
4.43–4.29 (m, 1.6H), 4.12–3.92 (m, 2.33H), 3.88–3.83 (m, 0.91H), 1.16–1.01 (m, 
44H). 13C NMR (100 MHz, CDCl3) δ α-anomer: 178.2, 178.0, 177.4, 177.0, 68.7, 
67.6, 67.5, 66.1, 61.1, 39.1, 38.8, 38.8, 38.7, 27.2, 27.1, 27.1; β-anomer: 178.1, 
176.9, 71.0, 70.9, 70.7, 66.7, 61.0, 60.6, 38.9, the rest of the peaks are not 




galactopyranoside)-1-trichloroacetimidate (70) (0.38 mg, 0.58 mmol) and 
(2S,3R,4E)-2-azido-3-benzoyloxyoctadec-4-en-1-ol (24) (0.21 g, 0.48 mmol) were 
dissolved in dry CH2Cl2 (7 mL), and the solution was stirred in the presence of 4Å 
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within 10 min at 0 oC. The reaction was slowly warmed to rt and stirred for 4 h. The 
reaction mixture was diluted with petroleum ether (15 mL) and then filtered. The 
filtrate was treated with saturated aqueous NaHCO3 (5 mL). The organic layer was 
separated, and the aqueous phase was extracted with CH2Cl2 (3 X 5 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated. Purification 
by combi flash column chromatography on silica gel (Acetone/hexane, 5:95) gave 
74 (0.23 g, 51% β-product) as a colorless oil:42 1H NMR (400 MHz, CDCl3) δ 8.03 (d, 
J = 7.5 Hz, 2H), 7.54 (t, J = 7.4, Hz, 1H), 7.42 (t, J = 7.7, Hz 2H), 5.90 (dt, J = 14.3, 
6.8 Hz, 1H), 5.59–5.50 (m, 2H), 5.38 (d, J = 1.3 Hz, 1H), 5.24 (dd, J = 10.5, 8.1 Hz, 
1H), 5.08 (dd, J = 10.4, 3.1 Hz, 1H), 4.56 (d, J = 7.9 Hz, 1H), 4.11 (dd, J = 10.0, 5.7 
Hz, 1H), 4.01–3.95 (m, 2H), 3.93–3.88 (m, 1H), 3.84 (dd, J = 10.2, 7.2 Hz, 1H), 3.64 
(dd, J = 10.2, 4.8 Hz, 1H), 2.05 (dt, J = 7.0, 7.0 Hz, 2H), 1.40–1.32 (m, 3H), 1.30–
1.22 (m, 28H), 1.16 (s, 9H), 1.14 (s, 9H), 1.10 (s, 9H), 0.86 (t, J = 7.0 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 177.9, 177.4, 177.0, 176.6, 165.1, 138.4, 133.3, 130.1, 
129.9, 128.6, 123.0, 101.1, 74.8, 71.3, 71.1, 68.6, 68.0, 66.8, 64.0, 61.2, 39.2, 38.9, 
38.9, 38.8, 32.5, 32.1, 29.8, 29.7, 29.5, 29.5, 29.3, 28.6, 27.3, 27.2, 22.8, 14.3.   
 
15-Hexadecyn-1-ol (79) 
1,3-Diaminopropane (13 mL) was added to a three neck round bottom flask charged 
with Li+ wire (0.18 g, 25 mmol) under N2.56 The flask was fitted with a condenser. 
The mixture was stirred at rt for 30 min. A slight exothermic reaction resulted as the 
Li+ dissolved, and a dark blue color was observed. The mixture was then stirred in a 
OH12
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preheated oil bath at 70 oC until the blue color was discharged (approximately 1 h), 
affording a white suspension of lithium amide. This white color quickly changes to a 
magenta color. The reaction was cooled to rt, followed by addition of tBuOK (2.10 g, 
16.8 mmol). The resulting dark yellow/reddish brown solution was stirred for 20 min 
at rt, and then 9-hexadecyn-1-ol (78) (1.00 g, 4.19 mmol) was added via syringe 
drop-wise. The reaction was stirred for 1 h and then poured into ice H2O (42 mL). 
The product was extracted with petroleum ether (3 X 20 mL). Extraction of product 
was difficult as it was crystalizing in the process; therefore Et2O (3 X 50 mL) was 
used to finish the extraction. The combined organic layers were washed with H2O 
(42 ml), 10 % HCl (42 mL) and brine (42 mL). The organic layer was dried (MgSO4), 
filtered and concentrated. The crude product was purified using flash column 
chromatography on silica gel (Petroleum ether/EtOAc, 90:10) to give 79 (697 mg, 
70%) as a white crystalline solid: mp 48.0−49.0 oC; IR (neat) 3286, 2916, 2848, 
1462, 1071, 720, 684, 627 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.57 (t, J = 6.7 Hz, 
2H), 2.13 (dt, J = 7.0, 2.6 Hz, 2H), 2.00 (s, 1H), 1.89 (t, J = 2.6 Hz, 1H), 1.50 (sept, 
J = 6.6 Hz, 4H), 1.38−1.23 (m, 20H); 13C NMR (100 MHz, CDCl3) δ 84.9, 68.2, 63.0, 
32.9, 29.8, 29.7, 29.6, 29.6, 29.2, 28.9, 28.6, 25.9, 22.8, 18.5; HRMS (ESI) calcd for 
C16H31O [M
 
+ H]+ m/z 239.2369, found 239.2374. 
 
15,16-Tetracosadiyn-1-ol (81) 
Cs2CO3 (4.22 g, 13.0 mmol), NaI (2.06 g, 13.7 mmol), and CuI (3.14 g, 16.4 mmol) 
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(3.00 g, 12.6 mmol) in dry DMF (5 mL) was added, drop-wise and the solution 
stirred for 10 min. Propargyl bromide 80 was added and the reaction mixture was 
stirred for 24 h (monitored by 1H-NMR).57 Saturated aqueous NH4Cl (30 ml) was 
added, and the product was extracted with Et2O (3 X 50 mL). The combined organic 
layers were washed with brine (3 X 15 mL), dried (MgSO4), filtered and 
concentrated. The crude product was purified using flash column chromatography 
on silica gel (petroleum ether/Et2O, 90:10), yielding 81 (1.60 g, 36%) as a yellowish 
solid. The product was light sensitive; therefore it was wrapped with aluminum foil 
and placed in the freezer immediately: mp 41.0−42.0 oC; IR (neat) 3286, 2917, 
2849, 1462, 1071, 683, 628 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.61 (t, J = 6.6 Hz, 
2H), 3.09 (dq, J = 2.4, 2.4 Hz, 2H), 2.12 (tt, J = 7.0, 2.2 Hz, 4H), 1.67 (br s, 1H), 
1.54 (quin, J = 6.7 Hz, 2H), 1.46−1.42 (m, 4H), 1.36−1.24 (m, 24H), 0.87 (t, J = 7.0 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 80.7, 74.7, 63.2, 33.0, 31.3, 29.8, 29.8, 29.7, 
29.6, 29.3, 29.1, 28.9, 28.6, 25.9, 22.4, 18.9, 18.9, 14.1, 9.9; HRMS (ESI) calcd for 
C24H43O [M
 
+ H]+ m/z 347.3308, found 347.3334. 
 
15Z,18Z-Tetracosadien-1-ol (82) 
Pd/BaSO4 (30.0 mg, 10% wt) and quinoline (0.1 mL) were added to a solution of 
15,16-tetracosadiyn-1-ol (81) (0.50 g, 1.4 mmol) in hexane.57 The reaction was 
purged for 10 min with H2 and then stirred under H2 for 3 h. The reaction was 
monitored by 1H-NMR. The reaction mixture was filtered through a pad of celite and 
the celite, was washed with hexane (20 mL). The filtrate was concentrated and 
11
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purified using flash column chromatography on silica gel (Petroleum ether/Et2O, 
95:5) to give 82 with 17% of its inseparable E-isomer (0.27 g, 53%) as a colorless 
oil: IR (neat) 2917, 2849, 1462, 1071, 683 cm-1; Peak assignments for 82: 1H NMR 
(400 MHz, CDCl3) δ 5.41−5.30 (m, 4H), 3.64 (t, J = 6.6 Hz, 2H), 2.77 (t, J = 6.5 Hz, 
2H), 1.57 (quin, J = 7.3 Hz, 4H), 1.39−1.26 (m, 31H), 0.89 (t, J = 6.6 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 130.4, 128.2, 33.0, 31.8, 29.8, 29.8, 29.8, 29.7, 29.6, , 
29.6, 27.5, 27.4, 26.0, 25.9, 14.3; HRMS (ESI) calcd for C24H47O [M
 
+ H]+ m/z 
351.3621, found 351.3621. 
 
15Z,18Z-Tetracosadienoic acid (83) 
Des Martin periodinane (0.16 g, 0.38 mmol) was added to a solution of 15Z,18Z-
tetracosedien-1-ol (82) (0.12 g, 0.35 mmol) in dry CH2Cl2 (1.3 mL) at 0 oC. The 
reaction was stirred at rt for 6h. TLC still showed incomplete consumption of the 
alcohol, and the reaction was placed in the fridge overnight. The next day, the 
reaction mixture was filtered through a pad of celite, the celite was washed with 
CH2Cl2 (10 mL). The combined filtrates were concentrated and purified by flash 
column chromatography on silica gel to provide 15Z,18Z-tetracosadienal as a 
colorless oil (53 mg, 43%, with E-isomer): IR (neat) 2920, 2850, 1700, 1650, 1510, 
1100, 1050, 850 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.76 (s, 1H), 5.41−5.30 (m, 4H), 
2.77 (t, J = 6.0 Hz, 2H), 2.41 (t, J = 7.2 Hz, 2H), 2.04 (dt, J = 6.3, 6.4 Hz, 4H), 1.61 
(quin, J = 6.7 Hz, 4H), 1.34−1.26 (m, 25H), 0.89 (t, J = 6.9 Hz, 3H); 13C NMR (100 
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27.4, 27.5, 27.4, 25.9, 22.8, 22.3, 14.3; HRMS (ESI) calcd for C24H45O [M
 
+ H]+ m/z 
349.3465, found 343.2579. NaHPO4 (0.14 g, 1.0 mmol) was added to a mixture of 
15Z,18Z-tetracosadienal (0.06 g, 0.18 mmol) and 2-methyl-2-butene (0.4 mL, 3.78 
mmol) in tBuOH (7 mL) and H2O (1.5 mL) at 0 oC. NaClO2 (0.02 g, 0.22 mmol) was 
added in small portions and the mixture stirred for 6 h. One more equiv of NaClO2 
was added, and the reaction was left in the fridge overnight. The next day, TLC still 
showed remaining aldehyde; so another equiv of NaClO2 was added, and the 
reaction mixture was stirred for 40 min at 0 oC. After this, TLC showed complete 
consumption of the aldehyde. Saturated aqueous Na2SO3 and pH7 phosphate 
buffer (1:1, 2 mL) was added to quench the reaction. The product was extracted 
with EtOAc (3 X 10 mL). The combined organic layers were washed with sat. NH4Cl 
(5 mL), brine (5 mL), dried (MgSO4), filtered and concentrated to give 83 (0.036 g, 
51%) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 5.41−5.30 (m, 4H), 2.77 (t, J = 
5.8 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 2.05 (dt, J = 7.0, 7.0 Hz, 4H), 1.63 (quin, J = 
7.2 Hz, 4H), 1.40−1.26 (m, 25H), 0.91−0.86 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 
180.5, 130.4, 128.2, 34.3, 32.8, 31.8, 29.9, 29.8, 29.7, 29.6, 29.5, 29.3, 27.5, 27.4, 
25.9, 22.8, 14.3. 
 
11-(p-Fluorophenyl)-10-undecynoic acid (87). PdCl2(PPh3)2 (0.31 g, 0.44 mmol) 
was added to a solution of p-fluoroiodobenzene (86) (1.67 g, 7.52 mmol) and  10-
undecynoic acid (85) (1.00 g, 5.49 mmol) in Et3N (12 mL). The reaction mixture was 
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was stirred in a preheated oil bath at 50 oC overnight. The reaction mixture was 
cooled to rt, and then passed through a pad of celite to remove the generated 
ammonium salt. The celite was further washed with Et2O (20 mL). The combined 
filtrates were concentrated and purified via flash column chromatography on silica 
gel (petroleum ether/EtOAc, 90:10) to give 87 (0.23 g) as a yellowish solid. 1H-NMR 
showed extra, unknown peaks. Peak assignments for the product: 1H NMR (400 
MHz, CDCl3) δ 7.35 (t, J = 5.7 Hz, 2H), 6.96 (t, J = 6.6 Hz, 2H), 2.39−2.33 (m, 4H), 
1.64 (quin, J = 5.0 Hz, 2H), 1.58 (q, J = 5.8 Hz, 2H), 1.44 (quin, J = 4.5 Hz, 2H), 
1.37−1.34 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 179.5, 162.2 (dC-F, J = 246.2 Hz) 
133.5, 133.5, 120.4, 115.6 (dC-F, J = 21.8 Hz), 90.2, 79.8, 34.2, 29.3, 29.2, 29.1, 
29.1, 28.9, 24.9, 19.5. 
 
(2S,3R,4E)-1-(β-D-Galactopyranosyloxy)-2-(N-tetracosanoylamino)octadec4en-
3-ol (89a). p-Nitrophenyltetracosaneoate (42) (0.04 g, 0.08 mmol) was added to a 
solution of (2S,3R,4E)-2-amino-1-(β-galactopyranosyloxy)octadec-4-en-3-ol (59) 
(0.03 g, 0.7 mmol) in pyridine (1 mL). The mixture was stirred in a preheated oil 
bath at 40 oC overnight. The reaction solution was concentrated and purified by 
flash column chromatography on silica gel (CH2Cl2/MeOH, 90:10) to give 89a as a 
white solid (17.2 mg, 32%): mp 182.0−183.0 oC; [α]25D  1.10 (c 1.25, CHCl3/MeOH); 
1H NMR (400 MHz, CDCl3/CD3OD, 3:2) δ 7.27 (d, J = 8.8 Hz, 1H), 5.69 (dt, J = 
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s, 1H),  3.88 (br s, 1H), 3.81–3.72 (m, 2H), 3.61 (app dd, J = 9.8 Hz, 1H), 3.56–3.50 
(m, 3H), 2.77 (t, J = 6.9 Hz,  2H), 2.02 (dt, J = 6.9, 6.9 Hz, 2H), 1.60–1.57 (m, 2H), 
1.36–1.26 (m, 62H), 0.88 (t, J = 6.4 Hz, 6H); 13C NMR (100 MHz, CDCl3/CD3OD, 
3:2) δ 175.5, 135.0, 130.2, 104.7, 76.0, 74.4, 73.0, 72.3, 70.0, 69.6, 62.5, 54.5, 
50.1, 33.2, 32.7, 30.5, 30.5, 30.4, 30.3, 30.2, 30.2, 26.8, 23.5, 14,6; HRMS (ESI) 
calcd for C48H94NO8 [M
 
+ H]+ m/z 812.6974, found 812.6982. 
 
(2S,3R,4E)-1-(β-D-Galactopyranosyloxy)-2-(N-15Z,18Z- 
tetracosadienoylamino)octadec-4-en-3-ol (89b). p-Nitrophenyl 15Z,18Z-
tetracosadieneoate (84) (28.0 mg, 0.06 mmol) was added to a solution of 
(2S,3R,4E)-2-amino-1-(β-galactopyranosyloxy)octadec-4-en-3-ol (59) (25 mg, 0.60 
mmol) in pyridine (1 mL). The mixture was stirred in a preheated oil bath at 40 oC 
overnight. The reaction was concentrated and purified by flash column 
chromatography on silica gel (CH2Cl2/MeOH, 90:10) to give 89b (21 mg, 46%) as 
an off white solid: mp 129.0−130.0 oC; [α]25D  – 0.68 (c 1.83, CH2Cl2/MeOH, 3:2); IR 
(neat) 3302, 2915, 1641, 1544, 1467, 1082, 718 cm-1; 1H NMR (400 MHz, 
CDCl3/CD3OD, 3:2) δ 5.70 (dt, J = 14.6, 6.6 Hz, 1H), 5.46 (dd, J = 15.3, 7.2 Hz, 1H), 
5.41–5.29 (m, 4H), 4.21 (d, J = 7.4 Hz, 1H), 4.00 (ddd, J = 7.3, 3.7, 3.7 Hz, 1H), 
3.82 (app  dd, J = 2.6 Hz, 1H), 3.81 (dd, J = 11.5, 6.6 Hz, 1H), 3.75 (dd, J = 11.5, 
5.0 Hz 1H), 3.62 (dd, J = 10.3, 3.2 Hz, 1H), 3.57–3.47 (m, 3H), 2.77 (t, J = 6.2 Hz,  
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1.27 (m, 55H), 0.88 (t, J = 6.9 Hz, 6H); 13C NMR (100 MHz, CDCl3/CD3OD, 3:2) δ 
175.6, 135.0, 131.0,  130.3, 128.9, 104.8, 76.1, 74.5, 73.1, 72.4, 70.0, 69.7, 62.5, 
54.5, 37.4, 33.2, 32.8, 32.4, 30.5, 30.5, 30.4, 30.3, 30.3, 30.2, 28.1, 28.1, 26.8, 
26.5, 23.5, 23.4, 14.7; HRMS (ESI) calcd for C48H90NO8 [M
 




undecanoylamino)octadec-4-en-3-ol (89c). p-Nitrophenyl 11-p-fluorobenzyl 
undecanoate (88) (28.0 mg, 0.06 mmol) was added to a solution of (2S,3R,4E)-2-
amino-1-(β-galactopyranosyloxy)octadec-4-en-3-ol (59) (20.0 mg, 0.04 mmol) in 
pyridine (1 mL). The mixture was stirred in a preheated oil bath at 40 oC overnight. 
The reaction was concentrated and purified by flash column chromatography on 
silica gel (CH2Cl2/MeOH, 95:5) to give 89c (17 mg, 52%) as an off white crystalline 
solid: mp 145.0−146.0 oC; [α]25D 0.14 (c 1.36, CH2Cl2/MeOH, 3:2); IR (neat) 3385, 
2916, 2849, 1636, 1511, 1468, 1224, 1068, 821.9, 719 cm-1; 1H NMR (400 MHz, 
CDCl3/CD3OD, 3:2) δ 7.13–7.09 (m, 2H), 6.93 (t, J = 8.8 Hz, 2H),  5.67 (dt, J = 14.7, 
6.6 Hz, 1H), 5.44 (dd, J = 15.3, 7.4 Hz ,1H), 4.20 (d, J = 3.6 Hz, 1H), 4.17 (dd, J = 
10.2, 4.5 Hz ,1H), 4.11 (dd, J = 7.4, 7.4 Hz, 1H), 3.98 (ddd, J = 7.3, 3.5, 3.5 Hz 1H), 
3.87 (app dd, J = 2.6 Hz, 1H), 3.81 (dd, J = 11.6, 6.7 Hz, 1H), 3.73 (dd, J = 11.5, 5.0 
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2.16 (t, J = 7.4 Hz, 2H), 2.01 (dt, J = 6.6, 6.6 Hz, 2H), 1.57 (quin, J = 6.8 Hz, 2H), 
1.37–1.25 (m, 36H), 0.87 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3/CD3OD, 
3:2) δ 175.5, 162.0 (dC-F, J = 240.0 Hz), 160.8, 139.4, 135.1, 130.5, 130.4, 130.1, 
128.6, 115.6 (dC-F, J = 21.8 Hz), 75.9, 74.3, 72.9, 72.2, 69.9, 69.5, 37.3, 35.9, 33.2, 
32.8, 32.5, 30.5, 30.5, 30.4, 30.6, 30.3, 30.3, 30.2, 30.2, 30.1, 30.026.8, 23.5; 
HRMS (ESI) calcd for C41H71FNO8 [M
 
+ H]+ m/z 724.5158, found 724.5147. 
 
(2S,3S,4R)-2-Azido-(3,4-dibenzoyloxy-1-tert-butyldiphenylsilyloxy)octadecane 
(91). BzCl (6.10 mL, 52.8 mmol) was added to a solution of (2S,3S,4R)-2-azido-1-
(tert-butyldiphenylsilyloxy)octadecane-3,4-diol (62) (5.00 g, 8.80 mmol) and DMAP 
(0.19 g, 1.6 mmol) in pyridine (78 mL). The reaction mixture was allowed to stir 
overnight. Ice-cold H2O (120 mL) was added to the reaction to quench it. The 
solution was extracted with CH2Cl2 (3 X 100 mL). The combined organic layers were 
dried (MgSO4), filtered and concentrated. Flash chromatography purification of the 
crude product on silica gel (petroleum ether/EtOAc, 95:5) gave 91 (5.43 g, 80%) as 
a colorless oil:53  [α]25D 6.21 (c 1.28, CH2Cl2); IR (neat) 2923, 2853, 2099, 1724, 
1451, 1260, 1104, 1068, 707, 503 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 
7.2 Hz, 2H), 7.79 (d, J = 7.2 Hz, 2H), 7.56 (dd, J = 7.8, 1.2 Hz, 2H), 7.49 (d, J = 7.3 
Hz, 3H), 7.46−7.42 (m, 1H), 7.33−7.22 (m, 8H), 7.14 (t, J = 7.3 Hz, 2H), 5.46−5.41 
(m, 2H), 3.93−3.87 (m, 1H), 3.81−3.75 (m, 2H), 1.72 (dt, J = 9.1, 9.1 Hz, 2H), 
1.35−1.14 (m, 24H), 0.96 (s, 9H),  0.79 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, 
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130.0, 129.9, 129.7, 128.7, 128.6, 128.0, 127.9, 73.3, 72.4, 64.3, 63.4, 32.1, 30.0, 
29.8, 29.8, 29.7, 29.6, 29.6, 26.8, 25.6, 22.9, 19.2, 14.3; HRMS (ESI) calcd for 
C48H64N3O5Si m/z 790.4610, found 790.4652. 
 
(2S,3S,4R)-2-Azido-3,4-dibenzoyloxy-1-(2,3,4,6-tetra-O-pivaloyl-β-
galactopyranoside)octadecane (92). (2,3,4,6-Tetra-O-pivaloyl- 
α-D-galactopyranoside)-1-trichloroacetimidate (70) (0.60 mg, 0.99 mmol) and 
(2S,3S,4R)-2-azido-(3,4-dibenzoyloxy)octadecan-1-ol (61) (0.45 g, 0.82 mmol) were 
dissolved in dry CH2Cl2 (13 mL), and the solution was stirred in the presence of 4Å 
MS (600 mg) at rt for 10 min. BF3•OEt2 in dry CH2Cl2 (1.46 µL in 2 mL) was added 
within 10 min at –10 oC and the reaction was slowly warmed to rt and stirred for 1.5 
h.42 The reaction mixture was diluted with petroleum ether (50 mL) and then filtered. 
The filtrate was treated with saturated aqueous NaHCO3 (10 mL). The organic layer 
was separated and the aqueous phase was extracted with CH2Cl2 (3 X 15 mL). The 
combined organic layers were dried (MgSO4), filtered and concentration. Purification 
by flash column chromatography on silica gel (petroleum ether/ EtOAc 95:5) gave 
92 (0.34 g, 39%, β-product) as a colorless oil: [α]25D –3.65 (c 1.00, CH2Cl2); IR (neat) 
2926, 2103, 1728, 1480, 1261, 1140, 710 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.00 
(d, J = 7.8 Hz, 4H), 7.57 (dt, J = 12.0, 7.4 Hz, 2H), 7.44 (t, J = 15.6, 7.8 Hz, 4H), 
5.49– 5.44 (m, 2H), 5.37 (d, J = 3.1 Hz, 1H), 5.22 (dd, J = 10.5, 8.1 Hz, 1H), 5.05 
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(m, 4H), 1.88–1.80 (m, 2H), 1.43–1.32 (m, 3H), 1.29–1.20 (m, 30H), 1.14 (s, 9H), 
1.09 (s, 9H), 1.08 (s, 9H), 0.86 (t, J = 6.7 Hz, 3H). 13C NMR (125 MHz, CDC13) δ 
177.9, 177.4, 177.0, 176.5, 133.7, 133.4, 130.0, 129.9, 129.8, 129.5, 128.7, 128.6, 
100.9, 73.0, 71.2, 71.1, 68.7, 68.6, 66.7, 61.4, 61.1, 38.9, 38.9, 38.8, 32.0, 30.3, 
29.8, 29.8, 29.8, 29.8, 29.8, 29.7, 29.7, 29.6, 29.5, 29.5, 29.5, 25.4, 22.8, 14.2; 
HRMS (ESI) calcd for C58H88N3O14 [M
 
+ H]+ m/z 1050.6261, found 1050.6300. 
 
(2S,3S,4R)-1-(β-D-Galactopyranosyloxy)-2-(N-15Z-
tetracosenoylamino)octadecan-3,4-diol (93a). p-Nitrophenyl 15Z-tetracosenoate 
(77) (33 mg, 0.07 mmol) was added to a solution of (2S,3S,4R)-2-amino-1-(β-
galactopyranosyloxy)octadecan-3,4-diol (60) (30 mg, 0.06 mmol) in pyridine (1 mL). 
The mixture was stirred in a preheated oil bath at 40 oC overnight. The reaction was 
concentrated and purified by flash column chromatography on silica gel 
(CH2Cl2/MeOH, 95:5) to give 93a (19 mg, 38%) as a white solid: mp 169.0−171.0 
oC; [α]25D  7.38 (c 0.82, CHCl3/MeOH, 3:2); IR (neat) 3330, 2917, 2849, 1637, 1545, 
1465, 1081, 1049, 721 cm-1; 1H NMR (400 MHz, CDCl3/CD3OD, 3:2) δ  5.38–5.30 
(m, 2H), 4.24–4.20 (m, 2H), 4.16 (dd, J = 10.3, 4.6 Hz, 1H), 3.87 (app dd, J = 2.7 
Hz, 1H), 3.82 (dd, J = 11.6, 6.8 Hz, 1H), 3.72 (ddd, J = 11.1, 11.1, 4.8 Hz, 2H), 
3.61–3.47 (m, 5H), 2.20 (t, J = 7.6 Hz, 2H), 2.01 (dt, J = 6.8, 6.8 Hz, 2H), 2.04–2.00 
(m, 2H), 1.68–1.57 (m, 3H), 1.53–1.51 (m, 1H), 1.47–1.27 (m, 56H), 0.88 (t, J = 6.0 
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74.5, 73.3, 72.4, 70.1, 70.1, 51.5,  37.4, 33.6, 32.7, 30.6, 30.6, 30.5, 30.4, 30.3, 
30.3, 30.2, 30.1, 28.0, 26.8, 26.7, 23.5, 14.6; HRMS (TOF) m/z calcd for C48H94NO9 
[M  – H]+ 828.6923, found 828.6915. 
 
(2S,3S,4E)-1-(β-D-Galactopyranosyloxy)-2-(N-15Z,18Z- 
tetracosadienoylamino)octadecan-3.4-diol (93b). p-Nitrophenyl 15Z,18Z-
tetracosadieneoate (84) (28 mg, 0.06 mmol) was added to a solution of (2S,3S,4R)-
2-amino-1-(β-galactopyranosyloxy)octadecan-3,4-diol (60) (27.0 mg, 0.06 mmol) in 
pyridine (1 mL). The mixture was stirred in a preheated oil bath at 40 oC overnight. 
The reaction was concentrated and purified by flash column chromatography on 
silica gel (CH2Cl2/MeOH, 95:5) to give 93b (19 mg, 40%) as a white solid: mp 
169.0−171.0 oC; [α]25D  8.81 (c 1.86, CHCl3/MeOH, 3:2); IR (neat) 3302, 2918, 2850, 
1637, 1467, 1082, 721 cm-1; 1H NMR (400 MHz, CDCl3/CD3OD, 3:2) δ  5.41– 
5.29(m, 4H), 4.23–4.22 (m, 2H), 4.14–4.12 (m, 1H), 3.87 (app dd, J = 2.0 Hz, 1H), 
3.82 (dd, J = 11.6, 6.8 Hz, 1H), 3.72 (ddd, J = 13.4, 13.4, 4.7 Hz, 2H), 3.61–3.47 (m, 
5H), 2.77 (t, J = 6.1 Hz, 2H), 2.20 (t, J = 7.4 Hz, 2H), 2.05 (dt, J = 6.4, 6.4 Hz, 2H), 
2.04–2.00 (m, 2H), 1.68–1.51 (m, 5H), 1.44–1.27 (m, 49H), 0.88 (t, J = 4.8 Hz, 6H); 
13C NMR (100 MHz, CDCl3 CDCl3/CD3OD, 3:2) δ 175.6, 131.0, 128.9, 76.3, 75.5, 
74.5, 73.3, 72.4, 70.1, 70.1, 62.6, 51.5, 37.4, 33.2, 32.8, 32.4, 30.7, 30.6, 30.4, 
30.3, 30.3, 30.2, 28.1, 28.1, 26.8, 26.8, 26.5, 23.5, 23.4, 14.7; HRMS (TOF) m/z 
















galactopyranoside)-1-trichloroacetimidate (70) (0.53 mg, 0.81 mmol) and 
(2S,3R,4E)-3-benzoyloxy-2-(N-tetrachlorophthalimido)octadec-4-en-1-ol (95) (0.69 
g, 1.03 mmol) were dissolved in dry CH2Cl2 (14 mL), and the solution was stirred in 
the presence of 4Å MS (500 mg) at rt for 30 min. BF3•OEt2 in dry CH2Cl2 (1.46 µL in 
0.5 mL) was added within 10 min at –30 oC. The reaction was stirred at this 
temperature for 2.5 h, diluted with CH2Cl2 (20 mL) and then filtered. The filtrate was 
extracted with H2O (3 X 20 mL). The organic layer was dried (MgSO4), filtered and 
concentrated. Purification by flash column chromatography on silica gel (petroleum 
ether/EtOAc, 95:5) gave 104 (0.64 g, 68% β-product) as a fluffy, clear solid: mp 
61.7−62.9 oC;  [α]25D  8.84 (c 1.05, CH2Cl2); IR (neat) 2925, 1724, 1480, 1363, 1276, 
1134, 739, 712 cm-1; 1H NMR (400 MHz, CDC13) δ 8.00 (d, J = 7.2 Hz, 2H), 7.54 (tt, 
J = 6.9, 1.2 Hz, 1H), 7.42 (t, J = 7.8, Hz, 2H), 5.93 (dd, J = 8.9, 8.9 Hz, 1H), 5.85 (dt, 
J = 14.8, 7.2 Hz, 1H), 5.34 (dd, J = 15.3, 8.5 Hz, 1H), 5.26 (s, 1H), 5.04–5.00 (m, 
2H), 4.71 (ddd, J = 10.0, 10.0, 4.1 Hz, 1H), 4.53–4.47 (m, 2H), 3.91–3.81 (m, 3H), 
3.73 (ddd, J = 12.8, 12.8, 7.2 Hz, 1H), 1.95–1.79 (m, 2H), 1.28–0.93 (m, 58H), 0.84 
(t, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDC13) δ 177.6, 177.3, 176.7, 176.5, 133.4, 
130.0, 129.9, 129.8, 128.6, 127.4, 124.3, 101.0, 72.7, 71.0, 70.9, 68.6, 66.5, 65.4, 
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27.1, 22.8, 14.2; HRMS (TOF) m/z calcd for C59H81Cl4NO4 [M –Cl4]+ 1029.5606, 
found 1048.4062.; α-anomer: 1H NMR (400 MHz, CDC13) δ 8.04 (d, J = 7.2 Hz, 
2H), 7.54 (t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.8, Hz 2H), 5.99–5.84 (m, 2H), 5.38 (dd, J 
= 15.4, 8.5 Hz, 1H), 5.21 (ddd, J = 3.6, 3.6, 3.6 Hz, 1H), 4.94 (dd, J = 6.2, 1.8 Hz, 
1H), 4.91 (s, 1H), 4.84 (ddd, J = 10.3, 10.3, 4.6 Hz, 1H), 4.75 (d, J = 1.8 Hz, 1H), 
4.49 (dd, J = 10.6, 10.6 Hz, 1H), 4.31 (dd, J = 12.0, 3.3 Hz, 1H), 4.14–4.06 (m, 1H), 
4.03 (dd, J = 12.1, 12.1 Hz, 1H), 3.92 (dd, J = 10.6, 4.6 Hz, 1H), 1.97–1.83 (m, 2H), 
1.33–1.25 (m, 12H), 1.17–1.14 (m, 30H), 1.06–1.04 (m, 16H),  0.88 (t, J = 6.6 Hz, 
3H); 13C NMR (100 MHz, CDC13) δ 177.9, 177.5, 177.3, 177.2, 130.0, 129.9, 128.7, 
127.4, 124.3, 105.0, 81.8, 80.1, 75.6, 73.2, 69.0, 63.0, 62.8, 53.4, 39.0, 38.9, 38.8, 
38.6, 32.3, 32.1, 29.9, 29.6, 29.6, 29.6, 29.1, 29.0, 27.3, 27.3, 27.1, 26.9, 22.9, 
14.3. 
 
(±)-α-bromotetracosanoic acid (117). Br2 (1.28 mL, 25.3 mmol) was added 
slowly over 10 min to a mixture of red phosphorus (0.25 g, 8.2 mmol) and 
tetracosanoic acid (41) (2.33 g, 6.32 mmol) at rt. The reaction mixture was then 
placed in a preheated oil bath at 95 oC and stirred for 6 h. 1H NMR showed 
incomplete consumption of starting material. Br2 (0.5 mL) was added, and the 
mixture was stirred for another 2 h, after which there was no starting material. H2O 
(20 mL) was then added, and the reaction was stirred for 20 min at 95 oC. The 
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organic layers were concentrated, and the residue recrystallized from hexane to 
give 117 as a brownish solid (2.02 g, 71%):45 1H NMR (400 MHz, CDCl3) δ 11.67 (br 
s, 1H), 4.24 (dd, J = 7.5, 7.5 Hz, 1H), 2.14−2.06 (m, 1H), 2.05−1.94 (m, 1H), 
1.54−1.46 (m, 1H), 1.43−1.26 (m, 37H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 176.4, 45.6, 34.9, 32.2, 29.9, 29.8, 29.7, 29.6, 29.5, 29.0, 27.8, 27.4, 
22.9, 14.3. 
 
(±)-α-hydroxytetracosanoic acid (118). 2 M aq. NaOH (23 mL) was added to 
(±)-α-bromotetracosanoic acid (117) (2.0 g, 4.5 mmol), and the mixture was 
allowed to stir at 85 oC for 30 h. The reaction was cooled to rt and then acidified to 
pH 2 with aqueous 2 M HCl. The product was extracted with Et2O (5 X 100 mL). 
The combined extracts were washed with H2O (100 ML), dried (Na2SO4), filtered 
and concentrated. The crude product was recrystallized from acetone to give (±)-α-
hydroxytetracosanoic acid as a white solid (0.88 g, 51%):45 1H NMR (400 MHz, 
CDCl3) δ 4.13 (dd, J = 6.0, 4.4 Hz, 1H), 1.83−1.74 (m, 1H), 1.71−1.62 (m, 1H), 1.45 
(quin, J = 7.2 Hz, 2H), 1.35−1.28 (m, 38H), 0.89 (t, J = 6.6 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 178.2, 71.6, 35.5, 33.1, 30.8, 30.8, 30.7, 30.6, 30.5, 26.2, 23.8, 14.8. 
 
(S)-α-Acetoxytetracosanoic acid (119). Amano lipase PS (0.22 g) was suspended 
in a solution of (±)-α-hydroxytetracosanoic acid (118) (0.23 g, 0.60 mmol) in THF 
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stirred in a preheated oil bath at 65 oC for 20 h. The reaction mixture was filtered 
through a pad of celite, and the celite was further washed with THF (30 mL). The 
combined filtrates were concentrated, and the resdue purified by flash column 
chromatography on silica gel (petroleum ether/EtOAc, 80:20%) gave 120 (0.02 g, 
17%, considering only the S-enantiomer reacted) as a white solid:45 Lit [α]25D  −8.9 (c 
1.0, CHCl3);58 [α]25D  −7.85 (c 1.0, CHCl3), IR (neat) 2915, 2848, 1725, 1464, 1224, 
1079, 719 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.01 (dd, J = 6.7, 6.7 Hz, 1H), 2.14 (s, 
3H), 1.89−1.83 (m, 2H), 1.46−1.39 (m, 3H), 1.34−1.26 (m, 37H), 0.88 (t, J = 7.0 Hz, 
3H); 13C NMR (100 MHz, CDCl3) δ 176.2, 170.9,  72.1, 32.2, 31.2, 29.9, 29.9, 29.8, 
29.8, 29.6, 29.3, 25.3, 22.9, 20.8, 14.3. 
 
(2S,3R,4E)-2S-(O-Acetyl-N-tetracosanoylamino)-1-(β-D-galactopyranosyloxy) 
octadec-4-en-3-ol (121a). p-Nitrophenyl  α-O-acetyl tetracosanoate (120) (26 mg, 
0.05 mmol) was added to a solution of (2S,3R,4E)-2-amino-1-(β-
galactopyranosyloxy)octadec-4-en-3-ol (59) (19 mg, 0.04 mmol) in pyridine (0.8 
mL). The mixture was stirred in a preheated oil bath at 40 oC overnight. The reaction 
was concentrated and purified by flash column chromatography on silica gel 
(CH2Cl2/MeOH, 95:5) to give 121a  (14 mg, 38%) as a white solid: mp 155.6−156.7 
oC;  [α]25D  −0.792 (c 1.42, CHCl3/MeOH); IR (neat) 2917, 2850, 1724, 1651, 1469, 
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1H), 5.70 (dt, J = 14.9, 6.6 Hz, 1H), 5.43 (dd, J = 15.4, 7.5 Hz, 1H), 4.90 (dd, J = 
6.1, 6.1 Hz, 1H), 4.28 (d, J = 7.2 Hz, 1H), 4.20 (dd, J = 10.5, 4.0 Hz, 1H), 4.13 (dd, J 
= 7.8, 7.8 Hz, 1H), 3.96 (dddd, J = 8.6, 8.6, 5.1, 5.1 Hz, 1H), 3.87 (app dd, J = 2.7 
Hz, 1H), 3.82 (dd, J = 11.5, 6.7 Hz, 1H), 3.73 (dd, J = 11.5, 5.0 Hz, 1H), 3.63 (dd, J 
= 10.4, 3.1 Hz, 1H), 3.58–3.49 (m, 3H), 2.13 (m, 3H), 2.01 (dt, J = 7.7, 7.7 Hz, 2H), 
1.42–1.26 (m, 64H), 0.88 (t, J = 6.4 Hz, 6H); 13C NMR (100 MHz, CDCl3/CD3OD, 
3:2) δ 172.1, 172.0, 135.4, 130.3, 104.7, 76.1, 75.3, 74.5, 72.5, 72.4, 70.0, 69.3, 
62.4, 54.5, 54.4, 33.3, 33.0, 32.9, 30.6, 30.6, 30.5, 30.4, 30.4, 30.3, 30.1, 26.2, 
23.6, 21.3, 14.8; HRMS (TOF) m/z calcd for C50H96NO10 [M + H]+ 870.7029, found 
870.6997. 
NaOMe (6.4 µL, 0.03 mmol) was added to a solution of (2S,3R,4E)-2S-(O-acetyl-N-
tetracosanoylamino)-1-(β-D-galactopyranosyloxy)octadec-4-en-3-ol (121a). (14 mg, 
0.02 mmol) in a mixture of CH2Cl2/MeOH (0.3:0.3 mL). The reaction was stirred at rt 
for 1 h, then neutralized with dowex (H+ resin). The mixture was filtered through a 
pad of celite, and the celite was washed with a 1:1 mixture of CHCl3 and MeOH (10 
mL). The filtrate was concentrated and purified using flash column chromatography 
on silica gel (CH2Cl2/MeOH, 90:10) to give (2S,3R,4E)-(β-D-galactopyranosyloxy)-
2S-(hydroxy-N-tetracosanoylamino)octadec-4-en-3-ol (9.4 mg, 71%) as a white 
solid: mp 181.0−182.0 oC;  [α]25D  −3.03 (c 0.94, CHCl3/MeOH); IR (neat) 3382, 
2918, 2850, 1724, 1468, 1072, 720 cm-1; 1H NMR (400 MHz, CDCl3/CD3OD, 3:2) δ 
7.57 (d, J = 8.3 Hz, 1H), 5.73 (dt, J = 14.5, 6.6 Hz, 1H), 5.46 (dd, J = 15.4, 6.9 Hz, 
1H), 4.22−4.19 (m, 2H), 4.08 (dd, J = 10.1, 5.6 Hz, 1H), 3.86–3.85 (m, 1H), 3.82 
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(dd, J = 11.7, 6.8 Hz, 1H), 3.76−3.67 (m, 2H), 3.55–3.47 (m, 3H), 2.03 (dt, J = 6.5, 
6.5 Hz, 2H), 1.83−1.74 (m, 1H), 1.59−1.50 (m, 1H), 1.36–1.26 (m, 66H), 0.88 (t, J = 
6.4 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 176.7, 135.2, 129.6, 104.8, 76.1, 74.4, 
72.9, 72.6, 70.0, 69.3, 62.5, 54.5, 35.5, 33.3, 32.8, 30.6, 30.5, 30.5, 30.4, 30.3, 




4-en-3-ol (121b). p-Nitrophenyl erucicoate (116) (29.5 mg, 0.06 mmol) was added 
to a solution of (2S,3R,4E)-2-amino-1-(β-galactopyranosyloxy)octadec-4-en-3-ol 
(59) (24 mg, 0.05 mmol) in pyridine (0.9 mL). The mixture was stirred in a preheated 
oil bath at 40 oC overnight. The reaction was concentrated and purified by flash 
column chromatography on silica gel (CH2Cl2/MeOH, 95:5) to give 121b (23 mg, 
55%) as an off white solid: mp 166.1−167.2 oC; [α]25D  0.877 (c 1.02, CHCl3/MeOH, 
3:2); IR (neat) 3278, 2917, 2850, 1645, 1551, 1468, 1069, 717 cm-1; 1H NMR (400 
MHz, CDCl3/CD3OD, 3:2) δ 7.47 (d, J = 9.1 Hz, 1H), 5.69 (dt, J = 14.9, 6.6 Hz, 1H), 
5.44 (dd, J = 15.4, 7.4 Hz, 1H), 5.37–5.30 (m, 2H), 4.21 (d, J = 7.4 Hz, 1H), 4.17 
(dd, J = 10.2, 4.4 Hz, 1H), 4.10 (dd, J = 7.4, 7.4 Hz, 1H), 4.00 (dddd, J = 7.6, 3.6, 
3.6, 3.6 Hz, 1H), 3.87 (app dd, J = 2.8 Hz, 1H), 3.81 (dd, J = 11.6, 6.7 Hz, 1H), 3.73 
(dd, J = 11.6, 5.0 Hz, 1H), 3.60–3.47 (m, 4H), 2.17 (t, J = 7.4 Hz, 2H), 2.01 (dt, J = 
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6H); 13C NMR (100 MHz, CDCl3/CD3OD, 3:2) δ 175.5, 135.1, 133.3, 130.7, 130.7, 
130.2, 104.7, 76.0, 74.3, 72.9, 72.3, 69.9, 69.6, 62.4, 54.3, 37.4, 33.3, 32.9, 32.8, 
30.7, 30.6, 30.5, 30.5, 30.4, 30.3, 30.2, 30.2, 30.2, 28.1, 26.8, 23.5, 14.7; HRMS 
(TOF) m/z calcd for C46H88NO8 [M + H]+ 782.6504, found 782.6468. 
 
(2S,3R,4E)-1-(β-D-galactopyranosyloxy)2-(N-elcosanoylamino)octadec-4-en-3-
ol (121c). p-Nitrophenyl elcosanoate (114) (12.0 mg, 0.03 mmol) was added to a 
solution of (2S,3R,4E)-2-amino-1-(β-galactopyranosyloxy)octadec-4-en-3-ol (59)  
(10 mg, 0.03 mmol) in pyridine (0.4 mL). The mixture was stirred in a preheated oil 
bath at 40 oC overnight. The reaction was concentrated and purified by flash column 
chromatography on silica gel (CH2Cl2/MeOH, 95:5) to give 121c (7.5 mg, 44%) as a 
white solid: mp 166.1−167.7 oC; [α]25D  1.72 (c 0.86, CHCl3/MeOH, 3:2); IR (neat) 
3297, 2916, 2849, 1645, 1545, 1467, 1083, 718 cm-1; 1H NMR (400 MHz, 
CDCl3/CD3OD, 3:2) δ 5.67 (dt, J = 14.8, 6.6 Hz, 1H), 5.43 (dd, J = 15.4, 7.4 Hz, 1H), 
4.19 (d, J = 7.3 Hz, 1H), 4.16 (dd, J = 10.2, 4.5 Hz, 1H), 4.09 (dd, J = 7.5, 7.5 Hz, 
1H), 3.97 (dddd, J = 3.5, 3.5, 3.5, 3.5 Hz, 1H), 3.86 (app dd, J = 2.7 Hz, 1H), 3.80 
(dd, J = 11.5, 6.7 Hz, 1H), 3.73 (dd, J = 11.5, 5.0 Hz, 1H), 3.58–3.46 (m, 4H), 2.15 
(t, J = 7.4 Hz, 2H), 2.00 (dt, J = 6.8, 6.8 Hz, 2H), 1.57 (quin, J = 6.5 Hz, 2H), 1.38–
1.24 (m, 54H), 0.86 (t, J = 6.5 Hz, 6H); 13C NMR (100 MHz, CDCl3/CD3OD, 3:2) δ 
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32.8, 30.6, 30.4, 30.4, 30.3, 30.2, 30.2, 28.1, 26.7, 23.5, 14.7; HRMS (TOF) m/z 
calcd for C44H86NO8 [M + H]+ 756.6348, found 756.6345. 
 
2S-(N-tert-Butyl carboxylate dimethyl oxazolidine)hexadec-4-yn-3-ol (124). n-
BuLi (2.5 M in Hex, 0.46 mL, 1.15 mmol) was added drop-wise to a solution of 1-
tridecyne (126) (0.22 mL, 0.96 mmol) in THF (1 mL) at -20 oC. After 10 min Garner 
aldydehe (125) (0.200 g, 0.87 mmol) in THF (0.5 mL) was added drop-wise.59 The 
solution was stirred at -20 oC for 7 h. Saturated aqueous NH4Cl (5 mL) was added. 
The two layers were separated, and the aqueous phase was extracted with Et2O (2 
X 10 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated. The crude product was purified using flash column chromatography 
on silica gel (petroleum ether/EtOAc, 95:5) to give 124 as a colorless oil (17 mg, 5% 
pure isolated product, 85.9 mg 124 with aldehyde): 1H NMR (400 MHz, CDCl3) δ 
4.71−4.50 (m, 2H), 4.12−4.05 (m, 2H), 3.91 (br s, 1H), 2.19 (dt, J = 7.0, 1.5 Hz, 2H), 
1.58−1.54 (m, 3H), 1.51−1.41 (m, 14H), 1.36−1.31 (m, 2H), 1.29−1.26 (m, 14H), 
0.87 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 154.4, 95.2, 86.9, 81.4, 78.1, 
76.9, 65.3, 64.4, 63.1, 32.1, 29.8, 29.7, 29.5, 29.3, 29.1, 28.8, 28.6, 26.0, 25.6, 
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Garner’s aldehyde (125). LiAlH4 (0.24 g, 6.2 mmol) was added to (2S)-tert-butyl 
carboxylate dimethyl oxazolidine-N-methoxy-N-methyl propanamide (131) (0.90 g, 
3.1 mmol) in THF (14 mL) at 0 oC.46 After 10 min TLC showed complete 
consumption of 131. NaHCO3 (5% aq., 10 mL) was added drop-wise slowly. The 
two layers were separated and the aqueous layer was further extracted with EtOAc 
(3 X 20 mL). The combined EtOAc layers were dried (MgSO4), filtered and 
concentrated. Purification via flash column chromatography on silica gel (petroleum 
ether/EtOAc, 95:5) gave Garner’s aldehyde as a colorless oil (0.51 g, 72%):  1H 
NMR (400 MHz, CDCl3) δ 9.60 (br s, 0.32H), 9.54 (br s, 0.57H), 4.32 (br s, 0.4H), 
4.19−4.18 (m, 0.58H), 4.11−4.02 (m, 2H), 1.64−1.42 (m, 15H).  
 
(2S)-N-tert-Butylcarboxylatedimethyloxazolidinepropanoic acid (130). 2,2-
Dimethoxy propane (2.5 mL) was added to a solution of Boc-L-serine (127) (2.00 g, 
9.75 mmol) and PTSA (53.0 mg) in THF (10 ml). The solution was stirred under 
reflux conditions for 24 h. The reaction was neutralized to pH 7 with solid Na2CO3. 
The mixture was filtered, and the filtrate was concentrated. Purification by flash 
column chromatography on silca gel (CH2Cl2/MeOH, 97:3) provided 125 as a 
brownish yellow oil (1.12 g, 47%):  1H NMR (400 MHz, CDCl3) δ 4.50 (app d, J = 6.2 









	   124	  
J = 9.2, 9.2 Hz, 0.5H), 4.14−4.10 (m, 1H), 1.67 (s, 1.5H), 1.61 (s, 1.5H), 1.53−1.51 
(m, 8H), 1.44−1.42 (m, 4H). 
 
(2S)-N-tert-Butylcarboxylatedimethyloxazolidine-N-methoxy-N-methyl 
propanamide (131). N,O-Dimethylhydrochloride (0.46 g, 4.7 mmol) was added to a 
solution of (2S)-tert-butylcarboxylatedimethyloxazolidinepropanoic acid (130) 
(1.12g, 4.55 mmol) in dry CH2Cl2 (18 mL) at −15 oC. NMM (0.51 mL, 4.66 mmol) 
was then added drop-wise, and the reaction was stirred for 5 min. EDC•HCl (0.90 g, 
4.69 mmol) was added in five portions over 20 min.60 After 1 h aqueous HCl (1 M, 5 
mL) was added to quench the reaction. The two layers were separated, and the 
aqueous layer was extracted with CH2Cl2 (10 mL). The combined organic phases 
were washed with saturated aqueous NaHCO3 (4 mL) and H2O (4 mL), dried 
(MgSO4), filtered and concentrated. The crude product was purified using flash 
column chromatography on silica gel (CH2Cl2/MeOH, 98:2) to yield 131 (0.90 g, 
68%) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 4.79 (dd, J = 7.1, 2.8 Hz, 
0.5H), 4.71 (dd, J = 7.3, 3.6 Hz, 0.5H), 4.20−4.15 (m, 1H), 3.97−3.90 (m, 1H), 3.71 
(d, J = 9.0 Hz, 3H), 3.20 (s, 3H), 1.69−1.67 (m, 3H), 1.53 (d, J = 9.0 Hz, 3H), 1.48 
(s, 4.5H), 1.40 (s, 4.5H); 13C NMR (100 MHz, CDCl3) δ 171.6, 170.8, 152.4, 151.5, 
95.2, 94.6, 80.7, 80.2, 66.3, 66.1, 61.4, 61.4, 58.1, 57.9, 37.8, 32.7, 28.6, 28.6, 
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2S-(N-tert-butyloxycarbonylamino)propanamide (133). Imidazole (2.64 g, 38.7 
mmol) was added to solution of (2S)-N-methoxy-N-methyl-2-(N-tert-
butyloxycarbonylamino)propanamide (132) (8.01 g, 32.3 mmol) in dry DMF (64 mL). 
TBDMSCl (5.10 g, 33.9 mmol) was then added, and the reaction was allowed to stir 
for 2 h. Saturated aqueous NH4Cl (150 mL) was added, and the product was 
extracted with Et2O (3 X 100 mL). The combined Et2O extracts were washed with 
H2O (3X 150 mL), dried (MgSO4), filtered and concentrated. The crude product was 
purified using flash column chromatography on silica gel (petroleum ether/EtOAc, 
95:5) to give 133 as a colorless oil (10.3 g, 88%):47 [α]25D  21.57 (c 0.2, CH2Cl2); IR 
(neat) 2930, 1714, 1663, 1471, 1390, 1365, 1251, 1167, 1110, 990, 836, 776 cm-1; 
1H NMR (400 MHz, CDCl3) δ 5.34 (d, J = 8.2 Hz, 1H), 4.75 (app ddd, J = 3.9, 3.9 
Hz, 1H), 3.85 (dd, J = 10.0, 4.7 Hz, 1H), 3.78 (dd, J = 9.9, 5.2 Hz, 1H), 3.75 (s, 3H), 
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δ 171.0, 155.6, 79.8, 63.7, 61.7, 52.7, 32.4, 28.6, 26.0, 18.5, 0.2, -0.5; HRMS (ESI) 
calcd for C16H35NO5Si [M
 
+ H]+ m/z 363.2310, found 363.2292. 
 
(2S)-1-(tert-Butyldimethylsilyloxy)-2-(N-tert-butyloxycarbonylamino)-4- 
penten-3-one (135). Vinyl magnesium bromide (134) (1 M in THF, 113 mL, 113 
mmol) was added drop-wise via an addition funnel to a solution of N-methoxy-N-
methyl (2S)-3-(tert-butyldimethylsilyloxy)-2 
-(N-tert-butyloxycarbonylamino)proanamide (133) (10.3 g, 28.3 mmol) in THF (86 
mL) at 0 oC. The reaction was slowly warmed to rt and allowed to stirred for 1h. The 
reaction was cooled to 0 oC and then HCl (0.1 M aq., 30 mL) was added to quench 
the reaction. The product was extracted with Et2O (3 X 75 mL). The combined Et2O 
layers were dried (MgSO4), filtered and concentrated. Purification by flash column 
chromatography on silica gel (Petreoleum ether/EtOAc, 95:5) yielded 135 (1.90 g, 
20%) as a colorless oil:47  1H NMR (400 MHz, CDCl3) δ 6.56 (dd, J = 17.4, 10.6 Hz, 
1H), 6.43 (dd, J = 17.4, 0.9 Hz, 1H), 5.83 (app d, J = 10.6 Hz, 1H), 5.51 (d, J = 6.8 
Hz, 1H), 4.59 (ddd, J = 7.5, 3.9, 3.9 Hz, 1H), 4.00 (dd, J = 10.3, 3.1 Hz, 1H), 3.85 
(dd, J = 10.3, 4.3 Hz, 1H), 1.44 (s, 9H), 0.83 (s, 9H), 0.01 (s, 3H), 0.00 (s, 3H); 13C 
NMR (100 MHz, CDCl3 ) δ 197.1, 155.4, 133.4, 129.6, 80.0, 63, 7, 59.8, 28.6, 26.0, 
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penten-3-ol (136). LiAl(Ot-Bu)3H (3.22 g, 12.7 mmol) was added to a solution of 
(2S)-1-(tert-butyldimethylsilyloxy)-2-(N-tert-butyloxycarbonylamino)-4-pentene-3-one 
(135)  (1.19 g, 5.76 mmol) in dry EtOH (23 mL) at −78 °C under N2. After being 
stirred for 5 h at −78 °C, the mixture was quenched slowly with aqueous 1 N HCl (19 
mL). The mixture was then diluted with H2O (50 mL). The two layers were 
separated, and the aqueous layer was extracted with EtOAc (3 X 75 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated. Purification 
by flash chromatography on silica gel (petroleum ether/EtOAc, 95:5 to 90:10) gave 
impure 136 (1.33 g) as colorless oil, which was carried forward to the next step 
without further purification.  
 
(2S,3R,4E)-1-(tert-Butyldimethylsilyloxy)-2-(N-tert-butyloxycarbonyl 
amino) hexadecen-3-ol (138). Pathway 1: Cat.1 (34 mg, 0.04 mmol) was added to 
a solution of (2S,3R)-1-(tert-butyldimethylsilyloxy)-2S-(N-tert-
butyloxycarbonylamino)-4-penten-3-ol (136) (1.33 g, 4.01 mmol) and 1-tridecene 
(2.9 g, 3.8 mL, 16 mmol) in dry CH2Cl2 (60 mL) at rt.47 The reaction was allowed to 
stir overnight. The solvent was evaporated, and the crude product was purified 
using flash column chromatography on silica gel (petroleum ether/EtOAc, 95:5) to 
provide 138 (0.22 g, 44%) as a slightly brownish oil.; Pathway 2: LiAl(Ot-Bu)3H 
(4.00 g, 15.7 mmol) was added to (2S,4E)-1-(tert-butyldimethylsilyloxy)-2-(N-tert-
butyloxycarbonylamino)hexadecen-3-one (141) (3.45 g, 7.12 mmol) in dry EtOH 
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was slowly added. The mixture was then diluted with H2O (50 mL). The two layers 
were separated, and the aqueous layer was extracted with EtOAc (3 X 75 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated. Purification 
by flash chromatography on silica gel (petroleum ether/EtOAc, 95:5 to 90:10) gave 
138 as a colorless oil (0.77 g, 29%): [α]25D  8.80 (c 0.8, CH2Cl2); IR (neat) 2924, 
2854, 1698, 1497, 1365, 1365, 1252, 1170, 1096, 965, 835, 776 cm-1; 1H NMR (400 
MHz, CDCl3) δ 5.75 (dt, J = 14.7, 6.7 Hz, 1H), 5.51 (dd, J = 15.5, 6.0 Hz, 1H), 5.22 
(d, J = 7.4 Hz, 1H), 4.19 (app ddd, J = 5.8, 5.8, 5.8 Hz, 1H), 3.94 (dd, J = 10.3, 2.9 
Hz, 1H), 3.75 (app d, J = 8.8 Hz, 1H), 3.57 (d, J = 4.3 Hz, 1H), 3.30 (app d, J = 7.8 
Hz, 1H), 2.05 (dt, J = 7.0, 7.0 Hz, 1H), 1.45 (s, 9H), 1.37 (quin, J = 6.6 Hz, 2H), 
1.32−1.26 (m, 16H), 0.89−0.87 (m, 12H), 0.07 (s, 3H), 0.07 (s, 3H); 13C NMR (100 
MHz, CDCl3 ) δ 156.0, 133.3, 129.7, 79.6, 74.9, 63.7, 54.7, 32.5, 32.1, 29.9, 29.9, 
29.8, 29.7, 29.6, 29.4, 28.6, 26.0, 22.9, 18.4, 14.3, -5.4, -5.4; HRMS (ESI) calcd for 
C27H56NO4Si [M
 
+ H]+ m/z 486.3973, found 486.3952. 
 
(2S,3R-4E)-3-benzoyloxy-1-(tert-Butyldimethylsilyloxy)-2-(N-tert-
butyloxycarbonylamino)hexadec-4-ene (139). BzCl (0.52 g, 0.43 mL, 3.7 mmol) 
was added to a solution of (2S,3R,4E)-1-(tert-butyldimethylsilyloxy)-2-(N-tert-
butyloxycarbonylamino)hexadec-4-en-3-ol (138) (0.45 g, 0.93 mmol) and DMAP (11 
mg, 0.09 mmol) in pyridine (10 mL). After 6 h more BzCl (0.43 mL) was added, and 
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reaction. The solution was extracted with CH2Cl2 (3 X 15 mL). The combined 
organic layers were dried (MgSO4), filtered and concentrated. Flash 
chromatography purification of the crude product on silica (petroleum ether/EtOAc, 
95:5) gave 139 (0.21 g, 38%) as a colorless oil:  [α]25D  14.28 (c 1.53, CH2Cl2); IR 
(neat) 2925, 2854, 1718, 1495, 1365, 1258, 1169, 1107, 1026, 965, 835, 776, 710 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 7.4 Hz, 2H), 7.55 (tt, J = 7.2, 1.4 Hz, 
1H), 7.23 (t, J = 7.8 Hz, 2H), 5.92−5.83 (m, 1H), 5.56−5.49 (m, 2H), 4.81 (d, J = 9.4 
Hz, 1H), 4.04−4.01 (m, 1H), 3.79 (dd, J = 10.6, 3.4 Hz, 1H), 3.67 (dd, J = 10.0, 4.2 
Hz, 1H), 2.01 (dd, J = 7.0, 7.0 Hz, 2H), 1.44 (s, 9H), 1.38−1.34 (m, 2H), 1.31−1.24 
(m, 16H), 0.88−0.86 (m, 12H), 0.02 (s, sH), 0.00 (s, sH); 13C NMR (100 MHz, 
CDCl3) δ 165.5, 155.6, 137.3, 133.1, 130.8, 129.9, 128.5, 125.0, 79.6, 74.6, 62.1, 
54.2, 32.6, 32.1, 29.9, 29.8, 29.8, 29.7, 29.6, 29.4, 29.1, 28.6, 26.1, 22.9, 18.4, 
14.3, -5.3, -5.4; HRMS (ESI) calcd for C34H 6 0 N 5 S i  [M
 




(140). HF•py (0.1 mL, 1.2 mmol) was added drop-wise to a solution of (2S,3R-4E)-
3-benzoyloxy-1-(tert-butyldimethylsilyloxy)-2-(N-tert-butyloxycarbonylamino) 
hexadec-4-ene (139)  (0.19 g, 0.30 mmol). HF•py (0.2 mL) was added in two 
portions in a 3 h interval. Saturated NaHCO3 (5 mL) was added. The product was 
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(MgSO4), filtered and concentrated. The crude product was purified by flash column 
chromatography on silica gel (petroleum ether/EtOAc/, 90:10) to give 140 as a 
colorless oil (105 mg, 73%):  [α]25D  13.56 (c 3.59, CH2Cl2); IR (neat) 2920, 2851, 
1715, 1670, 1528, 1367, 1316, 1250, 1162, 1108, 1069, 1026, 972, 714 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.03 (d, J = 7.9 Hz, 2H), 7.56 (t, J = 7.7 Hz, 1H), 7.44 (t, J 
= 7.5 Hz, 2H), 5.88 (dt, J = 6.7, 6.7 Hz, 1H), 5.59 (dd, J = 15.0, 7.6 Hz, 1H), 5.52 
(dd, J = 7.2, 7.2 Hz, 1H), 5.08 (d, J = 8.2 Hz, 1H), 3.94 ( br s, 1H), 3.72 (s, 2H), 2.68 
(br s, 1H), 2.04 (dt, J = 7.1, 7.1 Hz, 2H), 1.43 (s, 9H), 1.37 (quin, J = 6.1 Hz, 2H), 
1.30−1.23 (m, 16H), 0.87 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3 ) δ 166.5, 
156.0, 137.5, 133.5, 130.1, 130.0, 128.7, 124.9, 80.0, 75.1, 62.1, 54.8, 32.5, 32.1, 
29.8, 29.8, 29.8, 29.6, 29.5, 29.4, 29.0, 28.5, 22.9, 14.3; HRMS (ESI) calcd for 
C28H46NO5 [M
 
+ H]+ m/z 476.3371, found 476.3385. 
 
(2S, 4E)-1-(tert-Butyldimethylsilyloxy)-2-(N-tert-butyloxycarbonylamino) 
hexadec-4-en-3-ol (141). Cat. 2 (0.05 g, 0.08 mmol) was added to a solution of  
(2S)-1-(tert-butyldimethylsilyloxy)-2-(N-tert-butyloxycarbonylamino)-4- 
penten-3-one (135)  (3.69 g, 11.2 mmol) and 1-tridecene (3 mL, 16 mmol) in dry 
CH2Cl2 (170 mL) at rt. The reaction was placed in a preheated oil bath at 40 oC and 
stirred for 2 h. The solvent was evaporated, and the crude product was purified 
using flash column chromatography on silica gel (petroleum ether/EtOAc, 95:5) to 
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(neat) 2926, 2854, 1695, 1488, 1251, 1168, 1113, 834, 776 cm-1; 1H NMR (400 
MHz, CDCl3) δ 6.94 (dt, J = 15.6, 7.0 Hz, 1H), 6.26 (app d, J = 15.7 Hz, 1H), 5.51 
(d, J = 7.4 Hz, 1H), 4.52 (ddd, J = 8.0, 4.4, 4.4 Hz, 1H), 3.95 (dd, J = 10.2, 3.2 Hz, 
1H), 3.81 (dd, J = 10.1, 4.5 Hz, 1H), 2.20 (dt, J = 6.9, 1.2 Hz, 2H), 1.48−1.42 (m, 
12H), 1.30−1.24 (m, 15H), 0.86 (t, J = 6.6 Hz, 3H), 0.82 (s, 9H), −0.01 (s, 3H), −0.02 
(s, 3H) ; 13C NMR (100 MHz, CDCl3 ) δ 196.6, 155.5, 149.4, 127.1, 80.0, 63.9, 59.7, 
32.8, 32.1, 29.8, 29.7, 29.6, 29.5, 29.4, 28.5, 28.2, 25.9, 22.9, 18.4, 14.3, -5.4, -5.4; 
HRMS (ESI) calcd for C27H5 4 NO 4 S i  [M
 
+ H]+ m/z 484.3817, found 484.3838. 
 
(2S)-N-Methoxy-N-methyl 3-(tert-butyldiphenylsilyloxy)- 
(2S)-(N-tert-butyloxycarbonylamino)propanamide (145). Imidazole (3.18 g, 46.7 
mmol) was added to solution of (2S)-N-methoxy-N-methyl 2-(N-tert-
butyloxycarbonylamino)propanamide (132) (3.86 g, 15.6 mmol) in dry DMF (10 mL). 
TBDPSCl (6 mL, 23 mmol) was then added and the reaction was stirred overnight.47 
H2O (200 mL) was added to quench the reaction and the product was extracted out 
with Et2O (3 X 100 mL). The combined Et2O layers were dried (MgSO4), filtered and 
concentrated. The crude product was purified using flash column chromatography 
on silica gel (Petroleum ether/EtOAc, 95:5) to give 145 (5.68 g, 75%) as a colorless 
oil: [α]25D  11.00 (c 1.09, CH2Cl2); IR (neat) 2932, 1713, 1664, 1427, 1365, 1249, 
1166, 1108, 733, 701, 503 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.64 (tt, J = 5.9, 1.5 
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1H), 3.87 (app d, J = 4.8 Hz, 2H), 3.66 (m 3H), 3.19 (s, 3H), 1.44 (s, 9H), 1.04 (s, 
9H); 13C NMR (100 MHz, CDCl3) δ 170.9, 155.6, 135.8, 133.4, 129.9, 127.9, 79.7, 
64.3, 61.6, 52.7, 32.4, 28.6, 26.9, 19.4; HRMS (ESI) calcd for C26H3 9 N 2 O 5 S i  [M
 
+ 
H]+ m/z 487.2623, found 487.2632. 
 
(2S)-1-(tert-Butyldiphenylsilyloxy)-2-(N-tert-butyloxycarbonylamino)-4-penten-
3-one (146). Vinyl magnesium bromide (134) (1 M in THF, 95 mL, 95 mmol) was 
added drop-wise via an addition funnel to a solution of (2S)-N-methoxy-N-methyl 3-
(tert-butyldiphenylsilyloxy)-2-(N-tert-butyloxycarbonylamino)propanamide (145) 
(11.5 g, 23.7 mmol) in THF (70 mL) at 0 oC.47 The reaction was slowly allowed to 
warm to rt and allowed to stirred for 1.5 h. The reaction was cooled to 0 oC, and 
then HCl (aqueous 10%, 50 mL) was added. The product was extracted with EtOAc 
(3 X 50 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated. Purification using flash column chromatography on silica gel 
(petroleum ether/EtOAc, 95:5) yielded 146 (7.22 g, 67%) as a colorless oil: [α]25D  
56.61 (c 1.09, CH2Cl2); IR (neat) 2931, 1699, 1489, 1428, 1364, 1243, 1168, 1108, 
867, 733, 823, 738, 701 614, 503 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.62−7.58 (m, 
4H), 7.45−7.35 (m, 6H), 6.52 (dd, J = 17.4, 10.6 Hz, 1H), 6.34 (app d, J = 17.3 Hz, 
1H), 5.82 (app d, J = 10.6 Hz, 1H), 5.59 (d, J = 7.4 Hz, 1H), 4.68 (ddd, J = 7.8, 4.0, 
4.0 Hz, 1H), 4.01 (dd, J = 10.4, 3.4 Hz, 1H), 3.94 (dd, J = 10.4, 3.8 Hz, 1H), 1.46 (s, 
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133.0, 132.9, 130.1, 129.7, 128.0, 79.9, 64.4, 59.6, 28.6, 27.0, 19.4; HRMS (ESI) 
calcd for C26H36NO4Si [M
 
+ H]+ m/z 454.2408, found 454.2424. 
 
(2S,3R)-1-(tert-Butyldiphenylsilyloxy)-2-(N-tert-butyloxycarbonylamino)-
4penten-3-ol (147). LiAl(Ot-Bu)3H (4.17 g, 16.4 mmol) was added to a solution of 
(2S)-1-(tert-butyldiphenylsilyloxy)-2-(N-tert-butyloxycarbonylamino)-4-penten-3-one 
(146). (3.38 g, 7.45 mmol) in dry EtOH (15 mL) at −78 °C under N2.47 After being 
stirred for 6 h, the mixture was quenched slowly with aqueous HCl (1M, 25 mL) was 
added. The mixture was then diluted with H2O (50 mL). The two layers were 
separated, and the aqueous layer was extracted with EtOAc (3 X 75 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated. Purification 
by flash chromatography on silica gel (petroleum ether/EtOAc, 95:5 to 90:10) gave 
147 (2.15 g, 63%) as a colorless oil: [α]25D  20.88 (c 1.66, CH2Cl2); IR (neat) 3500 
(br) 2960, 2930, 2888, 2857, 1695, 1499, 1427, 1365, 1167, 1110, 822, 740, 701, 
611, 503  cm-1; 1H NMR (400 MHz, CDCl3) δ 7.65−7.62 (m, 4H), 7.47−7.37 (m, 6H), 
5.91 (ddd, J = 17.1, 10.6, 5.0 Hz, 1H), 5.41 (dt, J = 16.9, 1.6 Hz, 1H), 5.25 (dt, J = 
10.6, 1.8 Hz, 2H), 4.34−4.29 (m, 1H), 3.91(dd, J = 10.5, 3.6 Hz, 1H),  3.76 (dd, J = 
10.0, 3.3 Hz, 1H), 3.71 (br s, 1H), 3.29 (app dd, J = 7.6 Hz, 1H), 1.45 (s, 9H), 1.04 
(s, 9H); 13C NMR (100 MHz, CDCl3) δ 156.1, 137.9, 135.8, 132.7, 130.2, 128.1, 
116.3, 79.8, 74.8, 64.3, 55.0, 29.1, 28.6, 27.1, 19.4; HRMS (ESI) calcd for 
C26H38NOSi [M
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(2S,3R,4E)-1-(tert-Butyldiphenylsilyloxy)-2-(N-tert-butyloxycarbonylamino) 
hexadec-4-en-3-ol (148). Pathway 1: Cat.1 (19 mg, 0.02 mmol) was added to a 
solution of (2S,3R)-1-(tert-butyldiphenylsilyloxy)-2-(N-tert-butyloxycarbonylamino)-4-
penten-3-ol (147) (1.00 g, 2.19 mmol) and 1-tridecene (137) (2 mL, 8.8 mmol) in dry 
CH2Cl2 (33 mL) at rt. The reaction was stirred overnight. The solvent was 
evaporated and the crude product was purified using flash column chromatography 
on silica gel (petroleum ether/EtOAc, 95:5) to provide 148 (0.42 g, 31%) as a light 
brownish oil; Pathway 2: LiAl(Ot-Bu)3H (5.03 g, 19.8 mmol) was added to (2S,4E)-1-
(tert-butyldiphenylsilyloxy)-2-(N-tert-butyloxycarbonylamino)hexadec-4-ene-3-one 
(148a) (5.48 g, 8.99 mmol) in dry EtOH (36 mL) at −78 °C.61 After being stirred for 1 
h, the mixture was quenched slowly with aqueous HCl (1M, 20 mL) was added 
slowly. The mixture was then diluted with H2O (50 mL). The two layers were 
separated and the aqueous layer was extracted with EtOAc (3 X 50 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated. Purification 
by flash chromatography on silica gel (petroleum ether/EtOAc, 95:5 to 90:10) gave 
148 (4.08 g, 74%) as a colorless oil: [α]25D  13.05 (c 1.64, CH2Cl2); IR (neat) 2924, 
2854, 1698, 1498, 1428, 1365, 1169, 1111, 966, 822, 740, 701, 613, 504 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.64 (t, J = 12.2 Hz, 4H), 7.46−7.36 (m, 6H), 5.78 (dt, J = 
14.4, 6.5 Hz, 1H), 5.48 (dd, J = 15.4, 6.0 Hz, 1H), 5.19 (d, J = 7.0 Hz, 1H), 4.24 
(app ddd, J = 6.5, 6.5, 6.5 Hz, 1H), 3.91 (dd, J = 10.5, 3.6 Hz, 1H), 3.76 (dd, J = 
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Hz, 2H), 1.45 (s, 9H), 1.37−1.32 (m, 3H), 1.31−1.26 (m, 15H), 1.07 (s, 9H), 0.88 (t, J 
= 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3 ) δ 156.1, 135.8, 133.6, 132.8, 132.8, 
130.2, 129.4, 128.1, 79.7, 74.5, 64.3, 55.3, 32.6, 32.1, 29.9, 29.9, 29.8, 29.7, 29.6, 
29.5, 29.4, 28.6, 27.1, 22.9, 19.4, 14.3; HRMS (ESI) calcd for C37H60NO4Si [M
 
+ H]+ 
m/z 610.4286, found 610.4309. 
 
(2S, 4E)-1-(tert-Butyldiphenylsilyloxy)-2 
-(N-tert-butyloxycarbonylamino)hexadec-4-en-3-one (148a). Cat. 3 (30 mg, 0.04 
mmol) was added to a solution of (2S)-1-(O-tert-butyldiphenylsilyl)-2-(N-tert-
butyloxycarbonylamino)-4-pentene-3-one (146). (2.02 g, 0.441 mmol) and 1-
tridecene (2.2 mL, 8.8 mmol) in dry CH2Cl2 (65 mL). The reaction was allowed to stir 
in a preheated oil bath at 40 oC for 4h. The solvent was evaporated and the crude 
product was purified using flash column chromatography on silica gel (petroleum 
ether/EtOAc, 95:5) to give 148a (2.38 g, 88%) as a slightly brownish oil: [α]25D  41.8 
(c 1.0, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.62−7.58 (m, 4H), 7.44−7.34 (m, 6H), 
6.96 (dt, J = 14.1, 6.8 Hz, 1H), 6.23 (app d, J = 15.7 Hz, 1H), 5.62 (d, J = 7.7 Hz, 
1H), 4.63 (ddd, J = 7.9, 4.0, 4.0 Hz, 1H), 3.97 (dd, J = 10.4, 3.6 Hz, 1H), 3.92 (dd, J 
= 14.4, 4.0 Hz, 1H), 2.20 (dt, J = 7.0, 7.0 Hz, 2H), 1.45 (s, 9H), 1.31−1.26 (m, 19H), 
1.01 (s, 9H), 0.88 (t, J = 6.7 Hz, 3H), 0.82 (s, 9H); 13C NMR (100 MHz, CDCl3 ) δ 
196.4, 155.5, 149.7, 135.8, 135.7, 133.1, 133.1, 130.0, 127.9, 127.9, 127.0, 79.8, 
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19.5, 14.4; HRMS (ESI) calcd for C37H58NO4Si [M
 




TBAF (1.0 M in THF, 6.6 mmol, 6.6 mL) was added drop-wise to a solution of 
(2S,3R,4E)-1-(tert-butyldiphenylsilyloxy)-2-(N-tert-butyloxycarbonylamino)hexadec-
4-en-3-ol (148) (1.82 g, 2.98 mmol) in THF (60 mL) at 0 oC. The cooling bath was 
removed, and the mixture was stirred for 2 h at rt. Saturated aqueous NH4Cl (30 
mL) was added. The product was extracted with Et2O (3 X 100 mL). The combined 
organic layers were dried (MgSO4), filtered and concentrated. Purification by flash 
chromatography on silica gel (petroleum ether/EtOAc 60:40) provided 155 (0.82 g, 
74%) as a white solid: mp 54.1−55.4 oC; [α]25D −2.57 (c 1, CH2Cl2); IR (neat) 3342, 
2916, 2849, 1687, 1531, 1464, 1365, 1244, 1172, 1062, 1004, 906, 649 cm-1; 1H 
NMR (400 MHz, CDCl3) δ  5.75 (dt, J = 14.6, 6.6 Hz, 1H), 5.50 (dd, J = 15.4, 6.3 Hz, 
1H), 5.34 (d, J = 8.0 Hz, 1H), 4.27 (app ddd, J = 5.0, 5.0 Hz, 1H), 3.90 (dd, J = 11.2, 
3.2 Hz, 1H), 3.67 (app d, J = 11.0 Hz, 1H), 3.57 (br s, 1H), 3.10 (br s, 2H), 2.03 (dt J 
= 6.5, 6.5 Hz, 2H), 1.43 (s, 9H), 1.35 (t, J = 14.9 Hz, 2H), 1.24 (s, 16H), 0.86 (t, J = 
6.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 156.5, 134.2, 129.1, 80.0, 74.8, 65.3, 
55.7, 32.5, 32.1, 29.8, 29.8, 29.7, 29.5, 29.4, 29.3, 28.6, 22.9, 14.3; HRMS (ESI) 
calcd for C21H42NO4 [M
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(2S,3R,4E)-2-(Amino)hexadec-4-en-1,3-diol (123). TFA (4 mL) (2S,3R,4E)-2-(N-
tert-butyloxycarbonylamino)hexadec-4-en-1,3-diol (155) (0.77 g, 2.08 mmol) in 
CH2Cl2 (4 mL) at 0 oC. The reaction was stirred at 0 oC for 3.5 h, after which TLC 
still showed starting material. TFA (2 mL) was added, and the solution was stirred 
for an extra 30 min. 1 M NaOH was then added to pH 10. The product was 
extracted with EtOAc (3 X 75 mL). The combined organic layers were dried 
(MgSO4), filtered and concentrated. The crude product was carried forward to 
acylation, but some of it was saved and purified using flash column chromatography 
on silica gel (petroleum ether/EtOAc, 70:30) to give 123 as a yellowish, viscious oil: 
[α]25D −2.22 (c 0.64, MeOH); IR (neat) 2920, 2851, 1465, 1138, 1045, 970, 719 cm-1; 
1H NMR (400 MHz, CD3OD) δ  5.84 (dt, J = 14.6, 6.8 Hz, 1H), 5.51 (dd, J = 15.4, 
7.0 Hz, 1H), 4.19 (dd, J = 5.8, 5.8 Hz, 1H), 3.77 (dd, J = 11.2, 3.9 Hz, 1H), 3.63 (dd, 
J = 11.2, 7.8 Hz, 1H), 3.05 (ddd, J = 7.9, 4.8, 4.8 Hz, 1H), 2.13 (dt J = 6.8, 6.8 Hz, 
2H), 1.45 (quin, J = 7.6 Hz, 2H), 1.37−1.32 (m, 16H), 0.93 (t, J = 6.5 Hz, 3H); 13C 
NMR (100 MHz, CD3OD) δ 136.6, 129.9, 73.1, 61.9, 58.8, 33.9, 33.6, 31.3, 31.2, 
31.1, 31.0, 30.8, 30.8, 24.2, 14.9; HRMS (ESI) calcd for C16H34NO2 [M
 
+ H]+ m/z 
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(2S,3R,4E)-2-(N-15Z-Tetracosenoylamino)hexadec-4-en-1,3-diol (149). p-
Nitrophenyl 15Z-tetracosenoate (77) (1.26 g, 2.50 mmol) was added to a solution of 
(2S,3R,4E)-2-(amino)hexadec-4-en-1,3-diol 123 (0.77 g, 2.1 mmol) in pyridine (36 
mL). The mixture was stirred in a preheated oil bath at 40 oC overnight. The reaction 
was concentrated and purified by flash column chromatography on silica gel 
(CH2Cl2/MeOH, 95:5) to give 149 (0.61 g, 75%) as a white solid: mp 72.1−73.4 oC; 
[α]25D −2.51 (c 0.84, CDCl3/MeOH, 3:2); IR (neat) 2916, 2849, 1645, 1465, 720 cm-1; 
1H NMR (400 MHz, CDCl3) δ 6.22 (d, J = 7.3 Hz, 1H), 5.78 (dt, J = 14.5, 6.3 Hz, 
1H), 5.53 (dd, J = 15.4, 6.4 Hz, 1H), 5.38−5.31 (m, 2H), 4.31 (br s, 1H), 3.97−3.88 
(m, 2H), 3.70 (app d, J = 11.1 Hz, 1H), 2.70 (br s, 2H), 2.23 (t J = 7.4 Hz, 2H), 
2.08−1.99 (m, 6H), 1.67−1.60 (m, 3H), 1.40−1.26 (m, 49H), 0.88 (t, J = 6.6 Hz, 6H); 
13C NMR (100 MHz, CDCl3) δ 174.1, 134.5, 130.1, 129.0, 74.9, 62.8, 54.7, 37.1, 
32.5, 32.1, 30.0, 29.9, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 27.4, 26.0, 22.9, 
14.3; HRMS (ESI) calcd for C40H78NO3 [M
 
+ H]+ m/z 620.5976, found 620.5962. 
 
2S,3R,4E)-2-(N-15Z-Tetracosenoylamino)-1-triphenylmethoxyhexadec-4-en-3-
ol. TrCl (0.13 g, 0.45 mmol) was added to a mixture of (2S,3R,4E)-2-(N-15Z-
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0.45 mmol) in dry EtOAc (1.6 mL).62 The mixture was stirred in a preheated oil bath 
at 80 oC overnight. The solvent was evaporated under reduced pressure, and the 
crude product was purified by flash chromatography on silica gel (petroleum 
ether/EtOAc, 90:10) to provide (2S,3R,4E)-2-(N-15Z-tetracosenoylamino)-1-
triphenylmethoxy-hexadec-4-en-3-ol (0.21 g, 66%) as a yellowish oil: [α]25D  −1.54 (c 
0.85, CH2Cl2); IR (neat) 2921, 2851, 1642, 1448, 1074, 702, 632 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.40 (d, J = 7.2 Hz, 5H), 7.31 (t, J = 7.8 Hz, 5H), 7.27−7.23 (m, 5H), 
6.05 (d, J = 7.9 Hz, 1H), 5.64 (dt, J = 14.5, 6.4, 1H), 5.38−5.31 (m, 1H), 5.26 (dd, J 
= 15.4, 6.2 Hz, 1H), 4.20−4.16 (m, 1H), 4.06 (dddd, J = 7.7, 3.8, 3.8, 3.8 Hz, 1H), 
3.39 (dd, J = 9.7, 3.7 Hz, 1H), 3.35 (dd, J = 8.2, 0.0 Hz, 1H), 3.30 (dd, J = 9.8, 4.0 
Hz, 1H), 2.20 (t, J = 7.5 Hz, 2H), 2.01 (dt, J = 6.3, 6.3 Hz, 4H), 2.00−1.89 (m, 2H), 
1.64 (quin, J = 6.8 Hz, 2H), 1.34−1.26 (m, 50H), 0.88 (t, J = 7.0 Hz, 6H); 13C NMR 
(100 MHz, CDCl3) δ 173.5, 143.5, 134.8, 133.7, 130.1, 128.9, 128.7, 128.2, 127.5, 
87.6, 74.6, 63.3, 53.6, 37.1, 32.4, 32.1, 30.0, 29.9, 29.8, 29.7, 29.7, 29.6, 29.6, 
29.5, 29.5, 29.3, 27.4, 26.1, 24.7, 22.9, 19.8, 14.3; HRMS (ESI) calcd for C59H92NO3 
[M
 
+ H]+ m/z  862.7072, found 862.7116. 
 
(2S,3S,4E)-3-Benzoyloxy-2-(N-15Z-tetracosanoylamino)-1-
triphenylmethoxyhexadec-4-ene. BzCl (2.73 g, 2.26 mL, 19.5 mmol) was added 
to a solution of 2S,3R,4E)-2-(N-tetracosanoylamino)-1-triphenylmethoxyhexadec-4-
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The reaction mixture was allowed to stir overnight. Ice-cold H2O (50 mL) was 
added. The resulting mixture was extracted with CH2Cl2 (3 X 30 mL). The combined 
organic layers were dried (MgSO4), filtered and concentrated. Flash 
chromatography purification of the crude product on silica gel (petroleum 
ether/EtOAc, 95:5) gave (2S,3S,4E)-3-benzoyloxy-2-(tetracosanoylamino)-1-
triphenylmethoxyhexadec-4-ene (2.42 g, 63%) as colorless oil:  [α]25D  5.56 (c 1.4, 
CH2Cl2); IR (neat) 2922, 2852, 1720, 1449, 1265, 1108, 707 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.86 (d, J = 7.2 Hz, 2H), 7.47 (t, J = 7.4 Hz, 1H), 7.34−7.30 (m, 8H), 
7.27−7.23 (m, 9H), 5.80 (dt, J = 14.8, 6.7 Hz, 1H), 5.64−5.58 (m, 2H), 5.38 (dd, J = 
15.4, 7.5 Hz, 1H), 5.29−5.24 (m, 2H), 4.45−4.39 (m, 1H), 3.37 (dd, J = 9.6, 3.6 Hz, 
1H), 3.12 (dd, J = 9.6, 4.2 Hz, 1H), 2.03 (t, J = 7.5 Hz, 2H), 1.96−1.89 (m, 2H), 1.49 
(quin, J = 8.6 Hz, 2H), 1.34−1.26 (m, 54H), 0.80 (t, J = 6.2 Hz, 6H); 13C NMR (100 
MHz, CDCl3) δ 172.7, 165.5, 143.7, 137.4, 133.1, 130.5, 130.1, 129.9, 128.8, 128.5, 
128.1, 127.3, 125.3, 87.0, 74.6, 61.9, 51.3, 37.2, 32.5, 32.1, 30.0, 30.0, 29.9, 29.9, 
29.8, 29.8, 29.7, 29.7, 29.7, 29.6, 29.5, 29.529.1, 27.4, 26.0, 22.9, 14.3; HRMS 
(ESI) calcd for C66H96NO4 [M
 
+ H]+ m/z  966.7334, found 966.7241. 
 
(2S,3R,4E)-3-Benzoyloxy-2-(N-15Z-tetracosenoylamino)hexadec-4-en-1-ol 
(150). pTsOH•H2O (56 mg, 0.30 mmol) was added to a solution of (2S,3R,4E)-3- 
benzoyloxy-2-(N-tetracosanoylamino)-1-triphenylmethoxyhexadec-4-ene (0.26 g, 
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quenched with sat. NaHCO3 (10 mL) and the product was extracted with CH2Cl2 (3 
X 15 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated to give 150 (99 mg, 56%) as a creamy white solid:  [α]25D  12.6 (c 1.4, 
CH2Cl2); IR (neat) 2917, 2849, 1721, 1645, 1547, 1466, 1265, 1111, 963, 711 cm-1; 
1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 7.7 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.38 
(t, J = 7.7 Hz, 2H), 6.06 (d, J = 8.6 Hz, 1H),  5.85 (dt, J = 14.5, 6.7 Hz, 1H), 5.61 
(dd, J = 15.2, 7.7 Hz, 1H), 5.53 (dd, J = 7.5, 7.5 Hz, 1H), 5.35 (dt, J = 4.8, 0.0 Hz, 
2H), 4.27 (dddd, J = 10.7, 10.7, 2.9, 2.9 Hz, 1H), 3.75−3.68 (m, 2H), 2.19 (dt, J = 
14.3, 7.0 Hz, 2H), 2.07−1.97 (m, 6H), 1.61 (quin, J = 7.3 Hz, 2H), 1.33−1.24 (m, 
51H), 0.86 (t, J = 6.2 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 173.6, 166.8, 137.8, 
133.7, 130.1, 130.0, 129.9, 128.8, 125.0, 74.9, 62.1, 53.7, 37.1, 32.5, 32.1, 30.0, 
30.0, 29.9, 29.9, 29.9, 29.9,29.8, 29.8, 29.7, 29.7, 29.6, 29.6, 29.6, 29.5, 29.5, 29.4, 
27.4, 27.4, 26.0, 22.9, 14.3; HRMS (ESI) calcd for C47H82NO4 [M
 
+ H]+ m/z 




galactopyranosyl)-1-trichloroacetimidate (70) (0.19 g, 0.26 mmol) and (2S,3R,4E)-3- 
benzoyloxy-2-(N-15Z-tetracosenoylamino)hexadec-4-en-1-ol (150) (0.11 g, 0.17 
mmol) were dissolved in dry CH2Cl2 (3.7 mL), and the solution was stirred in the 
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mL) was added within 10 min at –10 oC and the reaction was stirred at this 
temperature for 4 h. The reaction mixture was diluted with petroleum ether (5 mL) 
and then filtered. The filtrate was treated with saturated NaHCO3 (50 mL). The 
organic layer was separated and the aqueous phase was extracted with CH2Cl2 (3 
X 10 mL). The combined organic layers were dried (MgSO4), filtered and 
concentration. Purification by flash column chromatography on silica gel (petroleum 
ether/EtOAc, 90:10) gave 151 (69 mg, 33%, β) as a colorless oil: [α]25D  0.591 (c 
1.04, CH2Cl2); IR (neat) 2921, 2852, 1740, 1461, 1275, 1141, 1073, 711 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.02 (d, J = 7.2 Hz, 2H), 7.54 (tt, J = 6.7, 1.3, Hz, 1H), 
7.43 (t, J = 7.8 Hz, 2H), 5.88 (dt, J = 14.5, 6.8 Hz, 1H), 5.73 (d, J = 9.1 Hz, 1H), 5.54 
(dd, J = 14.6, 7.3 Hz, 1H), 5.47 (app t, J = 7.5 Hz, 1H), 5.38–5.29 (m, 3H),  5.18 (dd, 
J = 7.7, 2.7 Hz, 1H), 5.07 (dd, J = 10.4, 3.2 Hz, 1H), 4.49–4.44 (m, 2H), 4.07 (dd, J 
= 9.8, 3.6 Hz, 1H), 3.89–3.79 (m, 3H), 3.64 (dd, J = 9.8, 3.6 Hz, 1H), 2.12 (dt, J = 
14.0, 7.4 Hz, 2H), 2.05–1.99 (m, 6H), 1.61–1.51 (m, 3H), 1.32–1.24 (m, 57H), 1.19–
1.16 (m, 1H), 1.14–1.11 (m, 27H),  0.87 (t, J = 5.9 Hz, 6H); 13C NMR (100 MHz, 
CDC13) δ 177.8, 177.4, 177.0, 172.8, 165.2, 137.6, 133.1, 130.5, 130.1, 129.8, 
128.6, 125.1, 100.9, 74.2, 71.2, 71.0, 69.2, 67.3, 66.7, 60.9, 51.0, 39.3, 39.0, 39.0, 
38.8, 37.1, 32.6, 32.1, 30.0, 30.0, 29.9, 29.9, 29.8, 29.8, 29.7, 29.7, 29.6, 29.5, 
29.5, 29.5, 29.2, 27.4, 27.4, 27.3, 27.2, 25.9, 22.9, 14.3; HRMS (ESI) calcd for 
C47H124NO13 [M
 
+ H]+ m/z 1222.9067, found 1222.9059.; trans-esterification 
sphingosine product 152: 1H NMR (400 MHz, CDC13) δ 8.03–8.01 (m, 2H), 7.57 (tt, 
J = 6.7, 1.6, Hz, 1H), 7.47–7.43 (m, 2H), 5.88 (dt, J = 14.4, 6.8 Hz, 1H), 5.76 (d, J = 
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9.2 Hz, 1H), 5.56 (dd, J = 12.4, 7.2 Hz, 1H), 5.50 (dddd, J = 7.3, 7.3, 0.9, 0.9 Hz, 
1H), 5.39–5.31 (m, 2H), 4.66–4.60 (m, 1H), 4.34 (dd, J = 11.6, 7.1 Hz, 1H), 4.18 
(dd, J = 11.6, 4.3 Hz, 1H), 2.15 (t, J = 7.1 Hz, 2H), 2.07–2.00 (m, 6H), 1.59 (quin, J 
= 8.0 Hz, 2H), 1.37–1.24 (m, 50H), 1.20 (s, 9H), 0.88 (t, J = 6.2 Hz, 6H); 13C NMR 
(100 MHz, CDC13) δ 178.8, 172.9, 165.6, 137.5, 133.4, 130.1, 129.9, 128.7, 124.5, 
74.9, 62.7, 51.2, 39.1, 37.1, 32.6, 31.1, 30.0, 29.9, 29.8, 29.7, 29.7, 29.7, 29.6, 
29.6, 29.6, 29.5, , 29.5, 29.4, 29.1, 27.4, 27.4, 25.9, 22.9, 14.3. 
 
(2S,3R,4E)--1-(β-D-Galactopyranosyloxy)-2-(N-15Z-
tetracosenoylamino)hexadec-4-en-3-ol (153). NaOMe (0.35 mL, 0.18 mmol) was 
added to a solution of (2S,3R,4E)-3-benzoyloxy-1-(2,3,4,6-tetra-O-pivaloyl-β-D-
galactopyranoside)-2-(N-15Z-tetracosenoylamino)hexadec-4-ene (151) (36 mg, 
0.03 mmol) in a mixture of CH2Cl2/MeOH (0.24:0.24 mL). The reaction was stirred 
at rt for 1 h and then neutralized to pH 2 with dowex (H+ resin). The mixture was 
filtered through a pad of celite, and the celite was washed with a 1:1 mixture of 
CHCl3 and MeOH (10 mL). The filtrate was concentrated and purified using flash 
column chromatography on silica gel (CH2Cl2/MeOH, 95:5) to give 153 (17 mg, 
76%) as a white solid: mp 158.0−159.1 oC; [α]25D  0.267 (c 1.01, CHCl3/MeOH, 3:2); 
IR (neat) 3298, 2916, 2849, 1644, 1545, 1467, 1083, 718 cm-1; 1H NMR (400 MHz, 
CDCl3/CD3OD, 3:2) δ 5.69 (dt, J = 14.9, 6.7 Hz, 1H), 5.45 (dd, J = 15.4, 7.4 Hz, 1H), 
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(dd, J = 7.5, 7.5 Hz, 1H), 4.00 (dddd, J = 7.9, 7.9, 4.4, 4.4 Hz, 1H), 3.87 (app d, J = 
2.6 Hz, 1H), 3.81 (dd, J = 11.5, 6.7 Hz, 1H), 3.73 (dd, J = 11.5, 5.0 Hz, 1H), 3.60–
3.48 (m, 4H), 2.17 (t, J = 7.4 Hz, 2H), 2.01 (dt, J = 6.3, 6.3 Hz, 6H), 1.58 (quin, J = 
6.8 Hz, 2H), 1.38–1.26 (m, 50H), 0.88 (t, J = 6.5 Hz, 6H); 13C NMR (100 MHz, 
CDCl3/CD3OD, 3:2) δ 175.6, 135.1, 130.8, 130.2, 104.7, 76.1, 74.4, 72.9, 72.3, 
70.0, 69.7, 62.4, 54.4, 37.4, 33.3, 32.9, 32.8, 30.6, 30.6, 30.5, 30.4, 30.4, 30.3, 
30.2, 28.1, 26.9, 23.6, 14.8; HRMS (TOF) m/z calcd for C46H88NO8 [M + H]+ 
782.6504, found 782.6502. 
 
(2S,3R,4E)-2-(ammonium)hexadecen-3-ol-1-phosphate (154). TMSBr (0.09 mL, 
0.70 mmol) was added drop-wise to a solution of (2S,3R,4E)-2-(amino)hexadecen-
3-ol-1-methyl phosphate (156) (0.04 g, 0.08 mmol) in CH2Cl2 (0.43 mL) at 0 oC. The 
reaction was stirred at rt for 30 min. AcOH (0.5 mL) was added, followed by the 
addition of ice water until precipitates were formed. The mixture was centrifuged 
and the H2O layer was removed. The solid residue was further washed with H2O (3 
X 10 mL) and centrifugation was repeated each time to remove the H2O. The solid 
residue was washed with a mixture of acetone/H2O (1:1 v/v, 3 X 5 mL). The sample 
was then left on the high vacuum to remove excess solvents to provide 154 (19 mg, 
63%) as a white solid: mp 154.9−156.4 oC; [α]25D  4.15 (c 0.17, MeOH); IR (neat) 
3435, 2918, 2849, 1543, 1463, 1243, 1028, 923, 510 cm-1; 1H NMR (400 MHz, 
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= 5.9, 5.9 Hz, 1H), 4.12 (ddd, J = 11.6, 7.3, 3.4 Hz, 1H), 4.04−3.96 (m, 1H), 
3.39−3.33 (m, 1H), 2.13 (dt J = 7.0, 7.0 Hz, 2H), 1.46 (quin, J = 7.2 Hz, 2H), 
1.39−1.32 (m, 17H), 0.93 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, MeOD) δ 135.7, 
127.0, 63.6, 61.8 (d, JC-P = 4.8 Hz), 56.4 (d, JC-P = 6.4 Hz), 32.2, 31.9, 29.6, 29.5, 
29.6, 29.5, 29.3, 29.2, 29.0, 22.5, 13.2, −1.2; 31p NMR (400 MHz, MeOD) δ 1.31; 
HRMS (ESI) calcd for C16H35NO5P [M
 
+ H]+ m/z 352.2247, found 352.2286. 
 
(2S,3R,4E)-2-(N-tert-butyloxycarbonylamino)hexadec-4-en-3-ol-1-methyl 
phosphate (156). P(OMe)3 (0.04 mL, 0.034 mmol) was added drop-wise to a 
solution of (2S,3R,4E)-1-(tert-butyldiphenylsilyloxy)-2-(N-tert-
butyloxycarbonylamino)hexadec-4-en-3-ol (148) (100 mg, 0.27 mmol) and CBr4 
(0.123 g, 0.371 mmol) in pyridine (0.13 mL) at 0 oC. The reaction was stirred at the 
same temperature for 4.5 h, after which the precipitate formed was filtered off and 
rinsed with EtOAc (15 mL). The filtrate was washed with brine (10mL). The two 
layers were separated and the organic layer was dried (MgSO4), filtered and 
concentrated. The crude product was purified using flash column chromatography 
on silica gel (petroleum ether/EtOAc, 60:40) to yield 156 (41 mg, 32%) as a 
colorless oil: [α]25D  5.56 (c 0.17, CH2Cl2); IR (neat) 2923, 2853, 1714, 1457, 1365, 
1249, 1171, 1036, 825 cm-1; 1H NMR (400 MHz, CDCl3) δ  5.76 (dt, J = 14.9, 6.7 
Hz, 1H), 5.48 (dd, J = 15.4, 6.7 Hz, 1H), 5.06 (d, J = 7.0 Hz, 1H), 4.31 (dddd, J = 
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1H), 2.01 (dt J = 6.8, 6.8 Hz, 2H), 1.42 (s, 9H), 1.37−1.33 (m, 2H), 1.30−1.24 (m, 
17H), 0.86 (t, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 134.9, 128.7, 79.9, 
72.6, 66.9 (d, JC-P = 2.8 Hz), 55.1, 54.7 (d, JC-P = 5.5 Hz), 32.5, 32.1, 29.9, 29.8, 
29.8, 29.7, 29.5, 29.4, 29.3, 28.5, 22.9, 14.3; 31p NMR (400 MHz, CDCl3) δ 1.85; 
HRMS (ESI) calcd for C23H47NO7P [M
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Chapter 2. 
2.1. Introduction 
2.1.1. Oxetanes as important scaffolds in natural product synthesis and 
methodological development 
A major area of research in the Howell group focuses on exploring the reactivity of 
oxetanes, particularly 2-methyleneoxetanes 158 and α-methylene-β-lactones 161 
respectively in designing new synthetic routes for the preparation of biologically 
interesting natural products and their analogs (Figure 30). In addition, the unusual 
exocyclic unsaturation present in 158 and 161 is taken advantage of to develop 
novel transformations. For example 2-Methyleneoxetanes such as 158 have been 
used by Liang et al. in a three-component reaction to synthesize a psico-oxetanocin 
164 and its analogs,63 and Keshipeddy et al.64 employed dispirohexanes (see 163) 
derived from 158 in their efforts to prepare laureatin (165). The focus of this 
dissertation is the olefin cross metathesis (CM) of α-methylene-β-lactones to access 
α-alkylidene-β-lactones 162 and their subsequent 1,4-reduction.  
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2.1.2. Olefin cross metathesis of α-methylene-β-lactones 
 In 2006, Howell and Raju demonstrated that α-methylene-β-lactone 16865 can 
undergo olefin cross metathesis (CM) with a variety of type I65 alkene cross partners 
169 to give tri-substituted α-alkylidine-β-lactones 170 (Table 1). The reactions 
proceeded in excellent yields with high Z-selectivity using either Grubb’s 2nd or 
Grubbs-Hoveyda 2nd generation catalysts (Cat. 1 and 2 respectively). The high Z-
selectivity of the reactions was attributed to steric effects from the CHPh2 group at 
the C-4 position of lactone 168. This steric argument was confirmed by a drop in the 
selectivity when the CHPh2 group was substituted with the (CH2)2Ph  (CM of 171 to 
give 172, Table 1). 
 
Entry R1 Catalyst Yield (%) Z:E 
1 (CH2)2OAc 1 84 >20:1 
2 (CH2)3OAc 1 90 >20:1 
3 (CH2)4OAc 1 85 >14.1 
4 (CH2)8OAc 1 84 >20:1 
5 Ph 1 55b >20:1 
6 (CH2)2CH3 1 94 11:1 
7 (CH2)2Br 1 93 >20:1 
8 CH2Cl 2 80 12:1 
9 (CH2)2OTBDMS 1 88 9:1 
10 CH2ORa 1 or 2 NR  
 
aReaction did not work with allylic alcohols, whether protected or not (R = Bn, Ac, TBDMS, or TBDPS);  bisolated Z-isomer 
yield 
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The CM methodology was extended in 2009 by Liang et al. to α-methylene-β-
lactams 173, furnishing tri- and tetra-substituted α-alkylidine-β-lactams 175 and 176 
respectively (Scheme 31).66 The tetra-substituted α-alkylidine-β-lactams exemplified 


















The versatility of the CM reactions prompted application studies, and substituted β-
lactones attracted our attention. β-lactones are a common moiety present in natural 
products, and many of these have been shown to have important biological 
activities. 
2.1.3. β-Lactones as inhibitors of fatty acid synthase (FAS) 
β-Lactones have been shown to be potent, irreversible inhibitors of serine hydrolase 
enzymes. For example, tetrahydrolipstatin (THL, orlistat 166), an anti-obesity drug, 
is an irreversible inhibitor of the thioesterase domain of fatty acid synthase (FAS).67 
FAS is the largest multi-component enzyme in eukaryotes, with six enzymatic 
domains (acyl carrier protein (ACP), β-ketoacyl synthase (KS), malonyl/acetyl 












R'  = CH2Ph




173a; R = H
173b; R = Me
R1






R1 = OAc, OTBDMS, Cl, CH3




CH2Cl2, reflux, 54-90 %
R' 2 mol%  Cat. 2
CH3
173a 174b
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thioesterase (TE)) (Figure 31) that work together to synthesize palmitic acid 
(177).68,69 FAS became a target for cancer therapy when it was found to be up-
regulated in tumor cells found in breast tissues and prostate glands.70-72 Cell 
proliferation was observed with the secretion of palmitic acid, and the inhibition of its 









































































Cycle is repeated 7 times
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Since this discovery, many research endeavors have been aimed at discovering 
compounds that can selectively inhibit FAS. Cerulenin (179) and C75 (178) inhibit 
FAS by binding to the β-ketoacyl synthase (KS) domain (Figure 31). Unfortunately, 
their therapeutic exploration was halted because their inhibitory mechanism was 
non-selective. They also bind to other important biological proteins, causing 
excessive weight loss.73 Orlistat (166), in contrast, selectively targets the 
thioesterase (TE) domain (Figure 32). This pocket has a serine residue (Ser 2308) 
that interacts with a palmitic acid precursor, causing hydrolytic cleavage of its 
thioester bond, thus producing palmitic acid (177). Orlistat competes and obstructs 
this action via nucleophilic addition of the enzyme to its carbonyl group leading to 





















Figure 32. Orlistat mediated inhibition of FAS: a. Proposed interactions of orlistat in 
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2.1.4. Development of synthetic routes to prepare β-lactones as FAS 
inhibitors 
The fact that orlistat is an irreversible inhibitor of FAS has generated a lot of interest 
in exploring β-lactones as cancer therapeutic agents and in the development of 
synthetic routes for their easy availability for biological analyses. A major pioneer in 
this area has been the Romo research group. They have made remarkable 
contributions by developing asymmetric reaction sequences that provide β-lactone 
libraries. Their first route was a ketene dimerization pathway to give alkylidene β-
lactones 182 that underwent hydrogenation to give cis β-lactones 183, which upon 
epimerization under basic conditions gave their corresponding trans β-lactones 184 
(Scheme 32).75 This methodology has two major drawbacks; the epimerization step 
is low yielding and is only applicable for synthesizing substrates with identical 
substituents (R groups). Regardless, a focused library of β-lactones, including the 
ketene dimers and cis- and trans-β-lactones, was assembled (Table 2) and the 
compounds were evaluated as FAS inhibitors. In general, the trans-β-lactones 
displayed the highest inhibitory activity, but it was cis -183d that showed the highest 
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Entry Compd. R Ki (µM) Entry Compd.  R Ki (µM) 
1 182a  17± 3 9 orlistat 
(166) 
 0.28± 0.06 
2 182b  13 ± 1 10 183a  23± 4 
3 182c 
 
>100 11 183b  14± 8 
4 182d 
 
5.0± 2.1 12 183c 
 
7.7 ±0.4 
    13 183d 
 
2.5± 0.5 
Entry Compd. R Ki (µM) 14 183e 
 
>100 
5 184a  4.0± 1.9 15 183f  35± 5 
6 184b  6.7 ± 1.0     
7 184c  6.3 ± 0.7     
8 184d  3.3 ± 0.2     
 
Table 2. Inhibitory activity of orlistat inspired β-lactones75 
 
The material depleting epimerization step in the ketene dimerization strategy was 
avoided by developing a second route; a tandem Mukaiyama Aldol lactonization 
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approach is also more suitable for diversification studies. It was used to synthesized 
orlistat (166), some derivatives, and other trans β-lactones, such as valollactone 
(188), which has a higher inhibitory activity than orlistat due to its better solubility. 
 
Scheme 33. Tandem Mukaiyama Aldol lactonization (TMAL) approach 
 
2.1.5. Purpose of study 
Extensive investigation of the promising therapeutic activities of β-lactones has 
been limited in scope, partly due to a lack of synthetic methodologies. Encouraged 
by the success in the preparation of α-alkylidine-β-lactones via CM,  we proposed 
the hydrogenation or diastereoselective 1,4-reduction of α-alkylidine-β-lactones as a 
strategy for the rapid assembly of β-lactones (Scheme 34). This approach would 
serve as a simple, efficient and flexible methodology for the synthesis of a library of 
β-lactones in just two steps from α-methylene-β-lactones. The CM of appropriate α-
methylene-β-lactones such as 189 with alkene cross partners 169 would facilitate 
access to a diverse class of unprecedented α-alkylidine-β-lactones like 190.  
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In addition to these advantages, the diastereoselective 1,4-reduction of the α-
alkylidine-β-lactones would represent the first application of such reductions with 
this class of exocylic enones. Hence, the successful implementation of this 
methodology would showcase CM as a valuable approach for disubstituted β-
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2.2. Discussion and results 
2.2.1. Research objective 
The goal of this study is to synthesize a library of β-lactones. The synthesis of (±)-
nocardiolactone (167), a trans β-lactone, was targeted to illustrate the practicality of 
the methodology. This was a starting point for the FAS inhibitor library development 
and was encouraged by the considerable inhibitory activities of compounds with 
simple alkyl side chains examined by Romo and colleagues in their SAR studies 
(Table 2).  
2.2.2. Retrosynthesis to (±)-nocardiolactone (167) 
Our plan to synthesize (±)-nocardiolactone (167) requires two reactions from α-
methylene-β-lactone 194, a CM with 1-nonadecene (193) to give α-alkylidene-β-
lactone 192, and diastereoselective 1,4-reduction (Figure 33). The α-methylene-β-
lactone 194 can be constructed from tetradecanal (195) following pathway A or B. 





























X = OMe; 196




X = OMe; 196, Pathway A
X = StBu; 197, Pathway B194
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2.2.3. Synthesis of (±)-nocardiolactone (167) 
The synthesis of (±)-nocardiolactone (167) commenced with the preparation of α-
methylene-β-lactone 194 (Scheme 35), initially via pathway A. Quinuclidinol-
catalyzed MBH reaction of tetradecanal 195 and methyl acrylate 196 furnished a β-
hydroxy ester, which was hydrolyzed with LiOH in EtOH to give acid 198. o-Nosyl 
chloride mediated lactonization of 198 in the presence of Na2CO3 as a base 
produced 194. While α-methylene-β-lactone 194 was readily prepared from this 
approach, pathway B provides it in a more efficient and direct sequence. DABCO 
catalyzed MBH reaction of tetradecanal 195 and t-butyl thioacrylate 197 gave MBH 









Scheme 35. Synthesis of α-methylene-β-lactone 194 
 
The prepared α-methylene-β-lactone 194 was then cross-coupled with 1-
nonadecene (193) using Grubbs 2nd generation catalyst (Cat. 1) to give (±)-
nocardiolactone precursor 192 as a mixture of Z/E-isomers (2.2:1) (Scheme 36). 
Hydrogenation of 192 under standard conditions furnished (±)-nocardiolactone 









1. Quinuclidinol, MeOH, 90%















CH3CN, 50 oC, 69%
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order to obtain (±)-nocardiolactone (167) predominantly, diastereoselective 








Scheme 36. CM to give (±)-nocardiolactone precursor 192 and its hydrogenation  
 
2.2.3.1. Diastereoselective 1,4-reduction to give (±)-nocardiolactone (167) 
Since there is no literature precedent for the diastereoselective 1,4-reduction of 
exocyclic enones like 192, known reduction conditions developed for acyclic enones 
and endo- and exo-cyclic enones of γ- and δ-lactones were investigated. As a 
starting point, main group metals shown to chemoselectively participate in 1,4-
reduction were explored. Exocyclic enone 192 was subjected to reducing agents 
such as L- or K-selectride and DIBAL-H (Table 3). L-Selectride (entry 1) gave 
inconsistent yields upon repetition, and no reduction was observed with K-selectride 
or DIBAL-H.  Mg077 catalyzed reduction was also attempted, and this gave opened 
reduced ester product (entry 4).  
Entry Reducing agent Solvent Temp (oC) Results 
1 L-Selectride THF -78 2.5/1 (trans/cis) with sma 
2 K-Selectride THF -78 to rt No reaction 
3 DIBAL-H THF -78 to 0 No reaction 
4 Mg0 MeOH rt Reduced ring opened product 
aResults were inconsistent on repetition, and material recovery was low, sm = starting material 





















dr                      1                                  :                        5
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Consequently, a variety of 1,4-reduction conditions utilizing transition metal hydride 
complexes were explored. Cobalt-hydride complex (203), generated in situ, was 
reported by Ikeno et al.78 as a successful reductant of various acyclic enones such 
201 (Scheme 37) and was examined here. Unfortunately, when 192 was treated 
under the same conditions, no reduction occurred. Only the starting material was 
recovered, even though the observation of the deep red color of 203 confirmed the 
successful formation of the hydride-complex. Warming the reaction gradually to rt 









Scheme 37. Cobalt-hydride (acetylacetonate) aluminum complex 1,4-reduction 
 
 
Standard Stryker [(Ph3P)Cu-H]6 reducing conditions were also tried. After 2h, 1H-
NMR analysis showed only the presence of starting material. Switching to the more 
reactive hot-Stryker reduction conditions utilized by Buchwald79 in the 
diastereoselective reduction of enones of γ-lactone 206, δ-lactam 207 and acylic 
enone 208 (Scheme 38) gratifyingly gave our first successful reduction. However, 
there was only 50% conversion and no diastereoselectivity. Purification wasn’t 
X
O Co(acac)2, DIBAL-H


























X = Me, OEt, NMePh
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performed to isolate the products because the starting material (E/Z isomers) and 








Scheme 38. Hot Stryker 1,4-reduction 
 
 Next, Bu3SnH catalyzed selective hydrogenation in the presence of ZnCl2 and 
Pd(PPh3)4, used by Nakata and co-workers80  for the reduction of exocyclic enone 
212 to 213 in their synthesis of polymaxenolides, was tested (Scheme 39). This 
reduction was anticipated to proceed via a palladium-catalyzed hydrostannation, 
followed by kinetic protonation.  Although the reaction worked, the outcome was 



































CuCl2 2H2O, PMHS, (R)-BINAP
tBuONa, Tol, Pentane, i-PrOH
CuCl2 2H2O, PMHS, (R)-BINAP
tBuONa, Tol, Pentane, i-PrOH
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After trying several more reduction conditions, NaBH4 catalyzed conjugate reduction 
was studied.  Iwasaki and co-workers have reported 1,4-reduction of α-alkylidene-γ-
lactones 214 by NaBH4 in the presence of transition metals (Co, Ni and Cu) (Figure 
34).81 The high diastereoselectivity of the reaction favoring trans isomer 216 
attracted our attention. This was as a result of the stereoselective protonation of 






Figure 34. Iwasaki and co-workers procedure for reduction of exocylic enone 214 
 
Protonation of enolate 218 upon conjugate addition of hydride unto 192 would 
govern the selectivity of the reduction of α-alkylidene-β-lactones (Figure 35). 
Delivery of the proton from the top face of 218 would give (±)-nocardiolactone 
(167), while protonation from the bottom face would give the cis-siomer 200. The 
latter would be projected to be predominant as a result of steric effects from the C4-
substituent, hindering protonation from the top face. To achieve facially selective 
proton delivery to 218 to favor (±)-nocardiolactone (167), other factors that could 
govern the reaction outcome, such as catalyst (and ligands attached), proton source 
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of transition metals, and cobalt emerged as the best, rather than nickel as reported 











Figure 35. Proposed mechanism to obtained (±)-nocardiolactone (167) 
 
The ligands on the catalyst were screened first, as depicted in Table 4 (entries 1, 2 
and 5). The use of Co(PPh3)2Cl2 (entry 5) gave the best diastereoselectivity. The 
temperature effect was investigated next. (±)-Nocardiolactone (167) being the 
thermodynamically more stable product, it was envisioned that perhaps elevating 
the reaction temperature would favor its formation. Unfortunately this hypothesis 
couldn’t be successfully tested with MeOH (which acts both as solvent and proton 
source). The reactions done at elevated temperatures (0 oC or higher) in MeOH 
gave reduced opened lactone product (entry 3), as a result of MeOH being involved 
in nucleophilic addition to the lactone ring. Substituting MeOH with iPrOH or tBuOH, 
bulky and non-nucleophilic proton sources prevented the formation of the open 
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(entry 4 and 6). However, the reaction time (entry 4, reaction time not shown) was 
longer, and DMF (entry 6) was difficult to remove. The used of BINOL (entry 7), a 
chiral proton source caused a slight drop in the diastereoselectivity. The combined 
experimental results lead to entry 5 being selected as the optimized reduction 
conditions. Although the 2:1 diastereoselectivity ratio wasn’t as high as desired, the 
first total synthesis of (±)-nocardiolactone (167) using CM and diastereoselective 
1,4-reduction reactions was now completed.  
 
Table 4. Screening of cobalt catalysts for optimum reduction conditions 
 
2.2.3.2. Synthesis of C3-analogs of (±)-nocardiolactone (167) 
The synthesis of (±)-nocardiolactone C3-analogs was undertaken after its 
successful preparation. In order to target a more comprehensive library, the x-ray 















Entry Catalyst Solvent Temperature        
(oC) 
Hydride Results 
1 CoCl2.6H2O THF : MeOH 




2 Co(acac)2 THF : MeOH 
(4 : 1) 
-5 NaBH4 2:3 cis/ trans  
3 Co(acac)2 THF : MeOH 
(4 : 1) 
0 NaBH4 1:4 cis/trans        
with opened ring 
4 Co(acac)2 THF : i-PrOH 
(4 : 1) 
0 NaBH4 1:2 cis/trans 
5 Co(Ph3P)2Cl2 
(18 mol%) 
THF : MeOH 
(4 : 1) 




DMF : CH2Cl2: 
 tBuOH 








DMF : CH2Cl2: 
 (R)-BINOL 





1:1.3 cis/trans   
	   164	  
The TE domain has four chambers (Figure 36a) in which it accommodates orlistat, 
namely the specificity channel (hosts the long chain of orlistat), the short-chain 
pocket (houses the short hexanoyl side chain), an interface cavity (fits the amide 
moiety) and an oxyanion hole (holds the carbonyl group). Because varied 
substituents at the C-3 position could reside in the short-chain pocket, it was 
targeted for the diversification studies. Substrate studies showing the optimum 
carbon chain for the specificity channel to be C-16 makes it less important for novel 
structure activity relationship (SAR) studies, reinforcing our choice of targeting the 
short chain pocket. When the short-chain pocket was viewed using PyMOL (a 
molecular visualization system), we noticed that the pocket has enough room to 
optimally fit a six-carbon chain, as in orlistat. Although the pocket was small, 
seemingly limiting the chain length of substituents at the C-3 position, the presence 
of certain amino acids residues couldn’t be over looked, because specific 
interactions between these and the inhibitor might result in greater activity. Three 
amino acids residues (Thr2342, Tyr2343 and Tyr2462) were found to be in close 
proximity to the hexanoyl tail of orlistat, also seen in the stereo view reported as by 



















Figure 36. a. Chambers of the thioesterease domain (TE) of FAS; b. stereo view of 
the short-chain pocket of the TE74 
 
 
These provided us with an insight for selecting substituents for our first 
diversification studies. Five additional alkene cross partners (219a–219e) were 
targeted including 1-heptene 219a to give a C-3 hexanoyl analog of nocardiolactone 
to compare with orlistat, three compounds (219b–219d) that have terminal aromatic 
moieties with varying carbon chain lengths to tap into possible π-π stacking 
interactions with the tyrosine residues (Tyr2343 and Tyr2462) and one substituent 
with a terminal amide group (219e) for potential H-bonding interaction with amino 
acid residues (Thr2342, Tyr2343 and Tyr2462).  
The CM reactions of 194 with the selected alkene cross partners (219a–219e) 
furnished seven novel α-alkylidene-β-lactones (Z/E-220, Z-221–Z-223 and Z/E-224) 
in high Z-selectivity with the phenyl substituents gave the Z-isomers specifically 
(Scheme 40). The Z/E isomers of 220 were separable but the Z/E isomers of 224 
were not fully separated, its Z-isomer was isolated pure after multiple column 
chromatography on silica gel. A 1:1 mixture of the Z/E isomers of 224 was included 
a. b. 
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in the library to see if the presence of the E-isomer would show any noticeable 











Scheme 40. Synthesis of α-alkylidine-β-lactones  
 
The α-alkylidene-β-lactones (220–224) were subjected to the optimized reduction 
conditions to give their corresponding reduced β-lactone products (trans/cis-226–
trans/cis-230) (Scheme 41), providing nine additional novel compounds. The 
trans/cis products (226–229) were separated but not the trans/cis isomers of 230. 
This was evaluated as a mixture (trans/cis, 80:20) after partial purification. The cis-
isomer (cis-230) was obtained with negligible trans-230 from hydrogenation after 





                                     Alkylidene lactone
                                         Z-/E-, (yield)
219a; CH3(CH2)4                220;  3.3/1,     97%
219b; Ph(CH2)4                  221;  Z-only,   68%
219c; Ph(CH2)3                  222;  Z-only,   51%
219d; Ph                            223;  Z-only,   40%
219e; H2NOC(CH2)4          224;  3.7/1,     73%

















1. SOCl2, DMF, CHCl3,
 reflux
2. aq. NH4OH, 0 oC, 85%














Scheme 41. Synthesis of reduced β-lactones 
  
Additionally, trans-226 and trans-227 were methylenated to provide extra probes 
231 and 232 respectively (Scheme 42). This was inspired by the earlier findings of 
Dollinger et al. of the comparable inhibitory activity of orlistat and its 2-





Scheme 42. 2-Methyleneoxetane analogs of trans β-lactones 
 
Thus, overall a library of 22 β-lactones was readily assembled for further evaluation 
from a single α-methylene-β-lactone 194 scaffold (Figure 37). This proves CM as a 
versatile approach for the rapid assembly of β-lactones.	  	  
CoCl2(PPh3)2, NaBH4
THF/MeOH, -5 oC
         β-Lactone
           trans /cis, (yield)
220; CH3(CH2)4                                226;     1.3/1,     44%                                                                                   
221; Ph(CH2)4                                  227;      2/1,       32%                                                   
222; Ph(CH2)3                                  228;     1.4/1,     46%
223; Ph                                             229;     2/1,        39%   






















trans-230/cis-230, 1: 5 (crude)
Hydrogenation of 224 to obtain cis-230
220–224
trans-226; R = CH3(CH2)4    














trans-231; R = CH3(CH2)4, 38%    
trans-232; R =  Ph(CH2)4, 40%
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2.2.4. Results: 
2.2.4.1. Inhibitory activity of β-lactone library against serine hydrolases 
The prepared β-lactone library was sent to the Cravatt lab at the Scripps Research 
Institute to be assayed as serine hydrolases inhibitors using competitive activity-
based protein profiling (ABPP). Since β-lactones have been shown to inhibit several 
serine hydrolase enzymes (characterized by the presence of a serine moiety in the 
active site that acts as a nucleophile and interacts with electrophiles),83 it was 
advantageous to screen our library against a broad spectrum of enzymes in a native 
biological sample, facilitating the targeting of different enzymes in a single screen. A 
powerful feature of ABPP is that it can be coupled to either LC/MS or gel readout to 
characterize numerous enzymes in parallel.84 Figure 38,85 shows a schematic 
workflow in ABPP. Known inhibitors of enzymes are added to a native biological 
sample as control vehicles to minimize unwanted interactions. The resulting mixture 
is then incubated with the chemical probes, which may bind selectively to the active 
site of enzymes. Gel or LC/MS reading allows detection and identification of 
enzymes in the biological samples. Faded spots in the gel or a decrease in bar 
sizes in LC/MS reflect enzymes targeted.  
	   170	  
 
Figure 38. Schematic diagram of ABPP85 
 
The inhibitory activity analysis of the prepared library probes using ABPP has 
worked in our favor, because when assayed with mouse membrane proteome none 
of the compounds except trans-229 (KC6-10-3) showed comparable activity to 
orlistat (THL) against FAS (FASN) (Figure 39a). Instead, most of the β-lactones 
targeted other enzymes, and trans-229 showed the broadest activity. Similar results 
were observed when β-lactones were profiled using the human membrane 
proteome (Figure 39b).86 A stable isotope labeling of amino acids in cell culture 
(SILAC) study was conducted with trans-229 to identify the inhibited enzymes 
(Figure 39c). Eight serine hydrolases were identified and divided into two groups 
based on their inhibition level. The first group included ABHD16A, PNPLA4, FAAH, 
ABHD2, CES2, and ABHD12 (all inhibited > 90%) and a second set was made up of 
FASN and ABHD3 (inhibited from 70-90%) at a final concentration of 25 µM. Among 
these enzymes, only FAAH and FASN, to our knowledge are well documented in 
	   171	  
terms of biological functions and already have selective inhibitors suitable for 







Figure 39. Identification of enzymes; a. screening of β-lactones against mouse 
brain membrane proteome; b. β-lactones against human membrane proteome; c. 
SILAC study with trans-229 (KC6-10-3)86    
 
 
ABHD16A (also called BAT5) was the most strongly inhibited enzyme and Z-224 
(KC01) was its most potent inhibitor (Figure 40).87 ABHD16A is hypothesized to 
generate lysophosphatidylserine (lyso-PS), an inflammatory lipid in mammalian 
systems (specifically in the brain), and is a highly desirable target for immunological 
and neuroimmunological studies. Z-224 (KC01) is the first reported potent inhibitor 
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a useful starting point for developing selective inhibitors that target a diverse range 
of other poorly characterized serine hydrolases. 
  




To further develop Z-224 (KC01) inhibitory activity, four structural analogs were 
generated (234–237) furnishing a second library (Figure 41). Their synthesis is 
shown in Scheme 43, following similar reaction sequences used in the preparation 
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CM of α-methylene-β-lactone238 (obtained from Christain Malapit a graduate in our 
lab) with alkene cross partner 129e yielded 234 (KCO2) as a mixture of Z/E-isomers 
(4:1 ratio) inseparable (Scheme 43). Therefore the isomers were evaluated as a 
mixture. Hydrogenation of 234 gave its corresponding reduced lactone 235 as a 
mixture of trans/cis-siomers (1:5 ratio) again inseparable and tested as a mixture. 
Because aldehyde 244, required to prepare α-methylene-β-lactone 247 is not 
commercially available it was prepared starting with the alkylation of 
phenylacetylene with iodide 239 to give alkylated product 241. This product was 
subjected under hydrogenation conditions to give its alkane analog 242. Desilylation 
of the hydroxyl group using TBAF gave alcohol 243, which was oxidized to aldehyde 
244 in the presence of Bobbitt’s salt (248) (courtesy of Dr. Bobbitt) and SiO2. 
Aldehyde 244 was reacted with methyl acrylate under MBH conditions catalyzed by 
3-quinuclidinol to afford MBH adduct 245. LiOH facilitated hydrolysis of methyl ester 
245 offered β-hydroxy acid 246. Lactonization of 246 facilitated by o-nosyl chloride 
yielded α-methylene-β-lactone 247, and its subsequent CM with 219e gave α-
alkylidene-β-lactone 245 as a mixture of Z/E-isomers. The Z-isomer 236 was 
obtained pure. The sulfonamide α-alkylidene-β-lactone 237 synthesis began with 
the preparation of cross partner 250 in three steps from 1-bromo-6-heptene 249. 
The displacement of the bromide in 249 with Na2SO3 gives a sulfonic acid 
intermediate. Chlorination of the acid with phosphorus oxychloride provided a 
sulfonyl chloride product, aminolysis of which using NH4OH finally gave sulfonamide 
250. The CM reaction of α-methylene-β-lactone 194 and 250 completed the 
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synthesis of 237 Both of its Z/E-isomers were formed and the pure Z-isomer was 





















Scheme 43. Synthesis of analogs 234–237 
Br
1) Na2SO3, H2O, 100 oC
2) POCl3, 130 oC


















n-BuLi, THF, 0 oC
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Synthesis of β-lactone probes 234 and 235
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Assessment of the β-lactones (234–237) for the inhibition of ABDH16A led to the 
identification of an inactive control probe 234 (KC02, tested as a Z/E, 4:1 mixture), 
(Figure 42 a and b). A SILAC study confirmed that Z-224 (KC01) is a potent, 
selective probe of ABHD16A (Figure 42c), indicated by the complete disappearance 
of the ABHD16A bar. Reduction in lyso-PSs in the human cancer cell line 
(COLO205 colon) was also observed as a result of Z-224 (KC01) inhibiting 
ABHD16A, providing compelling pharmacological and genetic evidence that 
ABHD16A is a major enzyme responsible for generating lyso-PSs in mammalian 





















Figure 42. α-alkylidene-β-lactone Z-224 (KC01) a selective inhibitor of ABHD16A; 
a. Gel spectrum of ABHD16A inhibitor Z-224 (KC01) and its inactive control probe 
234 (KC02); b. Concentration-dependent inhibition of the PS lipase activity of 
ABHD16A  with Z-224 (KC01) and 234 (KC02); c. Quantification of ABHD16A 
inhibiton with Z-224 (KC01) using SILAC; d. Concentration of lyso-PS from 







	   176	  
2.2.5. Conclusion 
In summary, a diverse set of 23 mostly new β-lactones including (±)-
nocardiolactone (167) has been prepared from a single α-methylene-β-lactone 
scaffold 194. The characterization of the library using competitive ABPP facilitated 
the discovery of previously uncharaterized serine hydrolase enzymes. Thus, ABPP 
amplifies the significance of a CM approach for discovering new chemical probes 
for enzyme inhibition in cell biology. This study is an initial tool for the 
identification/characterization of serine hydrolase enzymes, many of which are 
poorly understood in terms of the role they play in immunological functions, due to 
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2.2.6. EXPERIMENTAL 
2.2.6.1. General Experimental 
Tetrahydrofuran (THF) was dried using a solvent dispensing system (SDS) with a 
column of neutral alumina. Pyridine, toluene, dimethylformamide (DMF), methylene 
chloride (CH2Cl2), deuterated chloroform (CDCl3), methanol (MeOH), deuterated 
methanol (CD3OD) and ethanol (EtOH) were dried over 4 Å molecular sieves.  
All reagents were purchased from Acros, Aldrich or Alfa Aesar and used without 
further purification. All reactions were conducted under an atmosphere of N2 in 
glassware that had been dried overnight in an oven at 120 οC. Where appropriate, 
control of the reaction temperature was achieved with a solid CO2/acetone bath, an 
ice bath or a heated oil bath. 
NMR Spectra were obtained on a Bruker Avance DRX-400 (400 MHz 1H, 100 MHz 
13C), Bruker Avance (500 MHz 1H, 125 MHz 13C), or Bruker Avance (300 MHz 1H, 
75 MHz 13C) spectrometer. 1H and 13C chemical shifts are reported in parts per 
million (ppm) and calibrated to the residual CHCl3 peak at 7.26 and 77.23 
respectively in CDCl3. The following abbreviations are used for peak multiplicities: s 
(singlet); br s (broadened singlet); d (doublet); t (triplet); q (quartet); quin (quintet); m 
(multiplet); dd (doublet of doublet); ddd (doublet of doublet of doublet). Coupling 
constants, J, are reported in Hertz (Hz). 
IR spectra were recorded on a Brucker FT-IR spectrometer. GC/MS spectra were 
obtained on a gas chromatograph equipped with a HP-1 methyl siloxane column 
and detected on a low-resolution 5970 series mass selective detector. High-
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resolution mass spectra were obtained on a AccuTOF instrument equipped with a 
DART ionization source. Melting points were observed in open Pyrex capillary tubes 
and are uncorrected. Flash chromatography was performed on Silica Gel, 40 
micron, 32-63 flash silica. Thin layer chromatography was performed on silica gel. 
Compounds were visualized by UV, 5% phosphomolybdic acid in ethanol, 0.5% 
potassium permanganate in water or a solution of ethanol/H2SO4/AcOH/p-
anisaldehyde (135:5:1.5:3.7). 




Octylidene-4-tridecyloxetan-2-one (0.10 g, 0.20 mmol) (Z/E-192), was dissolved in 
a mixture of THF:MeOH (1.6:0.32 mL). This solution was cooled to −10 ˚C, 
followed by the addition of CoCl2(PPh)3 (0.02 g, 0.04 mmol) and then portion-wise 
addition of NaBH4  (39.0 mg, 1.2 mmol) within 10 min.81 The mixture was 
vigorously stirred for 2 h between −7 and −5 ˚C. The reaction mixture was filtered 
through a pad of celite, and the celite was then washed with CHCl3 (10 mL). The 
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Purification by flash chromatography on silica gel (petroleum ether/ EtOAc, 98:2) 
gave a mixture of trans-167/cis-200 (trans/cis 2/1),  (0.06 g, 61%) as a white solid. 
The isomers were separated by careful chromatography using the same solvent 
system. cis-200: mp 63−64 ˚C; IR (neat) 2916, 2849, 1790, 1464, 1146, 1076 cm-1; 
1H NMR (400 MHz, CDCl3) δ 4.52 (ddd, J = 9.9, 6.3, 4.1 Hz, 1H), 3.59 (ddd, J = 
8.1, 6.9, 6.9 Hz, 1H), 1.82−1.72 (m, 2H), 1.69−1.55 (m, 2H), 1.52−1.48 (m, 2H), 
1.39−1.26 (m, 52H), 0.88 (t, J = 7.0 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 172.6, 
76.0, 52.9, 32.1, 30.4, 29.9, 29.9, 29.9, 29.8, 29.7, 29.6, 29.6, 29.6, 29.5, 
27.8, 25.8, 24.2, 22.9,14.3; MS (EI) m/z 463 (M − CO2)+, 281, 207, 111, 97(100), 
83, 57; HRMS (ESI) calcd for C34H67O2 [M
 + H]+ m/z 507.5136, found 507.5158. 
trans-167; (±)-nocardiolactone: mp 64−65 ˚C (Lit.88 66−68 oC); IR (neat) 2915, 
2847, 1796, 1468, 1154, cm-1; 1H NMR (400 MHz, CDCl3) δ 4.21 (ddd, J = 6.8, 6.8, 
3.9 Hz, 1H), 3.17 (ddd, J = 10.3, 6.5, 4.0 Hz, 1H), 1.89−1.79 (m, 2H), 1.76−1.66 
(m, 2H), 1.45−1.25 (m, 54H), 0.88 (t, J = 7.0 Hz, 6H); 13C NMR (100 MHz, CDCl3) 
δ 171.9, 78.4, 56.4, 34.7, 32.1, 29.9,  29.9, 29.8, 29.7, 29.7, 29.6, 29.6, 29.5, 29.5, 
28.1, 27.2, 25.2, 22.9, 14.3; MS (EI) m/z 462 (M − CO2)+, 281, 207, 111, 97 (100), 
83, 57; HRMS (ESI) calcd for C34H67O2 [M
 
+ H]+ m/z 507.5136, found 507.5157. 
 
 (E/Z)-3-Octadecylidene-4-tridecyloxetan-2-one (Z/E-192). Cat. 1 (40 mg, 0.047 
mmol) was added to a solution of 3-methylene-4-tridecyloxetan-2-one (194) (0.25 
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The mixture was stirred overnight at 40 ˚C.65 The next day 1H NMR showed 
complete consumption of 194. The reaction was allowed to cool to rt followed by 
removal of CH2Cl2 under reduced pressure to yield a brownish residue. Purification 
of the residue by flash chromatography on silica gel (petroleum ether/EtOAc 98:2) 
gave Z/E-192, (Z/E, 2.2/1), (0.56 g, 75%) as a white solid. The isomers were 
separated by careful chromatography using the same solvent system. E-192: mp 
49−50 ˚C; IR (neat) 2917, 2849, 1791, 1466, 1127 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 6.33 (dt, J = 7.9, 1.4 Hz, 1H), 4.99 (m, 1H), 2.10 (dt, J = 7.4, 7.4 Hz, 2H), 
2.00−1.88 (m, 1H), 1.82−1.72 (m, 1H), 1.52−1.43 (m, 4H), 1.37−1.26 (m, 48H), 
0.88 (t, J = 6.5 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 164.6, 137.8, 134.2, 79.4, 
33.5, 32.1, 29.9, 29.9, 29.9, 29.9, 29.8, 29.7, 29.7, 29.7, 29.6, 29.5, 29.5, 29.4, 
29.1, 28.6, 24.9, 22.9, 14.3; MS (EI) m/z 194,117, 91 (100), 77, 65, 51; HRMS 
(ESI) calcd for C34H65O2 [M
 + H]+ m/z 505.4957, found 505.5003. Z-192: mp 
61.5−62.5 ˚C; IR (neat) 2914, 2848, 1795, 1471, 1117, 1070 cm-1; 1H NMR (400 
MHz, CDCl3) δ 5.84 (t, J = 7.5 Hz, 1H), 4.85 (t, J = 6.3 Hz, 1H), 2.48 (dt, J = 7.4, 
7.4 Hz, 2H), 1.86−1.73 (m, 2H), 1.47−1.39 (m, 4H), 1.35−1.26 (m, 48H), 0.88 (t, J 
= 6.5 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 164.4, 137.7, 136.5, 78.9, 34.0, 32.1, 
29.9, 29.9, 29.8, 29.8, 29.7, 29.7, 29.6, 29.6, 29.5, 29.5, 29.5, 29.3, 29.1, 29.1, 
24.8, 22.9, 14.3; MS (EI) m/z 460 (M –CO2)+, 355, 341, 293, 281, 236, 207 (100), 
194, 110, 95, 81, 67, 55; HRMS (ESI) calcd for C34H65O2 [M
 + H]+ m/z 505.4957, 
found 505.4957. 
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3-Methylene-4-tridecyloxetan-2-one (194). Pathway A:89 3-Hydroxy-2-methyl-
enehexadecanoic acid (198) (5.38 g, 18.9 mmol) was dissolved in dry CH2Cl2 (70 
mL). Oven-dried Na2CO3 (20.1 g, 18.9 mmol) was added, and the resulting 
suspension was stirred for 30 min.  o-Nosyl chloride (8.50 g, 37.7 mmol) was 
added, and the resulting mixture was stirred for 3 d. The reaction was diluted with 
CH2Cl2 (200 mL), and then 1 M HCl (200 mL) was added and separated. The 
aqueous layer was then extracted with CH2Cl2 (3 X 75 mL); the combined organic 
layers were dried (Na2SO4) and concentrated. Purification of the residue via flash 
chromatography on silica gel (petroleum ether/EtOAc 95:5) gave 194 (2.19 g, 43%) 
as a white solid: Pathway B:90 Hg(O2CCF3)2 (0.72 g, 1.68 mmol), was added to a 
solution of S-tert-butyl 3-hydroxy-2-methylenehexadecanethioate (199) (0.30 g, 
0.84 mmol) in dry CH3CN (50 mL). The reaction mixture was stirred in a preheated 
oil bath for 10 min at 50 ˚C. 1H NMR was used to monitor the reaction. The 
reaction mixture was filtered, and the filtrate concentrated. Purification of the 
residue by flash chromatography on silica gel (petroleum ether/EtOAc 95:5) gave 
194 (0.15 g, 67%) as a white solid: mp: 34−35.5 ˚C; IR (neat) 2916, 2849, 1810, 
1468, 1085, 962, 818 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.90 (dd, J = 2.0, 2.0 Hz, 
1H), 5.41 (dd, J = 1.7 1.7 Hz, 1H), 4.98−4.94 (m, 1H), 1.92−1.79 (m, 2H), 
1.54−1.40 (m, 2H), 1.37−1.26 (m, 20H), 0.88 (t, J = 6.7 Hz, 3 H); 13C NMR (100 
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29.6, 29.5, 24.8, 22.9, 14.3; MS (EI) m/z 266 (M+), 108, 95, 83 (100), 67, 55; 
HRMS (ESI) calcd for C17H31O2 [M
 + H]+ m/z 267.2319, found 267.2335.  
 
3-Hydroxy-2-methylenehexadecanoic acid (198). Tetradecanal (195) (4.93 g, 
23.2 mmol) and methyl acrylate (196) (4.20 mL, 46.8 mmol) were combined in an 
empty flask. 3- Hydroxyquinuclidine (0.74 g, 5.81 mmol) was added, followed by 
MeOH (0.70 mL). The resulting mixture was allowed to stir for 3 d.89 MeOH and 
excess methyl acrylate were removed under reduced pressure. The resulting 
residue was diluted with a H2O/sat. NH4Cl solution (5:1, 120 mL), and the resulting 
mixture was extracted with CH2Cl2 (3 X 50 mL). The combined organic layers were 
dried (Na2SO4) and concentrated. Methyl 3-hydroxy-2-methylenehexadecanoate 
was obtained as a white solid (5.82 g, 84%) and used without further purification. 
Methyl 3-hydroxy-2-methylenehexadecanoate (5.82 g, 19.5 mmol) was dissolved in 
EtOH/H2O (2:1, 45 mL). Lithium hydroxide monohydrate (0.45 g, 19.5 mmol) was 
added; the resulting solution was allowed to stir overnight. The reaction was 
quenched with 1 M HCl (200 mL), and the solution was extracted with CH2Cl2 (3 X 
100 mL). The combined organic layers were washed with H2O (100 mL) and dried 
(MgSO4); CH2Cl2 was removed under reduced pressure.
89 Purification of the 
residue by flash chromatography on silica gel (petroleum ether/EtOAc 85:15) gave 
198 (5.38 g, 95%) as a white solid: mp: 72.4−73.5 ˚C; IR (KBr) 3853, 2918, 2850, 
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1H), 4.43 (dd, J = 6.5, 6.5 Hz, 1H), 1.68−1.66 (m, 2H), 1.43−1.41 (m, 1H), 1.30−1.26 
(m, 22H), 0.90 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.4, 142.1, 
127.6, 71.8, 36.4, 32.1, 29.9, 29.9, 29.9, 29.8, 29.8, 29.6, 29.6, 26.0, 22.9, 14.3; MS 
(EI) m/z 266 (M – OH)+, 221, 192, 116, 101 (100), 83, 71, 57; HRMS (FAB) calcd for 
C17H32NaO3 [M
 + Na]+ m/z  307.2244, found 307.2258. 
 
S-tert-Butyl 3-hydroxy-2-methylenehexadecanethioate (199). DABCO (0.040 g, 
0.37 mmol) was added to a mixture of thio-tert-butyl acrylate (197)91 (1.14 g, 7.87 
mmol) and tetradecanal (195) (0.84 g, 3.7 mmol). The reaction mixture was allowed 
to stir for a week. It was diluted with CH2Cl2 (100 mL) and washed with 1 M 
aqueous HCl (50 mL), followed by sat. NaHCO3 (50 mL). The organic layer was 
dried (Na2SO4) and concentrated. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc 95:5) gave 199 (1.03 g, 84%) as slightly yellow oil: IR (neat) 
2921, 2852, 1655, 1456, 1363, 967, 721 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.05 (s, 
1H), 5.71 (d, J = 1.0 Hz, 1H), 4.38 (dd, J = 6.7, 6.7 Hz, 1H), 2.40 (br. s, 1H), 
1.65−1.56 (m, 2H), 1.49 (s, 9H), 1.45−1.41 (m, 1H), 1.33−1.25 (m, 21H), 0.88 (t, J = 
6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 195.8, 151.4, 121.7, 72.3, 48.4, 36.4, 
32.1, 30.0, 29.9, 29.8, 29.7, 29.6, 29.6, 25.9, 22.9, 14.3; HRMS (ESI) calcd for 
C21H41O2S [M
 + H]+ m/z 357.2822, found 357.2822. 
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SOCl2 (0.34 mL, 4.7 mmol), and a drop of DMF in CHCl3 (6 mL) was heated at 
reflux for 2 h. The reaction mixture was cooled to rt and then poured into a mixture 
of aqueous NH4OH (28-30%, 6 mL) and ice (6.3 g) and stirred for 2 h. The layers 
were separated, and the organic layer was dried (Na2SO4) and concentrated. 
Purification by flash column chromatography on silica gel (CH2Cl2/MeOH, 98:2) 
gave 219e (0.42 g, 85%) as a white solid: mp: 84.8−84.9 oC; IR (neat) 3355, 3178, 
2938, 1630, 1460, 1410, 1221 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.32 (br s, 1H), 
5.84 (br s, 1H), 5.79−5.69 (m, 1H), 4.95 (d, J = 17.2 Hz, 1H), 4.88 (d, J = 10.2 Hz, 
1H), 2.17 (t, J = 7.2 Hz, 2H), 2.02 (q, J = 6.4 Hz, 2H), 1.60 (quin, J = 7.5 Hz, 2H), 
1.39 (quin, J = 7.6 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 176.3, 138.5, 114.8, 
35.9, 33.5, 28.5, 25.1 MS (EI) m/z 127 (M+), 72, 59 (100); HRMS (ESI) calcd for 
C7H14NO [M
 + H]+ m/z 128.1070, found 128.1057. 
 
(E/Z)-3-Hexylidene-4-tridecyloxetan-2-one (Z/E-220). Cat. 1 (0.02 g, 0.04 mmol) 
was added to a solution of 3-methylene-4-tridecyloxetan-2-one (194) (0.20 g, 0.75 
mmol) and 1-heptene (219a) (0.15 g, 1.5 mmol) in dry CH2Cl2 (29 mL). The 
mixture was stirred overnight at 40 ˚C.65 The next day 1H NMR showed complete 
consumption of 194. The reaction was cooled to rt followed removal of the CH2Cl2 
under reduced pressure to yield a brownish residue. Purification of the residue by 
flash chromatography on silica gel (petroleum ether/EtOAc 98:2) gave Z/E-220 
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careful chromatography using the same solvent system. E-220: IR (neat) 2922, 
2852, 1813, 1464, 1117 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.33 (t, J = 7.6 Hz, 1H), 
4.99 (m, 1H), 2.11 (dt, J = 7.1, 7.1 Hz, 2H), 1.96−1.88 (m, 1H), 1.81−1.72 (m, 1H), 
1.50−1.43 (m, 4H), 1.31−1.26 (m, 24), 0.90 (m, 3H), 0.88 (t, J = 7.5 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 164.6, 137.8, 134.1, 79.4, 33.5, 32.1, 31.6, 29.9, 29.9, 
29.8, 29.7, 29.6, 29.6 29.5, 29.0, 28.3, 24.9, 22.9, 22.6, 14.3, 14.1; MS (EI) m/z 
336 (M+), 178 (100); HRMS (ESI) calcd for C22H41O2 [M
 
+ H]+ m/z 337.3101, found 
337.3124. Z-220: IR (neat) 2914, 2848, 1793, 1721, 1470, 1116, 1070, cm-1; 1H 
NMR (400 MHz, CDCl3) δ 5.84 (dt, J = 7.9, 1.0 Hz, 1H), 4.84 (dd, J = 6.2, 6.2 Hz, 
1H), 2.55−2.41 (m, 2H), 1.84−1.73 (m, 2H), 1.50−1.39 (m, 4H), 1.33−1.26 (m, 
24H), 0.89 (m, 3H), 0.88 (t, J = 7.0 Hz 3H); 13C NMR (100 MHz, CDCl3) δ 164.4, 
137.7, 136.4, 78.8, 33.9, 32.1, 31.4, 29.9, 29.9, 29.8, 29.7, 29.6, 29.6, 29.5, 29.0, 
28.7, 24.8, 22.9, 22.6, 14.3, 14.1; MS (EI) m/z 336 (M+), 275, 111, 81, 67, 55 
(100); HRMS (ESI) calcd for C22H41O2 [M
 
+ H]+ m/z 337.3101, found 337.3123. 
 
(Z)-3-(5-Phenylpentylidene)-4-tridecyloxetan-2-one (Z-221). Catalyst 1 (0.03 g, 
0.04 mmol) was added to a solution of 3-methylene-4-tridecyloxetan-2-one (194) 
(0.20 g, 0.75 mmol) and 6-phenyl-1-hexene (219b) (0.24 g, 1.50 mmol) in dry 
CH2Cl2 (29 mL). The mixture was stirred overnight at 40 ˚C.
65 The next day TLC 
showed incomplete consumption of 194; so 1 equiv more of 6-phenyl-1-hexene 
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was allowed to cool to rt, the CH2Cl2 was removed under reduced pressure to yield 
a brown residue. Purification of the residue by flash chromatography on silica gel 
(petroleum ether/EtOAc 97:3) gave Z-221 (0.20 g, 68%) as a wax: mp 34−35 ˚C; 
IR (neat) 2914, 2848, 1793, 1723, 1468, 1182.70, 1120, 1071 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.22−7.19 (m, 2H), 7.13−7.09 (m, 3H), 5.75 (t, J = 7.8 Hz, 1H), 4.77 
(dd, J = 6.0, 6.0 Hz, 1H), 2.56 (t, J = 7.2 Hz, 2H), 2.51− 2.38 (m, 2H), 1.77−1.69 
(m, 2H), 1.60 (quin, J = 7.6 Hz, 2H), 1.47−1.33 (m, 4H), 1.28−1.19 (m, 20H), 0.81 
(t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 164.4, 142.4, 138.0, 136.0, 
128.6, 128.5, 126.0, 78.9, 35.7, 33.9, 32.1, 30.9, 29.9, 29.9, 29.8, 29.7, 29.6, 29.6, 
29.5, 28.9, 28.5, 24.8, 22.9, 14.3; MS (EI) m/z 354 (M – CO2)+, 104, 91(100); 
HRMS (ESI) calcd for C27H43O2 [M
 
+ H]+ m/z 399.3263, found 399.3258. 
 
(Z)-3-(4-Phenylbutylidene)-4-tridecyloxetan-2-one (Z-222). Cat.1 1 (0.02 g, 0.04 
mmol) was added to a solution of 3-methylene-4-tridecyloxetan-2-one (194) (0.20 
g, 0.75 mmol) and 5-phenyl-1-pentene (219c) (0.44 g, 3.00 mmol) in dry CH2Cl2 
(29 mL). The mixture was stirred overnight at 40 ˚C.65 The next day TLC showed 
incomplete consumption of 194; so 1 equiv more of 5-phenyl-1-pentene (219c) 
was added and the reaction was allowed to stir for 6 h at 40 ˚C. After the reaction 
was allowed to cool to rt, the CH2Cl2 was removed under reduced pressure to yield 
a brown residue. Purification of the residue by flash chromatography on silica gel 
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(neat) 2921, 2852, 1805, 1454, 1067 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.31−7.27 
(m, 2H), 7.21−7.18 (m, 3H), 5.84 (t, J = 7.6 Hz, 1H), 4.86 (dd, J = 6.0, 6.0 Hz, 1H), 
2.67 (t, J = 7.2 Hz, 2H), 2.56 (dt, J = 7.8, 7.8 Hz, 2H), 1.84−1.77 (m, 4H), 
1.50−1.43 (m, 2H), 1.36−1.27 (m, 20H), 0.89 (t, J = 6.5 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 164.3, 141.8, 138.1, 135.8, 128.6, 126.2, 78.9, 35.6, 33.9, 32.1, 
30.8, 29.9, 29.9, 29.8, 29.7, 29.6, 29.6, 29.5, 28.8, 24.8, 22.9, 14.3; MS (EI) m/z 
384 (M+), 104 (100), 91; HRMS (ESI) calcd for C26H41O2 [M
 
+ H]+ m/z 385.3101, 
found 385.3114. 
 
(Z)-3-Benzylidene-4-tridecyloxetan-2-one (Z-223). Cat. 1 (0.01 g, 0.01 mmol) 
was added to a solution of 3-methylene-4-tridecyloxetan-2-one (194) (0.060 g, 
0.21 mmol) and styrene (219d) (0.050 g, 0.43 mmol) in dry CH2Cl2 (8 mL) The 
mixture was stirred overnight at 40 ˚C.65 The next day TLC showed incomplete 
consumption of 194; so 1 equiv more of styrene was added, and the reaction was 
allowed to stir for 6 h at 40 oC.  After the reaction mixture was allowed to cool to rt, 
the CH2Cl2 was removed under reduced pressure to yield a brown residue. 
Purification of the residue by flash chromatography on silica gel (petroleum 
ether/EtOAc 98:2) gave Z-223 (0.030 g, 40%) as a white solid: mp 61−62 ˚C; IR 
(neat) 2914, 2848, 1780, 1687, 1468, 1212, 1156, 1128, 1068 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.95 (d, J = 6.8 Hz, 2H), 7.43−7.41 (m, 3H), 6.53 (s, 1H), 4.96 (dd, 
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0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 163.3, 136.0, 133.4, 133.2, 
130.8, 130.4, 129.1, 78.0, 34.0, 32.1, 29.9, 29.9, 29.8, 29.7, 29.6, 29.6, 24.8, 22.9, 
14.3; MS (EI) m/z 342 (M+), 159, 130 (100); HRMS (ESI) calcd for C23H35O2 [M
 + 
H]+ m/z 343.2632, found 343.2655.  
 
(Z)-6-(2-Oxo-4-tridecyloxetan-3-ylidene)hexanamide (Z/E-224; KC01). Cat. 2 
(0.03 g, 0.04 mmol) was added to a solution of 3-methylene-4-tridecyloxetan-2-one 
(194) (0.20 g, 0.75 mmol) and hept-6-enamide (219e) (0.19 g, 1.5 mmol) in dry 
CH2Cl2 (29 mL). The mixture was stirred at 40 
oC for 48 h. After cooling to rt, the 
CH2Cl2 was removed under reduced pressure to yield a greenish brown residue. 
Purification by flash chromatography on silica gel (CH2Cl2/MeOH, 98:2) gave Z/E-
224 (Z/E, 3.7:1), (0.20 g, 73%) as an off white solid. The Z-isomer was separable 
from the E-isomer by careful column chromatography. The isomer E-224 was not 
obtained as a single compound, but chemical shifts for a number of the protons 
and carbons were identifiable: E-224: 1H NMR (400 MHz, CDCl3) δ 6.31 (t, J = 7.5 
Hz, 1H), 5.35 (br s, 2H) 5.00 (m, 1H), 2.28−2.23 (m, 2H), 2.16 (dt, J = 7.4, 7.4 Hz, 
2H), the remaining proton signals cannot be readily distinguished from those of the 
Z-isomer; 13C NMR (100 MHz, CDCl3) δ 174.6, 164.4, 138.3, 133.2, 79.4, 35.5, 
33.5, 32.1, 29.9, 29.8, 29.7, 29.7, 29.6, 29.6, 29.5, 28.9, 28.2, 28.1, 25.1, 25.0, 
24.8, 24.6, 22.9, 14.3. Z-224 (KC01): mp: 106−107 oC; IR (neat) 3384, 3196, 2915, 
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CDCl3) δ 5.86 (t, J = 8.0 Hz, 1H), 5.51 (br s, 1H), 5.27 (br s, 1H), 4.87 (dd, J = 6.5, 
6.5 Hz, 1H), 2.59−2.47 (m, 2H), 2.26 (t, J = 7.5 Hz, 2H), 1.82−1.77 (m, 2H), 
1.73−1.67 (m, 2H), 1.58-1.52 (m, 2H), 1.47−1.42 (m, 2H), 1.37−1.26 (m, 20H), 
0.88 (t, J = 6.8 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 175.0, 164.5, 136.2, 135.5, 
79.0, 35.8, 33.9, 32.1, 29.8, 29.8, 29.8, 29.8, 29.7, 29.6, 29.5, 29.4, 28.2, 28.0, 
24.8, 24.5, 22.8, 14.3; HRMS (ESI) calcd for C22H40NO3 [M




4-tridecyloxetan-2-one (Z/E-220) (0.03 g, 0.09 mmol), was dissolved in a mixture 
of THF:MeOH (0.70 mL: 0.14 mL). This solution was cooled to −10 ˚C, followed by 
the addition of CoCl2(PPh)3 (0.01 g, 0.01 mmol) and then portion-wise addition of 
NaBH4 (9.9 mg, 27.0 mmol) within 10 min.81 The mixture was vigorously stirred for 
2 h between −7 to −5 ˚C.  The reaction mixture was filtered through a pad of celite, 
and the celite was then washed with CHCl3 (5 mL). The filtrate was washed with 
2M HCl (5 mL), dried (MgSO4) and concentrated. Purification by flash 
chromatography on silica gel (petroleum ether/ EtOAc 98:2) gave mixture of 
trans/cis-226 (trans/cis 1.3/1), (14 mg, 44%). The isomers were separated by 
careful column chromatography using the same solvent system. cis-226 (colorless 
oil): IR (neat) 2921, 2852, 1820, 1464, 1121 cm-1; 1H NMR (400 MHz, CDCl3) δ 
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0.91−0.87 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 172.6, 76.0, 52.9, 32.1, 31.7, 
30.4, 29.9, 29.9, 29.7, 29.6, 29.6, 29.5, 29.3, 27.8, 25.8, 24.2, 22.9, 22.8, 14.3, 
14.2; MS (EI) m/z 294 (M − CO2)+, 207, 125, 111, 97 (100), 83, 69, 55; HRMS 
(ESI) calcd for C22H43O2 [M
 + H]+ m/z 339.3258, found 339.3295. trans-226 (waxy 
solid): mp 29−30 ˚C;  IR (neat) 2918, 2850, 1794, 1466, 1142, 1076 cm-1; 1H NMR 
(400 MHz, CDCl3) δ  4.24−4.17 (m, 1H), 3.18−3.13 (m, 1H), 1.85−1.79 (m, 2H), 
1.73−1.69 (m, 2H), 1.43−1.26 (m, 30H), 0.89−0.86 (m,  6H); 13C NMR (100 MHz, 
CDCl3) δ 171.9, 78.4, 56.4, 34.7, 32.1, 31.7, 29.9, 29.9, 29.8, 29.7, 29.6, 29.6, 
29.5, 29.2, 28.1, 27.2, 25.2, 22.9, 22.7, 14.3, 14.2; MS (EI) m/z 294 (M − CO2)+, 
281, 207, 125, 111, 97, 83 (100), 69, 55; HRMS (ESI) calcd for C22H43O2 [M
 + H]+ 
m/z 339.3258, found 339.3296. 
 
(cis/trans)-3-(5-Phenylpentyl)-4-tridecyloxetan-2-one (trans/cis-227). (Z)-3-(5-Phen-
ylpentyli-dene)-4-tridecyloxetan-2-one (Z-221) (0.10 g, 0.25 mmol) was dissolved 
in a mixture of THF:MeOH (2.0:0.4 mL). This solution was cooled to −10 ˚C, 
followed by the addition of CoCl2(PPh)3 (0.03 g, 0.04 mmol) and then portion-wise 
addition of NaBH4  (28.0 mg, 0.75 mmol), within 10 min.81 The mixture was 
vigorously stirred for 4 h between −7 to −5 ˚C. The reaction mixture was filtered 
through a pad of celite, and the celite was washed with CHCl3 (15 mL). The filtrate 
was washed with 2M HCl (10 mL), dried (MgSO4) and concentrated. Purification by 
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trans/cis-227 (trans/cis, 2/1), (0.03 g, 32%) as a colorless oil. The isomers were 
separated by careful column chromatography using the same solvent system. cis-
227: IR (neat) 2916, 2846, 1805, 1464, 1135, 1064 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.29−7.26 (m, 2H), 7.20−7.16 (m, 3H), 4.55−4.49 (m, 1H), 3.57 (ddd, J = 
8.9, 6.8, 6.8 Hz, 1H), 2.61 (t, J = 7.4 Hz, 2H), 1.82−1.70 (m, 2H), 1.68−1.52 (m, 
4H), 1.45−1.26 (m, 26H), 0.88 (t, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
172.5, 142.7, 128.6, 128.5, 125.9, 75.9, 52.8, 36.0, 32.1, 31.3, 30.4, 29.9, 29.9, 
29.8, 29.7, 29.6, 29.6, 29.5, 29.2, 27.7, 25.8, 24.1, 22.9, 14.3; MS (GC) m/z 356 
(M − CO2)+, 117, 104 (100), 91; HRMS (ESI) calcd for C27H45O2 [M + H]
+ m/z 
401.3414, found 401.3441. trans-227: IR (neat) 2921, 2852, 1819, 1454, 1114 cm-
1; 1H NMR (400 MHz, CDCl3) δ 7.32−7.28 (m, 2H), 7.20 (m, 3H), 4.23−4.19 (m, 
1H), 3.19−3.14 (m, 1H), 2.64 (t, J = 7.1 Hz, 2H), 1.87−1.80 (m, 2H), 1.74−1.63 (m, 
4H), 1.50−1.29 (m, 26H), 0.91 (br. t, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
171.8, 142.6, 128.6, 128.5, 125.9, 78.3, 56.3, 36.0, 34.6, 32.1, 31.3, 29.9, 29.9, 
29.8, 29.7, 29.6, 29.6, 29.5, 29.1, 28.0, 27.1, 25.2, 22.9, 14.3; MS (EI) m/z 356 (M 
− CO2)+, 117, 104 (100), 91; HRMS (ESI) calcd for C27H45O2 [M
 
+ H]+ m/z 
401.3414, found 401.3447. 
 
(cis/trans)-3-(4-Phenylbutyl)-4-tridecyloxetan-2-one (trans/cis-228). (Z)-3-(4-
Phenylbutylidene)-4-tridecyloxetan-2-one (Z-222) (0.05 g, 0.13 mmol)) was 




	   192	  
˚C, followed by the addition of CoCl2(PPh)3 (15.0 mg, 0.02 mmol) and then portion-
wise addition of NaBH4  (14 mg, 0.39 mmol) within 10 min.81 The mixture was 
vigorously stirred for 1.5 h between −7 to −5 ˚C. The reaction mixture was filtered 
through a pad of celite, and the celite was washed with CHCl3 (10 mL). The filtrate 
was washed with 2M HCl (5 mL), dried (MgSO4) and concentrated. Purification by 
flash chromatography on silica gel (petroleum ether/EtOAc 98:2) gave trans/cis-
228 (trans/cis, 1.4/1), (24 mg, 46%) as a colorless oil. The isomers were separated by 
careful column chromatography using the same solvent system. cis-228: IR (neat) 
2919, 2850, 1818, 1462, 1052 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.29−7.26 (m, 
2H), 7.20−7.16 (m, 3H), 4.51 (ddd, J = 10.0, 6.2, 4.0 Hz, 1H), 3.58 (ddd, J = 8.6, 
6.7, 7.7 Hz, 1H), 2.63 (t, J = 7.5 Hz, 2H), 1.85−1.77 (m, 1H), 1.75−1.62 (m, 6H), 
1.51−1.26 (m, 21H), 0.88 (t, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 172.4, 
142.3, 128.6, 126.0, 75.9, 52.8, 35.8, 32.1, 31.3, 30.4, 29.9, 29.9, 29.8, 29.7, 29.6, 
29.6, 29.5, 27.4, 25.7, 24.0, 22.9, 14.3; MS (EI) m/z 342 (M − CO2)+, 117, 104 
(100), 91; HRMS (ESI) calcd for C26H43O2 [M + H]
+ m/z 387.3258, found 387.3261. 
trans-228: IR (neat) 2917, 2851, 1804, 1470, 1140 cm-1; 1H NMR (400 MHz, CDCl3) 
δ  7.30−7.26 (m, 2H), 7.20−7.15 (m, 3H), 4.19 (ddd, J = 6.5, 6.5, 3.9 Hz, 1H), 3.15 
(m, 1H), 2.63 (t, J = 7.5 Hz, 2H), 1.90−1.81 (m, 2H), 1.79−1.62 (m, 4H), 1.51−1.26 
(m, 24H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.8, 142.3, 
128.6, 126.1, 78.3, 56.3, 35.8, 34.6, 32.1, 31.3, 29.9, 29.9, 29.8, 29.7, 29.6, 29.6, 
29.5, 28.0, 26.8, 25.2, 22.9, 14.3; MS (EI) m/z 342 (M − CO2)+, 117, 104 (100), 91; 
HRMS (ESI) calcd for C26H43O2 [M + H]
+  m/z 387.3258, found 387.3259. 
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(cis/trans)-3-Benzyl-4-tridecyloxetan-2-one (trans/cis-229). (Z)-3-Benzylidene-4-
tridecyloxetan-2-one (Z-223) (0.05 g, 0.15 mmol) was dissolved in a mixture of 
THF:MeOH (1.1 mL:0.05 mL). This solution was cooled to −10 ˚C, followed by the 
addition of CoCl2(PPh)3 (0.02 g, 0.03 mmol) and then portion-wise addition of 
NaBH4 (16.0 mg, 0.44 mmol) within 10 min.81 The mixture was vigorously stirred 
for 2 h between −7 to −5 ˚C. The reaction mixture was filtered through a pad of 
celite, and the celite was then washed with CHCl3 (5 mL). The filtrate was washed 
with 2M HCl (5 mL), dried (MgSO4) and concentrated. Purification by flash 
chromatography on silica gel (petroleum ether/EtOAc 99:1) gave trans/cis-229 
(trans/cis, 2/1), (0.02 g, 39%) as a wax. The isomers were separated by careful 
column chromatography using the same solvent system. cis-229 (white solid):  mp 
43−44 ˚C; IR (neat) 2917, 2849, 1797, 1466, 1136, 1067 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.34−7.30 (m, 2H), 7.24−7.21 (m, 3H), 4.60 (ddd, J = 10.0, 6.4, 3.6 Hz, 
1H), 4.01 (ddd, J = 9.0, 6.9, 6.9 Hz, 1H), 3.19 (dd, J = 15.1, 7.1 Hz, 1H), 2.98 (dd, 
J = 15.1, 9.0 Hz, 1H), 1.86−1.76 (m, 1H), 1.71−1.63 (m, 1H), 1.57−1.46 (m, 1H), 
1.37−1.26 (m, 21H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.7, 
137.9, 129.0, 128.6, 127.0, 76.3, 53.5, 32.1, 30.6, 29.9, 29.9, 29.8, 29.7, 29.6, 
29.6, 29.5, 25.8, 22.9, 14.3; MS (EI) m/z 300 (M − CO2)+, 117, 104 (100), 91; 
HRMS (ESI) calcd for C23H37O2 [M
 + H]+ m/z 345.2788, found 345.2817. trans-229 
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(400 MHz, CDCl3) δ 7.34−7.30 (m, 2H), 7.27−7.25 (m, 2H), 7.20 (d, J = 7.0 Hz, 
1H), 4.27 (ddd, J = 6.7, 6.7, 4.1 Hz, 1H), 3.45 (ddd, J = 9.5, 5.6, 4.2 Hz, 1H), 3.18 
(dd, J = 14.3, 5.7 Hz, 1H), 3.00 (dd, J = 14.3, 9.4 Hz, 1H), 1.83−1.74 (m, 1H), 
1.62−1.57 (m, 1H), 1.35−1.18 (m, 22H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 171.0, 137.4, 129.1, 128.9, 127.3, 77.8, 57.6, 34.4, 34.0, 32.1, 
29.9, 29.9, 29.8, 29.6, 29.6, 29.6, 29.3, 24.8, 22.9, 14.3; MS (EI) m/z 300 (M − 
CO2)+, 117, 104 (100), 91; HRMS (ESI) calcd for C23H37O2 [M
 




Oxo-4-tridecyloxetan-3-ylidene)hexanamide (Z/E-224) (0.050 g, 0.14 mmol) was 
dissolved in mixture of THF:MeOH (0.9:0.2 mL). This solution was cooled to −10 
oC, followed by the addition of CoCl2(PPh3)2 (0.01 g, 0.04 mmol) and then portion-
wise addition of NaBH4  (13 mg, 0.41 mmol) within 10 min. The mixture was 
vigorously stirred for 4 h between −10 to −7 oC. The reaction mixture was filtered 
through a pad of celite, and the celite was then washed with CHCl3 (10 mL). The 
filtrate was washed with 2M HCl (5 mL), dried (MgSO4) and concentrated. 
Purification by flash column chromatography on silica gel (CH2Cl2/MeOH, 98:2) 
gave an inseparable mixture of trans/cis-230 (trans/cis, 1.4:1) (18 mg, 35%) as an off 
white solid. Peak assignments for trans-isomer: 1H NMR (400 MHz, CDCl3) δ 5.34 
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2.23 (t, J = 7.4 Hz, 2H), 1.87−1.81 (m, 2H), 1.78−1.65 (m, 4H), 1.55−1.26 (m, 
26H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 175.2, 171.8, 78.3, 
56.3, 35.7, 34.6, 32.1, 29.9, 29.9, 29.8, 29.7, 29.6, 29.6, 29.5, 29.0, 27.9, 26.8, 
25.2, 22.9, 14.3; HRMS (ESI) calcd for C22H42NO3 [M
 




tridecyloxetan-3-ylidene)hexanamide (Z/E-224) (50.0 mg, 0.14 mmol) was 
dissolved in THF (2 mL). Pd/C (10 mol%, 4 mg, 0.004 mmol) was added to the 
solution. The mixture was purged with H2 gas for 5 min. It was then stirred under 
H2 gas for 2 h. The mixture was filtered through a pad of celite, and the celite was 
washed with THF (5 mL). The filtrate was concentrated and purified by flash 
column chromatography on silica gel (CH2Cl2/MeOH, 98:2) to give trans/cis-230 
(trans/cis, 1:9), (16 mg, 65%) as an off white solid. Careful chromatography under 
the same conditions provided the cis-230 in >95% purity: mp 98−101 ˚C; IR (neat) 
3393, 2918, 2849, 1795, 1649, 1417, 1132, 804 cm-1; 1H NMR (400 MHz, CDCl3) δ 
5.40−5.35 (br, 2H), 4.54−4.50 (m, 1H), 3.61−3.55 (m, 1H), 2.23 (t, J = 6.1 Hz, 2H), 
1.79−1.51 (m, 8H), 1.40−1.26 (m, 24H), 0.89−0.86 (m, 3H); 13C NMR (100 MHz, 
CDCl3) δ 175.2, 172.5, 75.9, 52.7, 35.8, 32.1, 30.4, 29.9, 29.8, 29.7, 29.6, 29.6, 
29.5, 29.0, 27.4, 25.8, 25.2, 23.9, 22.9, 14.3; HRMS (ESI) calcd for C22H42NO3 [M
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(trans)-3-Hexyl-2-methylene-4-tridecyloxetane (trans-231). (trans)-3-Hexyl-4-
tridecyloxetan-2-one (trans-226) (12 mg, 34 mmol) and Petasis solution (0.2 mL, 0.72 
M) were stirred in a pre-heated oil bath at 80 ˚C for 6 h.92 TLC showed remaining starting 
material so 0.2 mL more of the Petasis solution was added, and stirring was continued for 2 
h. Petroleum ether (10 mL) was added to quench the reaction, and the mixture was allowed 
to stir overnight. The mixture was then filtered through a pad of celite until the filtrate was 
colorless, and the filtrate was concentrated to 1 mL solution. Purification by flash column 
chromatography on silica gel (petroleum ether/ EtOAc/ Et3N, 96:3:1) gave trans-231(4.5 
mg, 38%) as a slightly yellow oil: IR (neat) 2924, 2854, 1689, 784 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 4.39 (m, 1H), 4.06 (br s, 1H), 3.72 (br s, 1H), 2.96−2.91 (m, 
1H), 1.85−1.78 (m, 1H), 1.71−1.62 (m, 3H), 1.29−1.26 (m, 30H), 0.89−0.86 (m, 
6H); 13C NMR (100 MHz, CDCl3) δ 167.9, 86.3, 78.5, 47.5, 36.0, 32.3, 32.2, 31.9, 
29.9 29.9, 29.7, 29.7, 29.6, 29.4, 27.0, 24.7, 22.9, 22.8, 14.3, 14.3; HRMS (ESI) 
calcd for C23H45O [M
 + H]+  m/z 337.3465, found 337.3469. 
 
(trans)-2-Methylene-3-(5-phenylpentyl)-4-tridecyloxetane (trans-232). (trans)-
3-(5-Phenylpentyl)-4-tridecyloxetan-2-one (trans-227), (11 mg, 27 mmol) and Petasis 
solution (0.080 mL, 0.50 M) were stirred in a pre-heated oil bath at 80 ˚C  for 5 h.92 
Petroleum ether (10 mL) was added to quench the reaction, and the mixture was allowed to 
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concentrated to 1 mL solution. Purification by flash column chromatography on silica gel 
(petroleum ether/EtOAc/Et3N 96:3:1) gave trans-232 (3.2 mg, 40%) as a colorless oil: 
IR (neat) 2922, 2852, 1687, 1454 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.30−7.26 (m, 
2H), 7.19−7.16 (m, 3H), 4.38 (m, 1H), 4.06 (m, 1H), 3.71 (m, 1H), 2.94−2.90 (m, 
1H), 2.64 (t, J = 7.5 Hz, 2H), 1.84−1.76 (m, 1H), 1.70−1.62 (m, 5H), 1.36−1.26 (m, 
26H), 0.91 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 167.8, 142.8, 128.6, 
128.5, 125.9, 86.2, 78.5, 47.5, 36.1, 36.0, 32.2, 32.1, 31.5, 29.9, 29.9, 29.8, 29.7,  
29.6, 29.4, 27.0, 24.7, 22.9, 14.3; MS (EI) m/z 398 (M+), 104 (100), 91; HRMS 
(ESI) calcd for C28H47O [M + H]
+ m/z 399.3621, found 399.3594. 
 
(Z/E)-6-(2-Oxo-4-(2-phenethyl)oxetan-3-ylidene)hexanamide (Z/E-234; KC02). 
Cat. 2 (0.026 g, 0.041 mmol) was added to a solution of 3-methylene-4-(2-
phenethyl)oxetan-2-one (238) (0.073 g, 0.41 mmol) and hept-6-enamide (219e) 
(0.053 g, 0.41 mmol) in dry CH2Cl2 (16 mL). The solution was stirred at 40 
oC for 24 
h.65 After the reaction was allowed to cool to rt, the CH2Cl2 was removed under 
reduced pressure to yield a greenish brown residue. Purification by flash 
chromatography on silica gel (CH2Cl2/MeOH, 99:1) gave Z/E-234 (KC02) (Z/E, 4:1) 
(0.050 g, 43%) as an off white solid: IR (neat) 3384, 3182, 2942, 1783, 1644, 1416, 
1218, 1179, 1135, 1096, 1014 cm-1; Peak assignment for Z-234: 1H NMR (400 MHz, 
CDCl3) δ 7.32−7.28 (m, 2H), 7.23−7.18 (m, 3H), 5.74 (td, J = 8.0, 1.2 Hz, 1H), 5.35 
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2.27−2.21 (m, 2H), 2.15−2.08 (m, 2H), 1.70−1.62 (m, 2H), 1.54−1.47 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 175.3, 164.3, 140.5, 137.9, 136.1, 128.8, 128.6, 126.6, 
78.1, 35.6, 35.1, 31.1, 28.3, 28.1, 24.6; The E-234: 1H NMR (400 MHz, CDCl3) δ 
7.32−7.28 (m, 2H), 7.23−7.18 (m, 3H), 6.32 (td, J = 7.8, 1.6 Hz, 1H), 5.49 (br s, 2H) 
4.99 (m, 1H), the remaining proton signals cannot be readily distinguished from 
those of the Z-isomer; 13C NMR (100 MHz, CDCl3) δ 174.9, 164.2, 140.6, 138.0, 
133.7, 128.8, 128.6, 126.6, 78.2, 35.4, 35.3, 31.1, 28.8, 28.1, 25.0; HRMS (ESI) 
calcd for C17H22NO3 [M + H]+ m/z 288.1594, found 288.1630. 
 
trans/cis-6-(2-Oxo-4-(2-phenethyl)oxetan-3-yl)hexanamide (trans/cis-235). 
(Z/E)-6-(2-Oxo-4-(2-phenethyl)oxetan-3-ylidene)hexanamide (Z/E-234) (0.031 g, 
0.011 mmol) was dissolved in THF (1 mL). Pd/C (10 mol%, 1.2 mg, 0.0011 mmol) 
was added to the solution. The mixture was purged with H2 gas for 5 min. It was 
then stirred under H2 gas for 2 h 15 min. The mixture was filtered through a pad of 
celite, and the celite was washed with THF (5 mL). The filtrate was concentrated 
and purified by flash column chromatography on silica gel (CH2Cl2/MeOH 98:1) 
trans/cis-235 (trans/cis, 1:5,) (19 mg, 60%) as an inseparable mixture and off 
white solid. IR (neat) 3392, 2938, 1796, 1646, 1416, 1135 cm-1; cis-235: 1H NMR 
(400 MHz, CDCl3) δ 7.33−7.29 (m, 2H), 7.24−7.19 (m, 3H), 5.58−5.50 (br, 2H), 
4.54 (ddd, J = 10.0, 6.4, 3.4 Hz, 1H), 3.59 (ddd, J = 9.2, 6.5, 6.5 Hz, 1H), 2.88 
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7.4 Hz, 2H), 2.10−2.01 (m, 1H), 1.98−1.78 (m, 1H), 1.83−1.90 (m, 1H), 1.67−1.50 
(m, 4H), 1.43−1.32 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 175.4, 172.2, 140.6, 
128.8, 128.7, 126.6, 74.7, 52.6, 35.7, 32.4, 31.8, 28.9, 27.3, 25.1, 23.9; trans-235: 
1H NMR (400 MHz, CDCl3) δ 4.54 (ddd, J = 8.6, 5.4, 4.1 Hz, 1H), 3.59 (ddd, J = 
7.6, 7.6, 3.9 Hz, 1H), the remaining proton signals cannot be readily distinguished 
from those of the cis-isomer; 13C NMR (100 MHz, CDCl3) δ 175.4, 171.5, 140.3, 
128.8, 128.6, 126.6, 77.4, 56.3, 36.2, 32.4, 31.5, 28.9, 27.7, 26.7, 25.1, 23.9; 1H 
HRMS (ESI) calcd for C17H24NO3 [M
 
+ H]+ m/z 290.1751, found 290.1754. 
 
(Z)-6-(2-Oxo-4-(9-phenylnonyl)oxetan-3-ylidene)hexanamide (236). Catalyst 1 
(0.025 g, 0.30 mmol) was added to a solution of 3-methylene-4-(9-
phenylnonyl)oxetan-2-one (247) (0.085 g, 0.30 mmol) and hept-6-enamide (219e) 
(0.038 g, 0.30 mmol) in dry CH2Cl2 (11 mL). The solution was stirred at 40 
oC for 3 
d.65 After the reaction was allowed to cool to rt, the CH2Cl2 was removed under 
reduced pressure. Purification of the residue by flash chromatography on silica gel 
(CH2Cl2/MeOH, 98:2) gave 236 (Z/E, 3.7:1), (0.068 g, 59%) as an off white solid. 
Further chromatography using Et2O gave pure Z-isomer: mp: 93−94 oC; IR (neat) 
3384, 3194, 2916, 2850, 1791, 1655, 1467, 1421, 1180, 1124, 1074 cm-1;  1H NMR 
(400 MHz, CDCl3) δ 7.29−7.25 (m, 2H), 7.18−7.15 (m, 3H), 5.84 (t, J = 8.0 Hz, 
1H), 5.50 (br s, 1H), 5.29 (br s, 1H), 4.86 (t, J = 6.2 Hz, 1H), 2.60 (t, J = 7.8 Hz, 
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2H), 1.62−1.53 (m, 4H), 1.49−1.41 (m, 2H), 1.30−1.29 (m, 10H); 13C NMR (100 
MHz, CDCl3) δ 175.0, 164.6, 143.1, 138.3, 135.6, 128.6, 128.4, 125.8, 79.1, 36.2, 
35.1, 33.9, 31.7, 29.6, 29.6, 29.6, 29.5, 29.5, 28.3, 28.1, 24.8, 24.6 HRMS (ESI) 
calcd for C24H36NO3 [M
 + H]+ m/z 386.2690, found 386.2699. 
 
(Z)-6-(2-Oxo-4-tridecyloxetan-3-ylidene)hexane-1-sulfonamide (237). Cat. 2 
(0.02 g, 0.03 mmol) was added to a solution of 3-methylene-4-tridecyloxetan-2-one 
(194) (0.16 g, 0.60 mmol) and hept-6-ene-1-sulfonamide (250) (0.15 g, 0.90 mmol) 
in dry CH2Cl2 (23 mL). The solution was stirred at 40 
oC for 48 h.65 After the 
reaction was allowed to cool to rt, the CH2Cl2 was removed under reduced 
pressure to yield a greenish brown residue. Purification by flash chromatography 
on silica gel (CH2Cl2/MeOH, 98:2) gave Z/E-237 (Z/E, 4:1) (0.19 g, 79%) as an off 
white solid. The Z-isomer, isolated as a white solid, was separable from the E-
isomer by careful chromatography using the same solvent system. Z-237: mp: 
79−80 oC; IR (neat) 2914, 2849, 1791, 1469, 1331, 1143 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 5.84 (t, J = 7.6 Hz, 1H), 4.92 (s, 2H), 4.86 (dd, J = 6.2, 6.2 Hz, 1H), 3.11 
(t, J = 7.3 Hz, 2H), 2.58−2.24 (m, 2H), 1.91−1.85 (m, 2H), 1.82−1.77 (m, 2H), 1.51 
(m, 4H), 1.45−1.39 (m, 2H), 1.34−1.25 (m, 20H), 0.87 (t, J = 6.7 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 164.6, 138.2, 135.6, 79.1, 55.1, 33.9, 32.1, 29.8, 29.8, 29.7, 
29.6, 29.5, 29.5, 28.3, 28.2, 27.4, 24.8, 23.6, 22.9, 14.3; HRMS (ESI) calcd for 
C22H42NO3 [M
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1-(tert-Butyldimethylsilyloxy)-10-phenyldec-9-yne (241). n-BuLi  (2.5 M in THF, 
12.5 mL, 31.2 mmol) was added to a solution of phenylacetylene (239) (3.43 mL, 
31.2 mmol) in THF (10 mL) at 0 oC. After 10 min a solution of 1-(tert-
butyldimethylsilyloxy)-8-iodooctane (240) (5.87 g, 15.6 mmol) and HMPA (10 mL) 
was added drop-wise. The resultant solution was stirred at 0 oC for 30 min, then 
allowed to slowly warm to rt overnight. Saturated aqueous NH4Cl (60 mL) was 
added. The layers were separated, followed by extraction of the aqueous layer with 
Et2O (3 X 30 mL). The combined organic layers were dried (MgSO4) and 
concentrated. The crude residue was purified by flash chromatography on silica gel 
(petroleum ether/EtOAc, 99:1) to yield 241 (2.56 g, 48%) as a colorless oil: IR (neat) 
2927, 2855, 1462, 1253, 1093, 834, 774, 754, 691 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.47−7.38 (m, 2H), 7.30−7.23 (m, 3H), 3.61 (t, J = 6.6 Hz, 2H), 2.40 (t, J = 7.1 Hz, 
2H), 1.64−1.57 (m, 2H), 1.53−1.44 (m, 4H) 1.38−1.33 (m, 6H), 0.90 (s, 9H), 0.05 (s, 
6H); 13C NMR (100 MHz, CDCl3) δ 131.8, 128.4, 127.6, 124.3, 90.6, 80.8, 63.5, 
33.1, 29.6, 29.4, 29.1, 29.0, 26.2, 26.0, 19.6, 18.6, −5.0; HRMS (ESI) calcd for 
C22H37OSi [M + H]+ m/z 345.2608, found 345.2596. 
 
1-(tert-Butyldimethylsilyloxy)-10-phenyldecane (242). Pd/C (10 mol%, 0.27 g, 
0.26 mmol) was added to a solution of 1-(tert-butyldimethylsilyloxy)-10-phenyldec-
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for 5 min and then stirred under H2 for 7.5 h. The reaction mixture was filtered 
through a pad of celite, and the filtrate was concentrated to provide 242 (2.21g, 
74%) as a colorless oil, which was clean based on 1H and 13C NMR and was used 
without further purification in the next reaction: IR (neat) 2925, 2853, 1462, 1252, 
1096, 834, 774, 679 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.29−7.25 (m, 2H), 
7.18−7.15 (m, 3H), 3.60 (t, J = 6.6 Hz, 2H), 2.60 (t, J = 7.6 Hz, 2H), 1.65−1.59 (m, 
2H), 1.51 (quin, J = 6.8 Hz, 2H) 1.34−1.28 (m, 12H), 0.90 (s, 9H), 0.05 (s, 6H); 13C 
NMR (100 MHz, CDCl3) δ 143.2, 128.6, 128.4, 125.8, 63.6, 36.2, 33.1, 31.7, 29.8, 
29.7, 29.7, 29.7, 29.6, 26.2, 26.0, 18.6, −5.0; HRMS (ESI) calcd for C22H41OSi [M 
+ H]+ m/z 349.2921, found 349.2919. 
 
10-Phenyldecane-1-ol (243). TBAF (1 M in THF, 15.0 mL, 15.0 mmol) was added 
drop-wise to a stirred solution of 1-(tert-butyldimethylsilyloxy)-10-phenyldecane 
242 (2.81 g, 7.5 mmol) in THF (140 mL) at 0 oC. The reaction was allowed to warm 
to rt and stir overnight. Saturated aqueous NH4Cl (100 mL) was added. The layers 
were separated, and the aqueous layer was extracted with EtOAc (3 X 50 mL). 
The combined organic layers were dried (MgSO4) and concentrated. The crude 
residue was purified by flash chromatography on silica gel (petroleum ether/EtOAc, 
90:10) to give (243) (1.41 g, 81%) as a colorless oil: IR (neat) 3431, 2919, 2848, 
1494, 1453, 1348, 1060, 717, 694 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.31−7.26 
(m, 2H), 7.20−7.17 (m, 3H), 3.64 (t, J = 6.6 Hz, 2H), 2.60 (t, J = 7.6 Hz, 2H), 
1,64−1.52 (m, 4H), 1.48 (br. s, 1H), 1.30−1.28 (m, 12H); 13C NMR (100 MHz, 
6
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CDCl3) δ 143.1, 128.6, 128.4, 125.7, 63.2, 36.2, 32.9, 31.8, 29.8, 29.7, 29.6, 29.5, 
25.9; HRMS (ESI) calcd for C16H27O [M + H]+ m/z 235.2056, found 235.2065. 
 
10-Phenyldecanal (244). 4-Acetamido-2,2,6,6-tetramethylpiperidine-1-
oxoammonium tetrafluoroborate (248) (2.01 g, 6.68 mmol) and SiO2 (2.01 g) were 
added to a solution of 10-phenyldecane-1-ol (243) (1.41 g, 6.07 mmol) in CH2Cl2 
(48 mL). The reaction mixture was stirred at rt overnight. The reaction mixture was 
then filtered through a pad of SiO2, and the filtrate was concentrated and used 
without further purification, as both 1H and 13C NMR showed clean 244 (1.26 g, 
90%) as colorless crystals: mp: 41−42 oC; IR (neat) 2913, 2847, 1698, 1411, 1282, 
1250, 1218, 942, 744, 696 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.76 (t, J = 1.8 Hz, 
1H), 7.29−7.25 (m, 2H), 7.18−7.15 (m, 3H), 2.60 (t, J = 7.5 Hz, 2H), 2.41 (td, J = 
7.3, 1.8 Hz, 2H), 1,66−1.57 (m, 4H), 1.30−1.29 (m, 10H); 13C NMR (100 MHz, 
CDCl3) δ 203.1, 143.1, 128.6, 128.4, 125.8, 44.1, 36.2, 31.7, 29.6, 29.5, 29.5, 29.3, 
22.3;  HRMS (ESI) calcd for C16H23O [M − H]+ m/z 231.1754, found 231.1734. 
 
Methyl 3-hydroxy-2-methylene-12-phenyldodecanoate (245). 10-
Phenyldecanal (244) (1.26 g, 5.45 mmol) and methyl acrylate (196) (0.98 mL, 10.9 
mmol) were combined in an empty flask. 3-Hydroxyquinuclidine (0.173 g, 1.36 
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stirred for 2 d. MeOH and excess methyl acrylate were removed under reduced 
pressure. The resulting residue was diluted with a H2O/saturated aqueous NH4Cl 
solution (5:1, 30 mL), and the resulting mixture was extracted with CH2Cl2 (3 X 15 
mL). The combined organic layers were dried (Na2SO4) and concentrated. 
Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 95:5) 
gave 245 (1.06 g, 61%) as a colorless oil: IR (neat) 3350 (br), 2924, 2853, 1717, 
1438, 1194, 1153 cm-1
 
; 1H NMR (400 MHz, CDCl3) δ 7.29−7.25 (m, 2H), 
7.19−7.15 (m, 3H), 6.22 (m, 1H), 5.81 (m, 1H), 4.39 (m, 1H), 3.78 (s, 3H), 
2.62−2.56 (m, 3H), 1.69−1.57 (m, 4H), 1.48−1.43 (m, 1H), 1.30−1.28 (m, 11H); 13C 
NMR (100 MHz, CDCl3) δ 167.2, 143.1, 142.7, 128.6, 128.4, 125.7, 125.1, 72.0, 
52.0, 36.4, 36.2, 31.7, 29.7, 29.7, 29.7, 29.6, 29.5, 26.0; HRMS (ESI) calcd for 
C20H31O3 [M + H]+ m/z 319.2268, found 319.2281. 
 
3-Hydroxy-2-methylene-12-phenyldodecanoic acid (246). Methyl 3-hydroxy-2-
methylene-12-phenyldodecanoate (245) (1.06 g, 3.37 mmol) was dissolved in 
EtOH/H2O (2:1, 8 mL). Lithium hydroxide (77 mg, 3.4 mmol) was added; the 
resulting solution was stirred overnight.89 The reaction was quenched with 1 M HCl 
(30 mL), and the solution was extracted with CH2Cl2 (3 X 20 mL). The combined 
organic layers were washed with H2O (30 mL) and dried (MgSO4); CH2Cl2 was 
removed under reduced pressure. Purification of the residue by flash 
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54%) as a colorless oil: IR (neat) 2919, 2848, 1685, 1622, 1493, 1435, 1284, 1181, 
1118, 1070 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.29−7.25 (m, 2H), 7.18−7.15 (m, 
3H), 6.38 (s, 1H), 5.91 (s, 1H), 4.42 (dd, J = 6.3, 6.3 Hz, 1H), 2.60 (t, J = 7.6 Hz, 
2H), 1.74−1.57 (m, 4H), 1.48−1.43 (m, 1H), 1.30−1.28 (m, 12H); 13C NMR (100 
MHz, CDCl3) δ 170.8, 143.2, 142.0, 128.6, 128.4, 127.6, 125.8, 71.8, 36.4, 36.2, 
31.7, 29.7, 29.7, 29.6, 29.5, 26.0; HRMS (ESI) calcd for C19H29O3 [M + H]+ m/z 
305.2111, found 305.2142. 
 
3-Methylene-4-(9-phenylnonyl)oxetan-2-one (247). 3-Hydroxy-2-methylene-12-
phenyldodecanoic acid (246) (0.40 g, 1.8 mmol) was dissolved in dry CH2Cl2 (7 
mL). Oven-dried Cs2CO3 (0.64 g, 1.8 mmol) was added, and the resulting 
suspension was stirred for 20 min. o-Nosyl chloride (800 mg, 3.6 mmol) was 
added, and the resulting mixture was stirred for 3 d. The reaction was diluted with 
CH2Cl2 (20 mL), and then 1 M HCl (20 mL) was added. The aqueous layer was 
separated and extracted with CH2Cl2 (3 X 15 mL). The combined organic layers 
were dried (Na2SO4) and concentrated. Purification of the residue by flash 
chromatography on silica gel (petroleum ether/EtOAc, 95:5) gave 247 (0.089 g, 
17%) as a colorless oil: IR (neat) 2926, 2854, 1821, 1080 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.27−7.23 (m, 2H), 7.17−7.13 (m, 3H), 5.87 (dd, J = 1.8, 1.8 Hz, 1H), 
5.38 (dd, J = 1.5, 1.5 Hz, 1H), 4.95−4.91 (m, 1H), 2.59 (t, J = 7.6 Hz, 2H), 
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10H); 13C NMR (100 MHz, CDCl3) δ 163.8, 146.6, 143.0, 128.5, 128.4, 125.7, 
115.0, 79.8, 36.1, 33.4, 31.6, 29.6, 29.5, 29.5, 29.4, 29.4, 24.7; HRMS (ESI) calcd 
for C19H27O2 [M
 
+ H]+ m/z  287.2006, found 287.1999.  
 
Hept-6-ene-1-sulfonamide (250). A solution of 7-bromo-1-heptene (249) (0.50 g, 
4.3 mmol), and sodium sulfite (0.65 g, 5.1 mmol) in H2O (3.0 mL) was refluxed 
overnight.93 After cooling to rt the aqueous solution was washed with Et2O (2.2 mL) 
before being evaporated to dryness. The resulting white solid was dried under 
vacuum at 130 oC for 1 h and then POCl3 (4.3 mL) was added, and the mixture 
was stirred for 4 h at 130 oC. The reaction mixture was evaporated, and the 
residue was taken up in CH3CN (5 mL), and a solution of NH4OH (28.0−30.0%, 10 
mL) in CH3CN (4 mL) was slowly added at 0 oC. The reaction mixture was stirred 
at 0 oC for 1 h before being diluted with CH2Cl2 (30 mL) and washed with H2O (20 
mL). The organic layer was dried (Na2SO4) and concentrated. Purification by flash 
column chromatography on silica gel (petroleum ether/EtOAc, 80:20) gave 250 
(0.29 g, 42%) as a white solid: mp: 52−52.5 oC; IR (neat) 3338, 3253, 2927, 1469, 
1294, 1134 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.78 (ddt, J = 17.0, 10.2, 6.4 Hz, 
1H), 5.03−4.94 (m, 2H), 4.84 (br s, 2H), 3.13−3.09 (m, 2H), 2.06 (q, J = 6.3 Hz, 
2H), 1.89−1.81 (m, 2H), 1.45−1.43 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 138.5, 
114.9, 55.3, 33.4, 28.4, 27.7, 23.8; HRMS (ESI) calcd for C7H16NO2S [M
 + H]+ m/z 
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